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Summary 
Despite many studies on pathology and aetiology during the past decades, the molecular 
mechanism(s) of melanoma development remains largely unknown. Therefore the purpose 
of this project was to establish a transgenic mouse model able to investigate the molecular 
mechanism(s) of melanoma aetiology mediated by N-Ras and PTEN genes. To achieve 
this, an inducible gene switch approach was employed exploiting the Cre/loxP recombinase 
system. This  approach  has the advantage of  avoiding embryonic lethality and helps to 
minimise  disease(s)  in  other  tissue(s)  that  may  interfere  with  animal  viability.  It  was 
envisaged that this inducible system would establish a model that accurately mimic the 
development  of  melanoma  in  humans.  A  disadvantage  being  that  the  tyrosinase-based 
promoter was only responsive to the inducer when melanocytes were proliferating. 
 
Initially,  regulator  vectors  were  created  by  sub-cloning  Cre  under  the  control  of  a 
melanocyte-specific  promoter  either  enhanced  tyrosinase  (EICre)  or  tyrosinase  related 
protein 2 (Trp2Cre). A Cre responsive, target N-Ras
lys61 transgene was also cloned, where 
expression was induced by Cre ablation of  ‘Stop' cassette (cmv.stop.N-Ras
lys61) together 
with a report target transgene (cmv.stop.EGFP) to aid in expression characterisation. 
 
The functional activity and gene-switch specificity of these constructs were subsequently 
confirmed employing co-transfection of regulator and report target into B16 melanoma 
cells, but to confirm their activity in primary melanocytes, melanocyte culture conditions had 
to be defined for optimum growth and transfection as there is no optimized commercial 
medium available for murine melanocyte culture unlike for human melanocyte.  In this 
study  therefore,  murine  primary  melanocyte  culture  method  (50/50)  has  been  defined, 
which exploited keratinocytes for initial melanocytes growth support as a feed layer. The 
other  advantages  of  this  50/50  medium  were  that  pigmented  cells  grew  without 
spontaneous transformation and gave the higher transfection efficiency compared to media  
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exploited  by  other  groups.  Using  primary  melanocytes  cultured  in  50/50  medium, 
transgene construction and identification of regulator expression were performed by RT-
PCR in vitro prior to in vivo analysis thereby avoiding unnecessary breeding. 
 
When concerns had arisen regarding an unexpected lack of melanoma phenotype in vivo 
particularly in addition of PTEN loss, this culture protocol supplied a successful test of 
oncogenic  potential  of  N-Ras
lys61  and  PTEN  loss  in  vitro,  where  N-Ras
lys61  expression 
transformed  melanocytes  and  PTEN  loss  promoted  N-Ras
lys61  to  give  more  aggressive 
cells. However a functional redundancy was identified, as transformed colonies were not 
immortalized and eventually senesced, possibly due to their opposing gene functions being 
on the same signalling  pathway; i.e. PTEN fails to provide additional genetic aberrant 
pathway(s) for the cross-talk with Ras signalling necessary to form malignant tumours. 
 
The in vivo experiments commenced by crossing transgenic expressers of EICre regulator 
with  target  cmv.stop.N-Ras
lys61,  to  generate  bigenic  EICre/N-Ras  mice.  Treatment  with 
Ru486 initially apparently failed to exhibit an abnormal phenotype, despite confirmation of 
N-Ras
lys61  expression  following  hair  plucking  to  initiate  the  hair  cycle  and  anagen 
melanocytes proliferation, therefore D5PTEN
flx/flx mutation was introduced. Unexpectedly, 
a similar result was obtained following treatment of EICre/D5PTEN
flx/flx/N-Ras
lys61 and 
EICre/D5PTEN
flx/flx  in  the  test  of  whether  PTEN  functional  loss  promoted  N-Ras
lys61 
tumourigenesis.  However  with  time,  at  12-15  months  (systemic)  Ru486  treatment, 
phenotypes of enlarged eyes and harderian gland adenomas were obtained in N-Ras
lys61 
expressing mice, whilst PTEN loss did not produce additional melanocytic phenotype. 
 
 This confirmation of in vivo activity prompted a more careful analysis of treated mouse 
skin that discovered the appearance of white hair at treated sites which gave a subtle grey 
appearance  to  the  coat  colour  compared  to  age  matched  untreated  littermates  or  non- 
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transgenic controls. Subsequent analysis found that melanocyte apoptosis was induced by 
N-Ras
lys61 mediated by caspsase-3, and this may explain the lack of melanomas. This new 
finding implied the existence of a cell defence system to protect mice from oncogenic 
expression, as a general feature or to overcome specific mutations that have the potential to 
induce melanoma. Furthermore, the same apoptotic pathway mediated by caspase-3 was 
mounted against PTEN functional loss. This implied a potential surveillance mechanism to 
compensate for PTEN function loss and also verified in vivo, the functional redundancy in 
melanocytes  between  these  two  genes  observed  in  vitro,  as  it  may  be  that  until  the 
appropriate  anti-apoptotic  pathway  overcomes  this  sentinel  mechanism,  PTEN  loss 
synergism with N-Ras
lys61 is insufficient for melanoma tumourigenesis.  
 
Due to the lack of melanoma, given the well characterized effects of the microenvironment 
in  melanoma  development,  this  study  assessed  the  consequences  of  keratinocytes 
disruption.  This  was  achieved  employing  a  keratinocyte-specific  K14Cre  regulator 
transgenic  line,  expressed  in  proliferative  basal  cells,  hair  follicles  and  stem  cells.  In 
Ru486-treated tetragenic compound K14Cre/EICre/cmv.stop.N-Ras
lys61/D5PTEN
flx/flx mice 
pigmented papillomas were produced. This identified a melanocyte survival loop generated 
by  microenvironment  disruption  that  enabled  anagen  melanocytes  to  escape  apoptosis 
during  papillomagenesis.  Furthermore,  the  mechanism  involved  elevated  Kit/SCF 
expression in papillomas. The co-localisation of Kit and TRP-2 positive melanocytes in 
papilloma  basal  layers  revealed  that  a  Kit/SCF  paracrine  survival  loop  resulted  in 
melanocyte survival. These results clearly demonstrated melanocyte cooperation with its 
immediate microenvironment consistent with the requirement for proliferative keratinocyte 
support of primary murine melanocyte cultures. Furthermore, these pigmented papillomas, 
may represent a model relevant to development of human seborrheic keratoses, which are 
pigmented benign lesions similar to papilloma, and neither nevi nor melanoma (4-6). These 
murine  data  suggest  that  these  lesions  may  arise  where  papilloma  formation  occurs  
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alongside  anagen  and  the  Kit/SCF  paracrine  survival  loop  creates  an  environment  in 
papillomas sufficient to incorporate the survival and proliferation of anagen melanocytes, 
although the further studies are necessary to confirm this. 
 
To date, most transgenic melanoma models employ H-Ras, with only recent development 
of a relevant N-Ras model where  constitutive,  but not inducible, N-Ras
lys61 expression 
throughout embryogenesis eventually gave a hyperplastic melanocyte phenotype which is 
consistent  with  the  report  of  N-Ras  mutation  common  in  congenital  nevi  but  less  in 
acquired nevi (9-13). As with H-Ras models, it appears that the CDKN2A locus deficiency 
is necessary for melanoma aetiology. In this study, unlike CDKN2A, PTEN loss failed to 
promote N-Ras melanoma tumourigenesis. This is possibly due to  regulating the same 
signalling  pathways,  creating  a  functional  redundancy,  and  the  same  susceptibility  to 
apoptosis from newly identified potential compensatory surveillance systems. These results 
show the necessity of cross-talk between multiple genetic pathways to achieve malignant 
tumour formation and also the advantage of an inducible gene-switch approach to identify 
useful compensatory systems by allowing addition/deletion of many different interesting 
genes. Taking the insights from this study further, logically the introduction of p16/p19 
deficient mice and/or other melanocyte/melanoma development related genes (specifically 
not  on  Ras  signalling  pathway,  e.g.  MC1R  pathways)  would  provide  an  up-to-date, 
superior  mouse  model  able  to  mimic  molecular  aetiology  of  human  melanoma  to 
investigate the functions and mechanisms of other genes such as MITF, B-Raf, MC1R etc 
involved in the development of human melanoma.    
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Chapter 1: Introduction  
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1.1. Overview of melanoma and mouse models 
Melanoma is a cancer that arises in pigment producing melanocytes that differentiate from 
neural crest progenitor cells during embryonic development and is most frequently found 
on  skin,  eyes  and  mucosal  surfaces.  As  with  all  cancers,  melanoma  aetiology  is  a 
multistage process (14). Thus it has been suggested that melanoma develops as a series of 
lesions initially from a benign melanocytic nevus (BN), through melanocytic dysplastic 
nevus,  to  the  radial  growth  phase  of  primary  melanoma  (RGP-CMM)  followed  by  the 
vertical  growth  phase  of  primary  melanoma  (VGP-CMM)  and  finally  to  metastatic 
melanoma (15-17). Although, while it remains arguable whether melanoma does indeed 
develop  directly  from  benign  melanocytic  nevus  (18-20),  it  is  clear  that  in  human 
melanoma the most clinically critical stage is the progression from the relatively benign 
radial growth phase (RGP) to the vertical growth phase (VGP) which is more likely to bear 
deadly metastatic potential (21;22). 
 
The frequency of malignant melanoma is increasing all over the world with over 132,000 
malignant melanoma cases reported globally each year and whilst melanoma is the lesser of 
the  common  forms  of  skin  cancer  basal  cell  carcinoma  (BCC)  and  squamous  cell 
carcinoma (SCC), it is by far the deadliest, given that it is the most likely to metastasize 
and  thus  is  responsible  for  6  of  every  7  deaths  from  skin  cancer  (23-25).  Moreover, 
melanoma  is  one  of  the  fastest  growing  cancers  in  the  USA  with  a  steady  3%  annual 
increase in incidence since the 1970s (3) given increased sun exposure, and it is estimated 
that each hour, one person in the United States dies from melanoma (26) and alarmingly, 
there has been a 10 percent increase in new cases of melanoma from 2004 to 2005 (25).  
Similarly in the UK the incidence of melanoma is increasing, with approximately 10 cases 
per 100,000 populations per annum both in men and in women. (27-29;29). 
 
Although the exact aetiology of melanoma remains unclear, melanoma is believed to be a  
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multifactorial disease in which many different environmental and genetic factors contribute 
to  the  development  of  disease.  Overexposure  to  ultraviolet  radiation  (UVR)  is  widely 
accepted as the underlying cause for melanoma development by dysregulation of immune 
system (30-34). There is accumulating evidence to show an association of melanoma with 
UV radiation, specifically of the intensive episodic exposure during the childhood and an 
increased incidence of malignant melanoma development in their later life time (35-38). 
Results from mouse model studies confirmed that neonatal  UV  exposure is critical for 
malignant melanoma induction. A single UV exposure for short time (16 minutes) on 2–3 
days  old  pups  are  able  to  induce  in  situ  cutaneous  malignant  melanoma  in  pigmented 
transgenic mice initiated by H-Ras activation, with a penetrance of 57% by 12 months (39). 
Furthermore, a single dose of UV irradiation of hepatocyte  growth factor/scatter factor 
(HGF/SF)  mice  at  age  3.5  days  resulted  in  melanoma  development  in  adults  (40). 
Therefore, experts suggested keeping children away from intensive UV exposure as an 
effective practical way to prevent melanoma development in later life. This effort may have 
had an effect on the decreased melanoma mortality rates, the onset of melanoma incidence 
levelling  out  and  beginning  to  decrease  in  younger  Australian  cohorts  as  a  result  of 
increased photo protection (41). Recent studies show the trend of increasing melanoma 
incidence  has  halted,  as  in  Swedish  children  (42),  while  the  incidence  of  invasive 
melanoma  among  people  younger  than  35  stabilised  since  the  Queensland  Melanoma 
Project was launched in early 1960’s. Although there maybe an element of a birth cohort 
effect as suggested for non-melanoma skin cancers by Giles (43), the primary prevention 
effort to decrease the overall melanoma incidence will take at least another 20 years (44) 
and a programme geared to early detection was believed to contribute to the increased 
melanoma  incidence  (45;46).  Nonetheless,  that  the  public  campaign  of  UV  protection 
contributed  to  the  eventual  decrease  in  melanoma  rate  was  implied  by  the  analysis  of 
melanoma  cases  on  the  Victorian  Cancer  Registry,  Melbourne,  Australian  in  1996  and 
2000, which revealed a significant decrease in rates of tumours < 1 mm thick in 2000;  
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whereas  little  change  (not  significantly)  in  the  age-standardized  annual  incidence  per 
100,000 people of in-situ or invasive melanoma was recorded (47).  
 
To investigate the molecular mechanism(s) of  disease development in vivo, conditional 
transgenic  approaches,  compared  to  the  un-conditional  transgenic  technology,  offers 
tractable models to aid in stage related disease developmental verification and functional 
analysis of disease susceptibility gene(s). However, as reported in this study, generation of 
a transgenic mouse model of inducible melanoma has proven more difficult than for other 
diseases, due to the murine melanocyte physiology, and in general the mouse has been a 
relatively poor model until recently with the advent of conditional approaches that prevent 
alternate  disease(s)  or  lethality  during  oncogene  expression  or  tumour  suppressor  gene 
(TSG) ablation.  
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1.2. Biology of the skin 
1.2.1. General biology of skin 
The external covering of an animal is skin which separates the organs from the surrounding 
environment to provide protection from harmful UVR and other harmful factors (including 
biological, physical and chemical insults). It perceives changes in the environment (e.g. 
temperature)  and  then  communicates  to  the  other  organs  of  the  body  to  activate  the 
homeostatic systems that protect animals from environmental extremes. 
 
1.2.2.  Structure of skin 
The skin consists of three layers: epidermis, dermis and subcutis. The external surface of 
the skin is the impermeable epidermis which has a multilayered, stratified structure. The 
epidermis is composed predominantly (95%) of keratinocytes that produce keratins which 
constitute 30% of the protein in the basal cells of the stratified epithelium and >85% in 
fully  differentiated  squamous.  Epidermis  expresses  predominantly  two  pairs  of  keratin 
polypeptides. Basal cells express K5 and K14, whereas K1/K10 pair is only synthesized in 
differentiating  epidermal  cells  following  basal  cell  division  and  entry  into  the  first 
suprabasal layer. The differentiation status of keratinocyte is controlled by extracellular 
calcium concentrations which are varies with epidermal location. Calcium concentration 
increases gradually from proliferative keratinocytes in the basal layer, through spinous and 
granular layers to the terminal differentiated, cornified layer of skin (48-50). Comprising 
approximately 5% of interfollicular human epidermal cells (but not mouse, see below) are 
the melanocytes, each surrounded by approximately 50–60 keratinocytes to form the so 
called ‘epidermal melanin unit’ that result from the close interaction between the epidermal 
melanocytes  which  synthesize  melanosomes  and  the  keratinocytes  which  acquired  the 
melanosomes  secondarily  and  served  in  their  transport  to  localise  above  the  nucleus 
(51;52).  The  epidermal  melanin  unit  was  proposed  as  the  fundamental  integrated 
multicellular system for melanin pigmentation.  
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The dermis, lies under the basement membrane and is conjugated to the epidermis through 
the dermal-epidermal junction to provide additional supportive structures to the skin. The 
dermis is composed mainly of a structural collagen matrix, elastin and ground substance 
although there are also epidermal appendages, nerve endings, resident cells and vessels 
embedded within the dermis. Below the densely packed dermal connective tissue is the 
subcutis layer, composed of fat lobules separated by fibrous trabeculae. This layer extends 
from the lower dermis to the fibrous surface of muscle, bone or cartilage and again its 
nature and composition varies between anatomical sites. 
 
1.2.3.  Hair follicles and the Hair Cycle 
Most areas of a mammal’s body are covered by a pilosebaceous structure with varying 
dense population dependant on the localization of body. This pilosebaceous structure is 
derived from the primitive epidermis and consists of a centrally positioned hair follicle. 
The hair follicle displays different histology during the hair cycle which runs from the 
proliferative  anagen  to  the  apoptotic  catagen  and  the  resting  telogen  phases.  A  typical 
mature hair follicle can be divided into three different parts (Fig 1): the lower portion (a 
transient component which exists only in the anagen and regresses in catagen phase of hair 
cycle) extends from the base to the insertion of the erector pili muscle; the part extending 
from the insertion of erector to the sebaceous duct is the middle portion where melanocyte 
stem cells reside in the bulge region (53); and the upper portion extends from the duct to 
the epidermal surface (54;55). In human skin, follicular melanocyte stem cells are thought 
to migrate to “niches” lacking melanocytes (53) and are potentially the source for both 
melanocytes of the hair follicle and of the epidermal melanin unit. However in murine skin, 
melanocytes are confined to the hair follicles (except a minor population in ears, tails and 
foot pad) as they mainly provide pigmentation for the hair (56;57) and are mostly absent 
from a resting follicle. Although the number of hair follicle in an adult mammal seems to  
  28 
be fixed, following stimulation, telogen phase hair follicles re-enter hair cycle and new 
anagen follicle grows from the stem cells resting in the bulge region located within middle 
portion, to give a new population of proliferating melanocytes (56;57). 
 
The ‘follicular-melanin unit’ resides in the proximal hair bulb of a typical hair follicle and 
consists of hair matrix melanocytes and keratinocytes, and partly regulated by the dermal 
papilla fibroblasts (58). Unlike the melanocytes in the epidermal melanin unit where every 
single cell is surrounded by approximately 50-60 keratinocytes, every melanocyte in the 
follicular-melanin unit is accompanied by about five keratinocytes in the hair bulb as a 
whole with the ratio of almost 1:1 in the basal epithelial layer next to the dermal papilla 
(59).  In  mice  the  follicular  melanocytes  are  derived  from  pre-melanocyte 
melanoblasts/stem  cells  which  migrate  from  the  neural  crest  and  arrive  at  the  foetal 
epidermis  and  subsequently  migrate  to  the  developing  follicle  in  neonates  via  SCF 
signalling during hair follicle morphogenesis to subsequently reside in the hair bulge/sub 
bulge region (53;60). Typically, these pigment cell sub-populations differ from epidermal 
melanocytes by being larger, more dendritic and by producing larger melanosomes after 
they have reached their respective distinct anatomic compartments of hair bulb (61) 
 
Hair bulb melanocytes are activated cyclically, with melanogenesis being tightly coupled to 
the hair growth cycle (62) (Fig 1). Hair  grows throughout a finite period of hair shaft 
formation (anagen), followed by a brief regression phase that results in the apoptosis-driven 
resorption of up to 70% of the hair follicle and when the majority of melanocytes die off 
following the hair bulb regression (catagen), and by a relatively quiescent period (telogen) 
when the transient portion of the hair follicle disappears (reviewed in (58)). Although the 
hair  bulb  melanocytes  generate  cyclically,  the  hair  bulb  melanocyte  system  has  been 
perceived as self-perpetuating. Therefore, although fully differentiated melanocytes in the 
hair  bulb  undergo  apoptosis  during  catagen  and  are  removed  from  the  regressing  hair  
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follicles (63), some less-differentiated melanocytes appear to survive in catagen phase (64). 
 
The  ‘‘re-differentiating’’  melanocyte  of  early  anagen  is  likely  to  be  a  newly  recruited 
immature melanocyte derived from a melanocyte reservoir stem cell located in the bulge 
region (Fig 1). Using a TRP2-lacZ transgenic mouse model, Nishimura et al revealed that 
melanocyte stem cells are not only immature, but also slow cycling, self-maintaining and 
are fully competent to regenerate progeny at early anagen, following hair cycle initiation. 
These cells not only provide the source of re-differentiating melanocytes in the hair bulb, 
but also have the capacity to enter vacant niches, including via migration to, the epidermis 
(53). Interesting, by investigating the effects of hair cycle phase on BCC tumourigenesis 
induced by radiation in mice lacking one Patched allele (Ptc1neo67/+), Mancuso et al, 
revealed  that  early  anagen  of  hair  cycle  irradiation  was  highly  susceptible  to  tumour 
induction (65). Moreover, tumour histology demonstrated a qualitative difference in BCC 
tumourigenesis, depending on hair growth phase at the time of exposure. An association of 
tumour and follicular outer root sheath of anagen skin was also revealed by examination of 
anatomic  and  immunohistochemical  relationships.  These  results  confirmed  the  role  of 
follicular  bulge  stem  cells  and  their  progenies  with  high  self-renewal  capacity  in  the 
formation of basal cell tumours (65). 
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Figure 1: Typical structure of the hair follicle and the cycle of hair follicle development. 
The lower portion of a typical follicle (the base to the insertion of the erector pili muscle) is 
a  transient  portion  in  anagen  that  regresses  in  catagen;  the  middle  portion  where  the 
follicular melanocyte stem cells reside, the part between the insertion of erector and the 
sebaceous duct; the upper portion extends from the duct to the epidermal surface (modified 
from  Nishimura  et  al,  Nature  416:  854,  2002).                                          .                      
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1.2.4.  Melanocytes and pigmentation 
The hair, skin and its pigmentation protect the body from harmful UVR, electro-magnetic 
radiation and other environmental insults such as physical, chemical and biological factors 
(25;66-69). In this highly complex regulation, a study by Bohm et al, demonstrated that 
one important molecule was a-MSH which regulates UVB induced apoptosis of human 
melanocyte. a-MSH not only induces photoprotective melanin synthesis but also reduces 
UVR induced DNA damage to protect skin from harmful UV radiation (66).  
 
The pigmentation is produced by resident epidermal dendritic cells, the melanocytes, which 
are neural crest-derived cells and differentiate from melanoblasts which actively migrate 
during development to their final destinations including the eye (choroids), the mucosa 
lining, the upper aerodigestive tract, the anorectal region, the inner ear and the skin where 
they terminally differentiate (70-73). The only pigment cells not arising from neural crest 
precursors are those of the retinal pigment epithelium (RPE), iris and ciliary body which 
are derived from epithelial cells in the optic cup (1). As revealed from studies of mostly 
murine models, follicular pigmentation is under complex genetic control involving more 
than 150 alleles at over 90 loci (74;75). 
 
1.2.5. Differences between melanocyte development in mouse and human skin  
In  general,  the  structure  and  histology  of  mouse  and  human  skins  are  quite  similar. 
Melanocyte  developmental  biology,  however,  is  obviously  different  between  these  two 
species.  Unlike  human,  mouse  inter-follicular  melanocytes  decline  from  birth  —fewer 
melanocytes  were  present  at  day  four  in  the  epidermis  and  non-follicular  epidermal 
melanocytes could not be detected at day eighteen after birth —and epidermal melanocytes 
are localised to the follicles where they increase after the birth for about two weeks and 
decline as the hair growth ceases on progression from anagen to catagen (56;57). Thus, 
most proliferative murine melanocytes are located in the follicles and protected from UV 
radiation  —hence  studies  revealed  that  UV  treatment  initiates  and  promotes  various  
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tumours  including  SCC,  BCC,  papilloma  and  fibrosarcoma  but  little  melanoma  (76). 
Indeed, the adult mouse skin is almost devoid of melanocytes except during the anagen 
phase  of  the  hair  cycle,  which  can  be  induced  following  environmental/experimental 
stimulation (e.g. hair plucking) when melanocytes arise from the melanocyte stem cells. 
Because there are few interfollicular melanocytes when the skin is in the resting telogen 
phase,  it  is  very  difficult  to  induce  melanoma  by  chemical  carcinogenesis  and  UVR 
exposure in the mouse (57;57). Thus, in contrast to the other tumour models, the mouse had 
not  been  a  good  model  for  studying  melanoma.  This  has  now  changed  by  employing 
transgenic and gene knock out/in technologies (1-3;23;77-82) that allow modelling various 
pathway defects and couple to UV exposure.   
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1.3. Introduction to melanoma 
1.3.1. Incidence of melanoma 
The  number  of  melanoma  cases  worldwide  is  increasing  faster  than  any  other  cancers 
(review  in  (83-85)).  Between  2  and  3  million  non-melanoma  skin  cancers  and 
approximately 132,000 malignant melanomas occur globally each year. Alarmingly, it is 
estimated that there are 4500 melanoma cases attributed to the estimated 10% decrease in 
ozone levels world-wide (24). Although excellent prevention and early diagnosis education 
programmes have levelled out the melanoma incidence in the past years, Australia still has 
the highest melanoma incidence with a lifetime risk of currently at 1 in 29 (86). In the 
USA, the incidence has increased 2000% since the 1930s and stands at a lifetime risk of 1 
in 62 in 2005 (24). In the UK melanoma incidence increased from 1.7 to 8.0 for men and 
3.1  to  9.7  for  women  respectively  per  100,000  population  from  1971  to  1997;  and  in 
Scotland from 1979 to 1998, the age-standardized incidence rose three fold for male and 
two fold for females per 100,000 population (21;83). 
 
1.3.2. Risk factors in general 
The exact aetiology of melanoma currently remains unknown, however, it is commonly 
considered  a  multifactorial  disease.  Many  different  factors  including  genetics  and 
behaviour  are  believed  to  predispose  an  individual  to  an  increased  lifetime  risk  of 
melanoma development. Major host factors include a family history of skin cancer, i.e. 
susceptibility genes; the number and type of nevi, and skin type/pigmentation have also 
been  identified  to  give  an  individual  and/or  combined  contribution.  An  association  of 
melanoma and exposure to UVR has been extensively reported and UVR is now believed 
to  be  the  most  causal  environmental  factor  contributing  to  increased  melanoma  risk 
(30;38;40;42;66;68;69;77-79;87-103).  Those  people,  with  fair  skin,  blue  eyes,  light 
coloured  hair,  many  moles,  freckles  and  who  burn  rather  than  tan,  especially  during 
childhood or who genetically have a family history of skin cancer, have a significantly  
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higher risk to develop melanoma in their life time than those people who have dark skin, 
brown eye, fewer moles, non-family history of skin cancer or are well protected from UVR 
exposure (24).  
 
1.3.3. UVR contribution to melanoma 
UVR can cause both non-melanoma skin cancer and fatal cancer of malignant melanoma. 
The extensive studies of an association of UVR and melanoma revealed that UVR causes 
melanoma through DNA damage, escape from cell growth arrest leading to failed DNA 
repair,  resistance  to  apoptosis  and  re-entry  into  the  cell  cycle  resulting  in  deregulated 
proliferation (23;106-109). Since VJ McGovern suggested an association between UVR 
and  melanoma  back  in  1952  ((104)  reviewed  in  (23)),  the  relationship  of  UVR  and 
melanoma has been extensively studied and therefore, UVR is now believed to be the most 
important environmental factor to the increased risk of melanoma although some cases (i.e. 
vulva melanoma) are apparently not linked to the UVR (105). 
 
There are accumulating evidences to show an association of UVR, specifically intensive 
episodic exposure during childhood and an increased incidence of malignant melanoma 
(35-38).  Such  an  association  has  also  been  proven  by  a  transgenic  model  employing 
metallothionein-gene promoter to force HGF/SF over expression in skin melanocytes and 
keratinocytes.  UV  irradiation  of  mice  at  age  3.5  days,  6  weeks  or  both,  showed  that 
melanoma development following UVR at both day 3.5 and 6 weeks was indistinguishable 
from that seen in single dose irradiation at day 3.5, whereas single dose irradiation at 6 
weeks resulted in  no melanoma development (40). Also recently, a single low dose of UV 
exposure on mouse pups aged 2-3 days produced malignant melanoma with a penetrance of 
57% within 12 month. Hacker et al, confirmed that neonatal UV exposure is critical for 
malignant melanoma induction, whilst H-Ras alone transgenic mice failed to produce any 
melanoma (39).   
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The neonatal melanocyte is more susceptible to UVR induced transformation than adult 
melanocyte, however the exact mechanism is unclear, but may derive from population of 
immature and not fully differentiated melanoblasts/stem cells with proliferative potential, 
still  located  in  newborn  skin  epidermis  (as  in  human  skin)  unlike  in  adult  the  fully 
differentiated melanocytes which are invariably located in the papillary dermis in adult 
dorsal skin where the cells are better protected. Therefore, UVB exposure at the neonatal 
stage  (children  in  human),  accelerated  the  development  and  increased  the  risk  of 
melanoma. Thus, WHO suggested that protecting children from sun burn is a good sensible 
and practical way to prevent melanoma development in their later life, especially those who 
have a family history of melanoma and thus may carry melanoma susceptibility gene(s) e.g. 
CDKN2A ablation. 
 
1.3.4.  Individual risk factors 
1.3.4.1. Family history 
An association of  family  history and melanoma is a general concept (88). There is no 
significant histological difference between familial and sporadic melanomas. Possibly due 
to  the  increased  awareness  of  melanoma  development  among  those  family  members, 
however, familial melanomas have some common factors which include development of 
disease at an earlier age, with a relatively smaller tumour size and lower Clark’s level 
compared  to  sporadic  melanomas  (110).  Familial  melanoma  patients  also  have  bigger, 
more  numerous  nevi  on  the  body  and  are  more  likely  to  develop  multiple  primary 
melanomas,  but  they  display  a  decreased  risk  of  other  non-melanoma  skin  cancer 
development (110;111).  
 
Based on a study of approximately 3000 patients versus 4000 control cohorts from many 
countries, geographically located in wide range of latitudes, thus ignoring the association of  
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melanoma  risk  and  UVR,  Ford  et  al.  revealed  that  first-degree  relatives  of  individual 
melanoma patients had a 2-fold increased risk compared to people without a family-history. 
Such an increased risk was also independent of age, number of nevi, hair and eye colour as 
well freckles (112). Several other studies also support the idea that a family history of 
melanoma stood as an independent high risk factor to the development of melanoma (113-
115).  For  instance,  Begg  et  al  examined  melanoma  incidence  in  the  relatives  of  2508 
patients  in  relation  to  population  incidence  rates,  and  the  authors  concluded  that  the 
relatives of melanoma patients were at a higher risk to develop melanoma, especially where 
relatives had been diagnosed at a young age (116). 
 
1.3.4.2. Number and type of nevi 
The total number of melanocytic nevi on the body, either congenital or acquired, has been 
demonstrated to have a strong association with cutaneous melanoma development whether 
self counted (117) or by examiners. Moreover, this association is not affected by the type of 
nevi (118-126). The evidence to support the relationship of nevi and melanoma is still 
accumulating. After a comprehensive literature search, Watt et al conducted a systematic 
analysis of existing data and analyzed results from eight studies containing a total of 432 
large  congenital  melanocytic  nevi  patients,  the  results  confirmed  that  large  congenital 
melanocytic nevi and total nevi numbers were associated with increased risk of melanoma 
development (127). Data obtained from 295 families unselected by family history and 53 
melanoma-prone families revealed that number of nevi influenced melanoma incidence in 
both families (128). More recent studies involving various numbers of patients and control 
cohorts are supportive for considering the number of nevi on the body as an independent 
melanoma developmental risk regardless of the type of nevi being either benign or atypical 
(113;129-132). In addition to Caucasian populations, in the Japanese, the number of nevi 
was also identified as a high risk factor for non-acral melanoma development but not for 
acral  melanoma  (133).  In  a  study,  a  multivariate  model,  carried  out  by  Nijsten  et  al  
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revealed that people with three or more atypical nevi were at a more than 10-fold increased 
risk of developing malignant melanoma compared to those without atypical nevi (134). 
Richtig et al, found 35.3% of ocular melanoma patients had more than 5 dysplastic nevi 
compared to only 1.2% in the control cohorts which suggested that more dysplastic nevi 
could  be  among  the  high  risk  factors  for  ocular  melanoma  development  as  well  as 
cutaneous melanoma (135). Thus the total number of nevi (regardless of type) and number 
of dysplastic nevi can both be considered as independent melanoma high risk factors. 
 
1.3.4.3. Other host factors 
In addition to a family history of skin cancer and the number/shape of nevi, other host 
factors including fair skin, the colour of eye and hair, freckles, age and sex have also been 
studied as individual risk factors for melanoma development. In general, white populations 
exhibited over a wide range average higher risk for melanoma development and females 
commonly have a higher incidence than males while non-white populations displayed a 
much lower incidence of melanoma development (94;136). Red hair conferred a two fold 
increased risk, which was not affected by adjustment for freckling, the number of nevi or 
skin  colour.  Light  skin  colour,  light  eyes  and  extensive  freckling  also  showed  an 
association with increased risk of melanoma development (130;137). Cho et al revealed 
that older age or light hair colour was each associated with significantly elevated risk of 
melanoma (113) and studies from Nijsten and Strouse et al confirmed age is also among 
those high risk factors of melanoma development (134;138). 
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1.3.5. Summary of incidence factors 
The actual aetiology of melanoma development varies among different cases and individual 
studies initiated by different consortia that took into account many risk factors, revealed 
that a conglomerate of individual factors were associated with melanoma risk. Among all 
factors, UVR is the most intensively studied and is now believed to be the most important 
environmental aetiologic factor. The strongest evidence for this conclusion comes from the 
broken increasing trend of melanoma incidence in children in Sweden and the stabilized 
incidence of invasive melanoma among those people younger than 35 years, who were 
born when the Queensland Melanoma Project was launched in early 1960’s. Each host 
factor, including susceptibility genes, family history of melanoma, total number of nevi 
and/or  dysplastic  nevi,  type  of  skin,  eye  and  hair  complexion,  age  and  sex,  could  be 
identified as an independent contributor to the high incidence of melanoma development, if 
it was isolated from the other ones for statistic analysis. As an independent melanoma high 
risk factor, however, any of such host factors could ‘co-operate’ with environmental UVR 
due to the common behaviour within the same family and therefore, the study of defining 
the exact mechanism underlying aetiology of melanoma will be a really complex project. 
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1.4. Genes and Melanoma 
1.4.1. Melanoma genes in general 
Whatever factors cause tumour development, the hallmark is the acquisition of multiple 
genetic defects involving the inactivation of tumour suppressor genes and/or activation of 
proto-oncogenes.  In  cutaneous  melanoma,  non-random  deletions  and  rearrangement  are 
seen in several regions of chromosomes including 1p, 6q, 7q, 9p, 10q, 11q, 12q, 17q, 18q 
and 20q (14;139-144). As mutation or loss of chromosome regions 1p36, 9p21 and 12q14 
occurred at high frequency in cancer prone families, some tumour suppressor genes which 
were located within these deleted regions became associated with melanoma have been 
subsequently identified as familial melanoma susceptibility genes (139;145-147). The most 
intensively studied TSGs involved in melanoma include p53, PTEN, CDKN2A (including 
p16
INK4a and p19
ARF), Kit/SCF, the oncogenes B-Raf, Ras, MITF, as well E-cadherin which 
acts as an anti-invasion gene and switches to N-cadherin expression to facilitate invasion 
through  the  dermal  matrix.  In  addition  to  familiar  melanoma  TSGs,  melanoma 
susceptibility genes such as MC1R, GST and many others, have been reported to modify 
and influence melanoma development. However the molecular mechanism of melanoma 
development is still poorly understood, although it is being intensively studied employing 
many different models. 
 
1.4.2. Ras genes 
1.4.2.1. Ras Family 
It was more than four decades ago that the first Ras member was discovered from the 
observations  of  viruses  causing  tumour  formation  in  mice  (148).  The  viral  genes 
responsible were called ras for rat sarcoma, and subsequently turned out to be mutated 
versions of mammalian genes that encode enzymes with intrinsic GTPase activity involved 
in trans-membrane signalling as molecular turnstiles. Following the discovery of H-Ras, 
later K-Ras (149) and N-Ras were discovered by transfection of human tumour DNA into  
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NIH 3T3 cells (150). These thus form the classic Ras family group of the small GTPase 
superfamily  and  express  closely  related  p21  Ras  proteins  with  similar  transmembrane 
signalling functions. 
 
Ras is a small GTPase, a name to distinguish from the large heterotrimeric GTPases, which 
functions as a molecular switch determined by the binding status of GDP-Ras (guanine 
diphosphate, inactive form) or GTP-Ras (guanine triphosphate, active form). GDP-bound 
Ras proteins are activated by GEFs, a large structurally diverse class of proteins family 
termed for Guanine-nucleotide Exchange Factors, which catalyze the release of GDP and 
then the displaced GDP is rapidly replaced by more abundant GTP to form the active GTP-
Ras form (151). Various GTPase activating proteins (GAPs) also bind to Ras proteins in 
their  GTP-bound  state.  GAPs  act  as  negative  regulators  by  greatly  enhancing  the  low 
intrinsic GTPase activity of the Ras proteins through hydrolysis of GTP to GDP to cause an 
allosteric change of the Ras to the inactive state. 
 
By  cycling between GTP- and  GDP-bound states, Ras proteins switch  their binding to 
effectors  on  and  off.  Well-recognized  downstream  effectors  of  Ras  proteins  are  the 
mitogen-activated  protein  kinase  (MAPK)  signalling  system  including  Raf  kinase  and 
phosphatidylinositol 3-kinase (PI3K), which is a negative regulatory target of the PTEN 
TSG  (152).  Ras-dependent  Raf  activation  promotes  cellular  proliferation  while  the 
activation of PI3K sustains cell survival. The functions of these GTPases are not limited to 
their roles in cell growth, proliferation and cell survival, Ras expression is also involved in 
cell  migration  and  adhesion  by  causing  marked  changes  in  integrin  profiles  (153).  A 
surprising  recent  development  of  Ras  gene  study  has  been  the discovery  that  germline 
mutations can occur in genes encoding Ras proteins and other components (e.g. B-Raf and 
MEK) in these signalling pathways, resulting in developmental defects such as Costello 
syndrome, Noonan syndrome (Fig 2) (154;155) although it is not expected that continual  
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expression of fully activated Ras is not sufficient for complete carcinogenesis, underlining 
the fact that many other molecular steps are needed for progression to tumour formation 
(152). 
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Figure 2: Mutations of Ras Signalling pathway are associated with human diseases other 
than tumourigenesis (modified from Downward J, Science 314 (5798): 433-434, 2006). 
Germline mutations can be occurred in genes encoding Ras proteins and other components 
(e.g. B-Raf, PTEN as well GEFs and GAPs) in these signalling pathways, resulting in 
developmental  defects  such  as  Costello  syndrome,  Noonan  syndrome,  Capillary 
malformation  rather  than  tumour  although  it  is  not  expected  that  cells  are  tolerant  of 
continual expression of fully activated Ras. 
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1.4.2.2 N-Ras 
Human  N-Ras  was  the  third  discovered  member  of  the  Ras  family  being  initially 
recognized in 1982 by DNA transfection of NIH 3T3 cells (150) and almost simultaneously 
isolated from a human fibrosarcoma cell line HT1080 (156), a neuroblastoma line SK-N-
SH  (157)  hence  N-Ras,  and  the  promyelocytic  leukaemia  line  HL60  (158).  Cross-
hybridization to the other cloned Ras genes (H- and K-) implied it to be a member of the 
Ras gene family and  studies with somatic cell hybrids located it to chromosome 1p32 
(156;159). A complete biological functional transforming or activated N-Ras together with 
its normal N-Ras proto-oncogene were isolated from human fibrosarcoma cell line HT1080 
and normal human fetal liver tissue respectively (160). 
 
Sequencing  analysis  concluded  that  N-Ras  encodes  a  189  amino  acid  sequence  with  a 
predicted size of 21-KDa protein and homology to functional human H- and K-Ras genes.  
Comparing the coding sequence of the three genes, it is revealed that N-Ras differs by only 
15% of amino acids and 27% of nucleotides (within the coding sequence) from H-Ras, 
(16% and 24% for K-Ras respectively), but these differences are not evenly distributed 
throughout the whole coding sequence. The first two exons have an almost identical amino 
acid sequence, differing by only 4 amino acids out of 97 whilst the third exon shows a little 
more divergence of 9/53 between N- and H-Ras. The most striking divergence between N-
Ras and the other two Ras proteins are within the 4
th exon (49 amino acids) with a 15 
amino acids difference from H-Ras, whereas 22 positions are different from K-Ras. This 
major  variable  region  is  located  near  the  C  terminus  just  upstream  from  a  conserved 
cysteine residue that is required for post-translational processing, membrane localization 
and transforming activity of the proteins. C terminus of the p21 Ras protein within exon 4 
is necessary and sufficient to anchor the protein on the plasma membrane and the binding 
of lipid through Cys-186 is required for the migration of the protein from its synthesis in 
the cytosol to the plasma membrane (161). It is likely, therefore, that the fourth exon- 
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encoded  domain  of  the  p21  protein  product  of  Ras  genes  may  play  a  vital  role  in 
determining the different functions of three Ras gene products (162). 
 
As indicated above, the location of the introns within the coding sequence is identical for 
all three Ras genes. The sequence and length of each intron, however, are significantly 
different, hence the size of the whole genes are dissimilar. Thus, the K-Ras gene spans 
more  than  35-kb,  whereas  N-  and  H-Ras  genes  span  approximately  only  7-  and  3-kb 
respectively. Furthermore, the structural difference of the Ras mRNAs is also considerable, 
in contrast to the 1.2-kb H-Ras transcript (163), K-Ras produces  a much larger 5.5-kb 
transcript  which  produces  two  subtypes  of  K-Ras  4A  and  4B  by  alternative  coding  of 
fourth  exons  (164;165),  whereas  N-Ras  produces  two  transcripts  of  2.2-  and  5.2-kb  in 
length  (156;158;160).  There  is  no  publication  yet  to  show  whether  these  two  different 
transcripts  of  N-Ras  produce  different  functional  subtype  proteins  as  K-Ras  does  by 
alternative reading frame. 
 
1.4.2.3. Ras mutation in human cancer 
Activating Ras gene mutations are estimated to occur in 25-30% of human tumours. N-Ras 
mutations are common in leukaemia (166) and melanoma, whereas K-Ras mutations are 
almost  ubiquitous  in  pancreatic  tumour  and  also  quite  common  in  lung  and  colorectal 
cancers, whilst H-Ras mutations are found mainly in bladder and kidney cancers (166-168). 
In  many  tumours  where  Ras  gene  mutations  are  absent,  the  Ras  proteins  are  often 
overexpressed  (169;170).  Dysregulation  of  the  Ras  activation  state  also  contributes  to 
human  cancers,  for  instance  many  growth  factor  receptors  and  Ras  GEFs  possess 
transforming properties, whereas both neurofibromin NF1-a Ras GAP or Ras association 
family member 1A (RASSF1A), a putative Ras inhibitor, act as tumour suppressor genes 
(171;172). Often as a counter to oncogenic Ras expression in both primary rodent and 
human cells, a permanent G1 arrest is accompanied by accumulation of p53, p16
INK4a and 
p21
CIP1 (173). Activating Ras mutations are commonly found at codon 12, 13 or 61, which  
  44 
render  the  encoded  GTPase  protein  constitutively  active  and  thus  subsequently  growth 
stimulatory (167). The Ras family of small GTPase proteins functions as a relay switch 
downstream of cell surface tyrosine kinase receptors and upstream in the Ras-Raf-MAPK-
Erk signalling pathway respectively, which transduces various growth signals from the cell 
surface to the nucleus (168) (Fig 2). 
 
The K-Ras mutation studies found that the majority of mutations were at codons 12, 13 and 
61(174-176). These mutations are somatic rather than germ-line and consist of single base-
pair substitution which leads to the single amino acid change. While the wild-type K-Ras 
gene encodes for glycine at codon 12, the most common amino acid substitution was found 
to be aspartic acid most for glycine (46%), followed by valine (32%),  arginine (13%), 
cysteine  (5%),  serine  (1-2%)  and  alanine  (<1%).  Such  mutations  result  in  constitutive 
activation with Ras state in the GTP-bound and cell proliferation (174;175). 
 
  In human, primarily observed Ras mutations are H-Ras gene rather than K-Ras or N-Ras in 
the  cancers  of  urinary  tract  and  bladder  (166).  The  loss  of  abnormal  H-Ras  allele  and 
amplification of mutant H-Ras were also found in aggressive breast cancer (180). One tenth 
of GTPase activating proteinase activity of the wild type H-Ras revealed the role of cell 
proliferative promotion by H-Ras mutation (179).  
 
  H-Ras can be activated by truncation of a 5' uncoding exon (exon-1) in absence of mutation 
(181) leading to over expression of the normal allele, thus the specific point mutations of 
H-Ras codons may not be necessary for transformation. However, in various chemicals 
(dimethylbenzanthracene-DMBA,  dibenz[c,h]acridine-DB[c,h]ACR  or  benzo[a]pyrene  -
B[a]BP)  induced  mouse  skin  cancer  models  either  by  complete  or  initiation-promotion 
protocols as well in hepatoma model (4-aminobiphenyl - 4-ABP) induced tumours have a 
specific A----T transversion at the second nucleotide of codon 61, the hottest mutation code  
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for the other two Ras alleles (K-, and N-) in human cancers, of the H-Ras gene(182-185). 
The G12V and Q61L versions of H-Ras were initially discovered as the consequences of 
oncogenic mutations in H-Ras genes and later shown to result in a constitutively active 
form  of  H-Ras  (165;177).  G12E  mutation  of  H-Ras  was  revealed  by  analysis  of  nine 
mammary carcinomas induced by a single injection of nitroso-methylurea into 50-day-old 
Buf/N female rats, contained a transforming H-Ras-1 gene (178). And in human, analysis 
of primary SCC and BCC occurring on sun-exposed body sites for mutations in codons 12, 
13,  and  61  of  H-Ras  revealed  that  there  were  46%  SCC  and  31%  BCC  harbouring  a 
specific mutation at the second position of H-Ras codon 12 (GGC----GTC), predicting a 
glycine-to-valine amino acid substitution (186). Such an unusual high incidence for H-Ras, 
possibly  reflected  the  Caucasian  population  employed  in  this  Texas-based  study,  is  in 
conflict with the previous study (187) and a latter study carried out by Campbell et al in 
which the authors are capable to detect 4-8% of the total alleles of Ras mutation, while 
there is no mutation at all in all screened BCC and SCC samples (188). 
 
N-Ras mutations are primarily detected in Leukaemia (166), but also detected in many 
other diseases including melanoma (see below), non-melanoma skin cancer, brain cancer, 
stomach  cancer,  myelodysplastic  syndrome,  thyroid  cancer,  embryonic  lung  cancer  and 
rhabdomyosarcomas (187;189-195). In malignant melanoma, various reports cite a high 
mutation rate of N-Ras which remained the hottest mutated and most studied gene (9;196-
201) until the discovery of the B-Raf V600E mutation (200). In melanomas, as with N-Ras 
activation in the human fibrosarcoma cell line HT1080 (160), sequence comparison with 
normal alleles showed only one base pair difference at codon 61(202). Both functional and 
genetic  evidence  indicate  that  B-Raf  and  N-Ras  act  linearly  in  the  signalling  pathway, 
which  is  confirmed  by  almost  mutual  exclusiveness  of  mutations  in  these  genes  and 
consequent Erk activation (200;202-204). 
1.4.2.4. N-Ras mutation in melanoma  
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In melanoma it is the N- allele of Ras family activated typically via mutation at codon 61. 
Initial reports of association of N-Ras and melanoma suggested a mutation frequency of 
approximately 5-10% (205;206) but later studies have shown that the frequency was higher 
than previously thought. Ball et al showed up to 69% N-Ras mutations at codon 61 in 
malignant melanoma (207), whereas the other detectable mutation rates are various from 13 
to  46%  employing  different  type  and  number  of  analysed  samples  (9;196-201;208). 
Comparing sequences of both the active and inactive alleles at the very first time of N-Ras 
gene isolation, the only difference detected between two alleles was a C to A transversion 
at codon 61 which results in an amino acid alteration of glutamine (CAA) in the normal 
gene to lysine (AAA) in the transforming allele (160). This result indicated that N-Ras 
mutations of codon 61 could be the major target to constitutively activate N-Ras protein in 
tumours. The subsequent studies confirmed that codon 61 CAA(Gln, Q)→ AAA(Lys, K) 
and CGA(Arg, R) mutations have such a high frequency, detected in many N-Ras mutated 
melanomas, it suggests a hypermutability phenotype resulting  in a potential hereditary 
predisposition to melanoma development in certain patients (9;197;201;209-211). 
 
In general, point mutations in N-Ras at codon 61 are detected in 20-30% of all melanoma 
cases with slightly higher incidence in metastatic than in primary melanomas. However, up 
to 95% familial melanoma cases which harbour an INK4a mutation have detectable N-Ras 
codon 61 mutation (212-214), indicating that N–Ras mutation (codon 61) in melanoma 
coupled well with INK4a mutation and thus, tumour suppressor gene CDNK2A (p16
INK4a 
and p19
ARF, see below) deficient background mouse was employed to create the recent first 
successful N-Ras transgenic melanoma mouse model (215). Previous models (below) had 
been limited to activating H-Ras expressing transgenic mouse models, which although rare 
in  humans,  such  mutations  could  induce  melanoma  following  chemical  initiation  or 
neonatal  exposure  of  UV  (39;216)  or  on  a  CDKN2A  deficient  background  (217-219). 
Analysis  of  N-Ras  mutation  at  codons  12,  13  and  61  from  both  dysplastic  nevi  and  
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congenital nevi, found no mutation detected in 18 dysplastic nevi, but 28% congenital nevi 
(12/43)  contained  N-Ras  mutation  (9).  A  similar  (19%)  (11)  and  a  very  high  N-Ras 
mutation rate (82%) (220) were detected in congenital nevi by more recent studies, but 
again a low incidence (5.9%) (12) was revealed in common benign nevi. N-Ras mutations 
are thought to occur early in primary melanomas rather than in the metastatic stage and that 
once the mutations have occurred, they persist throughout tumour progression (202), which 
unlike another highly mutated gene B-Raf that mutation frequency is significantly less in 
primary melanoma cases than reported in both nevi and metastatic melanoma (213). 
 
1.4.2.5. Transgenic mouse models of Ras and melanoma 
Although  the  majority  of  Ras  mutations  in  either  melanoma  cell  lines  or  melanoma 
specimens  are  N-Ras,  the  first  melanoma  transgenic  model  of  Ras-mediated  melanoma 
utilized a H-Ras not N-Ras transgene (216). In this model, the 1.3-Kb tyrosinase promoter 
was employed to target the mutated human T24 H-Ras (V12G) oncogene expression in 
pigment-producing  cells  of  transgenic  mice.  There  were  only  two  survived  transgene 
carrying founders which had altered coat colour, deeply pigmented skin with multiple nevi 
but  no  melanoma.  Histopathological  analysis  of  the  tissues  revealed  hyperpigmentation 
and/or melanocytic hyperplasia in the skin, eyes and inner ear. Although the activated H-
Ras transgenic mouse itself failed to produce melanoma, cutaneous melanoma could be 
induced following treatment of UV exposure or DMBA, whilst TPA treatment induced a 
small number of papillomas but no nevi or melanomas. Cell lines generated from those 
induced melanomas showed chromosomal abnormalities of homozygous or partial allelic 
deletions  in  the  region  of  chromosome  4  where  the  CDKN2A  gene  resides  to  express 
p16
INK4a and p19
ARF (221;222). Subsequently, a transgenic mouse model of spontaneous 
cutaneous melanomas was successfully generated by expressing activated H-Ras (V12G) 
on an INK4a-deficient background (217). Further by using Tet on/off switch system, the 
first  conditional  mouse  melanoma  model  was  successfully  generated  and  the  results  
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revealed  that  the  melanoma  genesis  and  maintenance  were  strictly  dependent  upon 
expression of H-Ras V12G, but again this model was also required to be produced on 
INK4a  deficient  background  (223),  hence  the  attempts  in  this  study  to  investigate  if  a 
similar but separate requirement for another TSG, PTEN, loss existed. To investigate the 
molecular targets of UV's mutagenic actions, a melanoma model driven by active H-Ras 
and  loss  of  p19
ARF  function  was  generated.  In  this  model,  UV  accelerates  melanoma 
formation  and  moreover,  all  UV  exposure  induced  melanoma  harbouring  p16  loss  and 
CDK6 amplification which identify components of the Rb pathway as critical biological 
targets of UV-induced mutagenesis in the development of murine melanoma in vivo (224). 
 
All  mouse  melanoma  models  described  above  involved  activated  H-Ras.  In  human 
cutaneous melanoma, however, a predominantly activated Ras gene is not the H- but N- 
allele (specifically Q61K), and only very recently has an N-Ras mouse model more closely 
mimicking the human disease been successfully produced. This transgenic mouse model 
was generated by targeting expression of activated human N-Ras (Q61K) to the melanocyte 
lineage  through  embryonic  development  by  a  similar  tyrosinase  regulatory  sequence 
employed in Chin’ model and again, to engender the appropriate phenotypes (see section 
4),  this  was  performed  in  a  CDKN2A  deficient  background.  Additional  investigations 
revealed that fibroblast growth factor 2 (FGF2) was not essential for melanoma progression 
and  metastasis  in  such  a  CDKN2A  deficient  N-Ras  induced  mouse  model  (215;225). 
Hence, given that PTEN is the second most frequently mutated TSG in melanoma after 
p16/p19 (see below), with intimate links to p53, prior to these Ras models, this project had 
commenced to analyse the effects of inducible PTEN loss for similar responses to that of 
p16/p19  knockout.  But  as  outlined  below,  this  study  found  an  apparent  redundancy  of 
PTEN functional loss with N-Ras expression and the induction of an apoptotic mechanism 
which is sensitive to a pathway of early N-Ras activation as well as to PTEN functional 
loss that compensates to its normal PTEN function.  
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1.4.3. PTEN 
1.4.3.1. Biology of gene 
The second most commonly deleted TSG in melanoma (226), PTEN  (Phosphatase and 
Tensin homolog deleted on chromosome Ten) was named based on function, sequence and 
location on chromosome. Mapping of homozygous deletions on chromosome 10q23 led to 
the virtually simultaneously isolation and identification of PTEN gene in 1997 from two 
groups giving the additional name of MMAC1 for mutation in multiple advanced cancers 
(227;228), while a third group identified the same gene a few months later in a search for 
new dual-specificity and epithelial cell-enriched phosphatase and named it TEP-1 for TGF-
beta-regulated and epithelial cell-enriched phosphatase (229). 
 
The PTEN gene is approximately 50-kb in size containing 8 introns and 9 exons to encode 
a 403 amino acid protein. PTEN was initially identified as a TSG because PTEN loss in the 
vast  majority  (>90%)  of  human  glioblastoma.  These  initial  studies  also  indicated  that 
10q23.3 abnormalities were commonly mutated in multiple advanced cancers, hence the 
appellation MMAC1 (above). There is seen 99.75% homology of the amino acid between 
human and mouse suggesting it represents a highly conserved gene whose regulation and 
activities play important roles in cellular processes (227-229). 
 
Structure  analysis  of  PTEN  gene  has  identified  two  major  domains:  N-terminal 
phosphatase domain from the first amino acid to 185aa and C-terminal domain from amino 
acid 186 to 403 (230-232). The N-terminal phosphatase domain, where PTEN mutations 
mainly  occur,  is  composed  of b-sheets  surrounded  by  a-helices  giving  a  structure  that 
resembles previously characterized protein tyrosine phosphatases and an enlarged active 
site that can account for its ability to bind phosphatidylinositol 3,4,5-triphosphate (PIP3)  a 
major substrate of PTEN. 
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The  C-terminal  domain  was  further  divided  into  three  sub-domains  including  a  lipid-
binding C2 domain, PEST domain and a PDZ domain. The C2 domain including amino 
acids 186 to 351 appears to bind PTEN to the plasma membrane, and it might orient the 
catalytic domain appropriately for interactions with PIP3 and other potential substrates. 
The PEST domain includes amino acids 350 to 375 and 379 to 396, which are critical for 
PTEN stability. Mutagenesis studies demonstrate that phosphorylation of certain serine and 
threonine  residues  S380,  T382  and  T383  within  this  domain  can  modulate  both  the 
enzymatic activity and the stability of PTEN. Protein kinase CK2 is known to be a key 
enzyme that regulates the phosphorylation of this C-terminal cluster of serine and threonine 
residues, which modulates PTEN stability and proteasome-mediated degradation. At the 
end of the C-terminus is a PDZ domain which is important in protein-protein interactions 
thought to play  roles in altering the balance of PTEN effects on potential downstream 
signalling targets (e.g. Akt/PKB  Protein Kinase B), versus some other system, such as 
Rac  signalling.  The  C-terminal  domain  is  composed  of  antiparallel  b-sheets  which  are 
linked together by short a-helices. 
 
1.4.3.2. PTEN gene functions   
PTEN  is  now  known  to  play  major  roles  not  only  in  suppressing  cancers  including 
melanoma  (below),  but  also  in  embryonic  development,  cell  migration  and  apoptosis. 
PTEN is a dual-specificity phosphatase which dephosphorylates protein substrates as well 
as lipid substrates. Thus one primary function of PTEN is to act as a lipid phosphatase in 
the  regulation  of  crucial  signal  transduction  pathways  (233).  Myers  et  al  revealed  that 
enzymatic activity of PTEN is necessary for its ability to function as a tumour suppressor 
because  mutations  in  PTEN  resulted  in  the  ablation  of  phosphatase  activity  (234). 
However,  biological  primarily  relevant  targets  of  PTEN  were  not  phosphoproteins  but 
rather  inositol  phospholipids  (233),  which  was  confirmed  using  several  independent 
patient-derived  PTEN  mutants  which  retained  protein  phosphatase  activity  but  lost  the  
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ability  to  dephosphorylate  PtdIns  (235;236).  The  finding  that  PTEN  dephosphorylate 
PtdIns phosphates leads to a model for how PTEN acts as a tumour suppressor that links 
PTEN to PI3K control (237) and regulation of AKT activity (238) ─a critical pathway 
which  controls  the  balance  between  survival  and  apoptosis  through  many  different 
downstream genes during tumourigenesis (Fig 3). Accumulating evidence has proved that 
PTEN,  as  a  tumour  suppressor,  regulates  cell  survival  signalling  through  the  PI3-
kinase/Akt  pathway.  PTEN  opposes  the  action  of  PI3-kinase  by  dephosphorylating  the 
signal lipid PIP3, a second messenger essential for the translocation of Akt to the plasma 
membrane where it is phosphorylated and activated by phosphoinositide dependent kinase 
(PDK) 1 and PDK2. PI3K activated Ras stimulates several downstream targets including 
the serine/threonine protein kinase Akt,  an important protein involved in many different 
pathways to affect a variety of important cell functions (233;236;239-243). 
 
Recently, using transfected MCF-7 Tet-Off breast cancer cell lines, two different nuclear 
localization sequence mutant PTEN genes were compared with those cells transfected with 
wild-type  PTEN.  Chung  et  al    concluded    that  cytoplasmic  and  nuclear  PTENs  play 
different roles,  that nuclear PTEN is required for cell cycle arrest consistent with binding 
to  p53  (244)  whereas  cytoplasmic  PTEN  is  required  for  apoptosis  and  moreover,  they 
down-  or  up-regulate  different  proteins  respectively.  Their  observations  suggested  that 
nuclear-cytoplasmic portioning regulates the cell cycle and  apoptosis differentially, and 
nuclear import of PTEN play an essential role during the carcinogenesis (245). Indeed, the 
recently  published carcinogenesis study demonstrated that PTEN loss promotes H-Ras 
mediated  papillomagenesis  via  dual  up-regulation  of  AKT  activity  and  cell  cycle 
deregulation,  but  malignant  conversion  proceeds  through  PTEN-associated  pathways 
requiring TPA promotion (246). This later result being consistent with our findings in this 
study where N-Ras cooperation with PTEN resulted in only papillomas (section 3.9).  
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Germ-line  mutations  of  PTEN  causes  Cowden  syndrome   an  increased  risk  for 
development of tumours in a variety of tissues, and Bannayan-Riley-Ruvalcaba syndrome 
(227;228;231;234;247). Unlike relative high gene ablation often detected in melanoma cell 
lines (248), tissue samples underline that mutations of PTEN are not an essential event in 
the  onset  of  malignant  melanoma  of  the  skin,  but  could  have  an  impact  on  tumour 
progression (249). Although point mutation of PTEN can be less common in some short-
term  cell  lines  (STC,  7%)  and  melanoma  specimens  (1-11%),  over  30%  (up  to  58%) 
samples  revealed  loss  of  PTEN  heterozygosity  (LOH)  (87;101;147;248-258).  Altered 
PTEN  expression  is  common  in  primary  melanoma  and  is  associated  with  aggressive 
melanoma  behaviour  (259).  Indeed,  PTEN  inhibited  the  tumourigenicity  of  B16F10 
melanoma cells in soft agar assay and its anti-metastatic function was also revealed by 
experimental  pulmonary  metastatic  animal  model.  Employing  this  model,  the  authors 
revealed  that  PTEN  tumour  suppressor  protein  inhibits  tumourigenicity  and  metastasis 
through regulation of MMP, IGFs and VEGF expression (260). Also, PTEN deficiency was 
necessary  for  TGF-beta  type  I  receptor  induced  invasive  behaviour  of  SV40  large  T 
immortalised melanocytes (261). PTEN is the second most abnormal TSG in melanoma 
after CDKN2A (250;252) but yet its involvement in melanoma has not been relatively well 
studied in the few models to date nor its functional role(s) well detailed. PTEN co-operates 
with p16 and H-Ras in melanoma both in vivo and in vitro experiments implicated that 
PTEN  involved  in  mouse  melanoma  development  (262).  Thus  in  addition  to  existing 
transgenic mouse melanoma models (e.g. p16, Ras and others), the creation of a PTEN-
melanoma mouse model is useful for complementary/interactive studies. Furthermore, it 
may imply new insights on disease progression and melanocyte development, for instance 
in an attempt to generate a PTEN null mouse model, mice die at the embryonic stage 
demonstrated that PTEN is also essential for embryonic development (243), and PTEN 
deficiency from E12.5 revealed that neurological defects cause premature lethality in these 
mice and PTEN deficiency increases susceptibility to carcinogen-induced melanoma (263).  
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Figure  3:  PTEN  roles  in  cell  signalling  pathways  (Modified  from  B.  Stiles  et  al. 
Developmental  Biology  273:  175–184,  2004).  As  a  lipid  phosphatase,  PTEN 
dephosphorylates  PIP3  to  inhibit  the  growth  factor  signals  transduced  through  PI3K, 
normal cellular physiology. PTEN deficiency thus leads to accumulation of PIP3 that trans-
activates several signalling molecules including PDKs, S6 kinase, mTOR and AKT. This is 
a  well  characterised  molecular  mechanism  that  helps  to  control  the  balance  between 
apoptosis  and  cell  survival  through  downstream  pro-apoptotic  factors  such  as  BAD, 
caspase 3/9 etc. PTEN also inhibits PI3K signalling to trans-activate p53 and to result in 
cell growth suppression which is mediated by its ability to block cell cycle progression in 
the G1 phase through down-regulation of cyclins and up-regulation of the CDK inhibitors 
p21 and p27 expression. 
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1.4.3.3. PTEN and melanoma 
In  the  initial  analysis,  commonly  mutated  in  glioblastomas,  PTEN  mutations  were  not 
detectable in the few melanoma samples (only 4) analysed (227;228) which may reflect 
that  PTEN  mutation  is  less  common  in  primary  melanoma  than  in  cell  lines  (264). 
However, other studies in melanoma cell lines and primary or metastatic melanomas soon 
demonstrated  that  disruption  of  PTEN  by  allelic  loss  or  mutation  contributed  to  the 
pathogenesis of malignant melanoma (147;248;257;258;265). Furthermore, as found for B-
Raf genes (266-269), to date no PTEN abnormality has been observed in uveal melanoma 
unlike in cutaneous melanoma(270). 
 
Considering that gross genetic lesions of chromosome 10 occur in 30-50% of sporadic 
human melanomas, Robertson et al developed an in vitro loss of heterozygosity approach 
in which a wild-type chromosome 10 was transferred into melanoma cells and selected for 
breakage as well for regional deletion. The overlap of these events at band 10q23, the site 
of PTEN location, provided direct evidence that PTEN is a potential target in malignant 
melanoma and furthermore, vectors containing full-length PTEN or mutant PTEN were 
transfected into both PTEN expressing normal and abnormal melanoma cell lines revealed 
that  transfected  normal  PTEN  expression  caused  dramatic  reduction  of  cell  growth  in 
PTEN expressing abnormal parental cells but neither in PTEN expressing normal parental 
cells nor in those mutant PTEN transfected cells (256). Further studies supported a role for 
PTEN  loss  in  the  pathogenesis  of  melanoma  finding  that  while  PTEN  expression  was 
observed  in  benign  melanocytic  lesions,  it  was  lost  in  a  large  proportion  of  primary 
cutaneous melanomas (255).  
 
The synergism of PTEN loss with other genes during melanoma development was also 
investigated. PTEN functions as a lipid and protein phosphatase that down-regulates Akt 
and  MAPK  signalling,  potentially  suggesting  that  Ras  and  PTEN  have  antagonistic  
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functions in both protein and lipid kinase signalling pathways (reviewed in (271)). A useful 
model for elucidating the role of omega-6/omega-3 fatty acid ratio in tumourigenesis, a fat-
1 mice line was recently engineered which can convert n-6 to n-3 fatty acids and have a 
balanced ratio of n-6 to n-3 fatty acids in their tissues and organs independent of diet. 
Implanting mouse melanoma B16 cells into fat-1 transgenic, PTEN gene was significantly 
up-regulated in the fat-1 mice to inhibit tumour growth and formation (272). 60% and 56% 
mutation of B-Raf in cell lines and metastatic melanoma respectively together with 80% 
and 100% PTEN alteration demonstrated a possible cooperation between B-Raf activation 
and PTEN loss in melanoma development (254). P53 and PTEN mutations were always 
accompanied  with  B-Raf  alterations,  while  PTEN  loss  was  found  in  association  with 
CDKN2A  or  P53  mutations  in the  absence  of  B-Raf  activation  (87).  In  examining  the 
biological consequences of Pten and/or Ink4a/Arf deficiency in cells and mice, You et al 
found  that  relative  to  single  mutant  controls,  Ink4a/Arf-/-PTEN+/-  mouse  embryonic 
fibroblast  cultures  exhibited  faster  rates  of  growth  in  reduced  serum,  grew  to  higher 
saturation  densities,  produced  more  colonies  upon  low  density  seeding,  and  showed 
increased  susceptibility  to  transformation  by  oncogenic  H-Ras.  Ink4a/Arf  deficiency 
reduced tumour-free survival and shortened the latency of neoplasia associated with PTEN 
heterozygosity. Compound mutant mice also exhibited an expanded spectrum of tumour 
types including melanoma and squamous cell carcinoma. Therefore, the authors concluded 
that the co-operation of PTEN with p16 and H-Ras in melanoma both in vivo and in vitro 
experiments implicated the involvement of PTEN in mouse melanoma development (262). 
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1.4.4. Kit/SCF 
Kit and its ligand SCF (stem cell factor, also called as Kitl for ligand of Kit, SL or SLF for 
steel factor and MGF for mast cell growth factor) were identified as gene products of the W 
mutant mouse and Sl mutant mouse loci. Both of them are known to play important roles in 
melanoblast/melanocyte survival, migration and differentiation during embryogenesis, and 
may also help to define the melanocyte stem cell niche (53). Loss or significant reduction 
of expression/function of Kit in malignant melanoma indicated that this signalling system 
plays an essential role during melanoma development, possibly at the critical late stage 
transition from RGP to VGP melanoma ((273) and reviewed in (274)). 
 
1.4.4.1. Gene discovery and specificity 
Kit  was  initially  isolated  from  a  feline  fibrosarcoma  and  identified  in  1986  as  the 
transforming gene of the Hardy-Zuckerman 4 feline sarcoma virus termed v-kit (275), and 
soon after its 145-Kd cellular homolog c-kit (thereafter termed as Kit) was cloned and 
sequenced (276). It was virtual simultaneously found that Kit is allelic with the dominant 
white spotting (W) of mice in 1988 (277;278). Whilst the mutations within Steel (Sl) locus 
in mutant mice give rise to a phenotype very similar to mutations in Kit, resulting in the 
discovery of SCF. It was demonstrated that the product of the Steel locus was identical to 
SCF, the ligand for Kit (279;280), hence the name of Kitl. 
 
Four isoforms of Kit have been identified in human while two isoforms occur in mice as a 
result of alternative splicing (281;282), due to alternate use of 5f splice donor sites (283). 
Similarly, alternative splicing of the human SCF pre-mRNA transcript results in secreted 
and membrane-bound forms of the protein and their different/synergism active functions 
during  melanocyte  development  were  also  revealed.  Soluble  SCF  is  required  for 
melanoblast dispersal and initial survival during migration, while membrane-bound form of 
SCF promotes melanocyte precursor survival in the dermis (284).  
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1.4.4.2. The role of Kit/SCF in melanocyte development 
SCF in mammalian skin is generally thought to be an important regulator of melanocyte 
and mast cell survival, migration and proliferation. By analysis of both molecules in wild 
type and white spotting mutant mice, Kit and SCF were shown to play multiple roles in the 
development of melanocyte in murine ontogeny. Functional blockade of Kit by specific 
monoclonal  antibody  illustrated  distinct  Kit  dependent  and  independent  stages  during 
melanocyte development. During mouse skin development, Kit positive cells are present in 
the SCF-producing areas at the time when melanoblasts proliferate and differentiate (285). 
Comparing results of injections of recombinant human SCF and a Kit inhibitory antibody 
K44.2, SCF injection increased, whereas Kit inhibition decreased the number, size and 
dendricity  of  melanocytes.  Expression  of  melanocyte  differentiation  antigens  was  also 
markedly  increased  by  treatment  with  SCF  but  decreased  by  Kit  inhibitor  treatment. 
Increased Ki67-positive (cellular marker for proliferation) melanocytes in the SCF-treated 
tissue and loss of melanocytes with a Kit inhibitor, suggest a direct proliferative effect of 
SCF  signalling.  These  findings  demonstrate  that  the  Kit/SCF  pathway  has  a  role  of 
controlling cutaneous melanocyte homeostasis (286). The data from in situ hybridization 
analysis,  comparing  the  expression  profiles  of  Kit  and  SCF  transcripts  during  mouse 
embryogenesis,  confirmed  that  Kit  and  its  ligand  SCF  complex  (Kit/SCF)  provides  a 
homing mechanism during melanoblast stem cell migration in early development, as well 
as in the late stage development for cell proliferation, differentiation and survival (287).  
 
Employing TRP2 (tyrosinase related protein 2, also referred to as Dct) expression, as a 
melanocyte-specific  marker  probe  to  investigate  the  mechanism  of  SCF  mutation  in 
melanocyte development, the results revealed that the membrane-bound SCF was necessary 
for  the  melanoblast  survival  but  not  the  early  migration  and  initial  differentiation 
(284;288). However, in later studies targeting SCF expression to epidermal keratinocytes, 
the results not only suggested that SCF was involved in melanocyte survival but also that it  
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stimulated the migration and promoted proliferation and differentiation in vivo (60). As 
SCF regulates integrin expression at the protein level and that SCF has pleiotropic effects 
on attachment and migration to extracellular matrix (ECM) ligand, it suggests therefore that 
SCF  could  alter  melanocyte  adhesion  and  migration  involving  ECM  ligand,  to  control 
melanocyte  migration  during  the  development  of  skin  (289).  The  mutations  of  the  Kit 
receptor  tyrosine  kinase  encoded  at  the  W  locus  do  not  alter  early  migration  or 
differentiation of melanoblasts, but rather severely affect survival, crucially up until E11 
and  Kit  plays  an  important  role  for  melanoblast  proliferation  in  later  development 
(290;291). Using lacZ report transgene controlled by the SCF promoter, detected report 
expression in the dermal papillae of the hair follicle also revealed SCF roles to support 
melanocyte growth and development in the hair follicle (292), which is consistent with the 
findings  in  this  study  that  melanocytes  survived  through  the  SCF/Kit  loop  during  the 
papillomagenesis induced by disruption of melanocytes microenvironment (section 4.4). 
 
1.4.4.3. Kit/SCF and melanoma 
A Kit expression-pattern comparison study of normal human and murine skin melanocytes 
versus melanoma cells implied that loss or a marked reduction in Kit gene expression either 
promoted or was a consequence of transformation in melanocyte. While Kit protein was 
readily observed in normal human skin and murine melanocytes, malignant melanoma and 
cell lines established from melanoma samples, or transformed murine melanocytes, did not 
express detectable levels of Kit mRNA or protein (293;294).  
 
Unlike cutaneous melanoma, however, Kit expression was demonstrated in most choroidal 
melanoma tumours (75%) by immunohistochemistry and western blotting analysis (295). 
Whilst  in  acral  lentiginous  melanomas,  Kit  was  strongly  expressed  in  all  cases  where 
melanoma cells grew in the basal layers of the epidermis, but was lost in melanomas which 
grew  in  the  upper  layers  of  the  epidermis  or  vertically  into  the  dermis  (294).  This  is  
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consistent with the findings in this study, that Kit expressing melanocytes were primarily 
located in the basal epidermal layers of the pigmented papillomas, induced to assess effects 
of the microenvironment (see section 3.10). Apart from SCF, however, there is evidence to 
show that additional mast cell growth factors are secreted by fibroblasts and keratinocytes, 
indicating a complex orchestration of several growth factors in the regulation of cutaneous 
growth and differentiation in which SCF plays only one part of this regulation (296).  
 
Kit  loss  or  significant  reduction  in  cutaneous  malignant  melanoma  and  melanoma  cell 
lines, suggested a key role of Kit/SCF during melanoma development. Introduction or re-
activation of Kit and SCF activity in melanoma cells produced several biological responses. 
SCF inhibited rather than stimulated the growth of metastatic melanoma cells as opposed to 
those  observed  in  normal  melanocytes  and  similarly,  and  enforced  Kit  expression  in 
melanoma cells significantly inhibited their growth and metastatic potential in nude mice 
(297). These opposite effects in melanoma cells compared to normal melanocytes may be 
the results of abnormal signal transduction by Kit in response to SCF, given that the loss of 
function of Kit, as well as the enhanced expression of MACM, an adhesion molecule, is 
regulated by transcription factor AP-2, which does not express in metastatic melanoma 
(297;298). Furthermore, melanoma cell lines, particularly those known to metastasize in 
vivo, lose the ability to express membrane-bound SCF-2 isoform but not the soluble SCF-1 
isoform, which indicates that the different expression patterns of SCF isoforms could serve 
as  a  prognostic  markers  for  malignant  melanoma  (299).  The  majority  of  invasive  and 
metastatic malignant melanomas fail to express Kit suggesting Kit has a TSG role which is 
lost  during  melanoma  development  and  indeed  only  2  cases  of  metastatic  malignant 
melanoma (2%) possessed Kit expression (due to a Kit-activating mutation) (300). The Kit 
mutation incidence in melanoma may differ between anatomical sites as well since UVR 
exposure studies found Kit mutation and/or amplification in 39% of mucosal, 36% of acral 
and 28% of melanomas on chronically sun-damaged skin, but there is no mutation detected  
  60 
in melanomas of skin without chronic sun damage (301) similar to previous report (300). 
 
1.4.4.4. Kit/SCF and apoptosis 
The loss of Kit expression in malignant melanoma may allow melanoma cells to escape 
SCF/Kit-mediated  apoptosis  pathway  and  therefore  contribute  to  tumour  metastasis. 
Enforcing Kit expression in Kit-negative, highly  metastatic human melanoma cells and 
subsequent analysis of tumourigenic and metastatic potential, concluded that Kit-positive 
cells produced significantly slower growing tumours and fewer lung metastases than did in 
control cells (273). On the other hand, exposure of Kit-positive melanoma cells in vitro and 
in vivo to SCF triggered apoptosis of these cells but not of Kit-negative melanoma cells or 
normal melanocytes. Similar results were obtained from the analysis of Ewing's sarcoma 
and peripheral neuro-ectodermal tumours (302;303). In contrast to the data obtained from 
metastatic melanoma cells, as expected, SCF removal increased apoptosis significantly in 
cultured neural crest cells (NCC) and further increases were achieved by addition of Kit 
functional blocking antibody to obstruct SCF/Kit pathway during a SCF-dependant period 
(304). 
 
Disruption  of  MITF  in  melanocytes  or  melanoma  triggered  profound  apoptosis  can  be 
rescued by Bcl-2 over expression and, Bcl-2 down-regulation in Kit functional blocking 
induced NCC apoptosis demonstrated that Bcl-2 played an essential role in such a SCF/Kit 
mediated apoptosis (305;306). Data obtained from the melanocyte apoptosis analysis of Kit 
(w-v) and p53 double mutant mice demonstrated that defective Kit signalling in vivo results 
in  apoptosis  through  a  p53-independent  pathway  in  melanocyte  and  mast  cell  lineages 
although by a p53-dependent pathway in male sperm cell apoptosis (306;307) 
 
Fas, a member of tumour necrosis factor superfamily of receptors and an upstream cell 
death inducer in human cancers, functions through recruiting adaptor factor FADD (Fas- 
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associated  protein  with  a  Death  Domain)  which  then  serves  as  a  docking  surface  and 
facilitates auto-processing and activation of other molecules to trigger a caspase cascade (8, 
10) to transduce apoptotic signal (308). It plays an important role in SCF/Kit mediated 
melanocyte/melanoblast apoptosis.  
 
Fas up-regulation was observed in chemotherapy (cyclophosphamide) induced apoptosis of 
hair follicular melanocytes, which confirmed by significant decreasing apoptosis in Fas 
knock-out mice (309). Employing neural crest cell line (NCCmelb4), Kimura et al revealed 
that up-regulation of Fas together with Caspase-8 play an important role in regulating the 
SCF/Kit mediated NCC apoptosis during embryogenesis while other molecules of Bcl-2, 
Erk  and  RSK  (ribosomal  S6  kinase)  downregulated  (306).  Taking  together,  SCF/Kit 
mediated apoptosis related to many factors including molecules on Fas-apoptosis pathway 
(310) as well as anti-proliferation molecules but not in a p53 dependant fashion. However, 
which caspase molecule downstream of Fas induced apoptotic pathway transduces Kit/SCF 
mediated apoptotic signal is not well investigated although caspase-8, a molecule upstream 
of caspase-3 in Fas signalling pathway, activation was revealed.  
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1.4.5. CDKN2A 
1.4.5.1. General biology of the gene 
The  CDKN2A  (Cyclin-Dependent  Kinase  Inhibitor  2A)  locus  located  on  chromosome 
9p21 was identified as a cancer hot spot because of its high frequency of homozygous 
deletion in many cancer cell lines derived from different tumour types (311-313). Two 
different  CDKN2A  mRNAs  have  been  identified  in  several  different  tissues  and  two 
transcripts arise from different promoters (314;315). The a form is identical to the cDNA 
reported to encode the p16
INK4a protein, which inhibits cell-cycle progression by repressing 
the activity of CDK4/6 cyclin complexes via preventing the phosphorylation of pRb (316). 
Its coding sequence is divided into three exons: the first exon comprises 150 base pairs to 
encode amino acid 1 to 50, exon 2 of 309 base pairs which encode amino acids 51-152, and 
a very small exon 3 of only 12 base pairs which encode the last 4 amino acids of 153 to 
156. The b form is identical to a form in exons 2 and 3 but contains a different exon 1 
(exon 1b) which is transcribed from its own promoter. The altered resulting RNA of exon 
1b incorporates exons 2 and 3 and specifies a distinct protein p14
ARF (p19
ARF in mouse) 
because exon 2 is translated in a different reading frame to that used for p16
INK4a, hence the 
name of ARF (alternative reading frame). The b form transcript encodes p14
ARF protein, 
which is entirely different in its amino acid sequence from p16
INK4a (317). 
 
Numerous studies have been performed in attempts to understand the cancer suppression 
activities of p16
INK4a, and the results obtained have shown accumulation of p16
INK4a in 
response to diverse cancer relevant stimuli, including passage in culture, growth at high 
density,  DNA  damage,  oncogene  activation  and  advancing  age  (reviewed  in  (318)). 
p16
INK4a  deficient  mice  develop  phenotypically  normal  but  are  prone  to  tumours  and 
sensitive to carcinogens, which suggest  a little or no role of p16
INK4a   in normal mice 
development  but  instead  serves  to  limit  inappropriate  or  aberrant  cellular  proliferation. 
Polymorphism data of p16
INK4a protein and its susceptibility to UV-induced melanoma in  
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fish suggest that its role in abrogating neoplasia is conserved over a large phylogenetic 
distance while tumour-permissive hypomorphic mutations have also been found in mice 
and humans (319-321). 
 
Mice with exon 1b disruption (p16
INK4a normal) developed tumours indicated that p19
ARF 
functions as a tumour suppressor gene in its own right (322) in human. Furthermore, the 
genetic data collected from human cancers clearly supports and complements the results 
obtained from the mouse (reviewed in (318)). Analysis of cloned cDNA of p19
ARF revealed 
that cell-cycle arrest induced by p19
ARF expression could not be abrogated by D-type cyclin 
expression  (317)  and  displayed  different  functions  from  p16
INK4a  protein  on  cell  cycle 
control (323). p19
ARF was overexpressed in p53-null cells and the tumours obtained in 
p19
ARF deficient but p53 normal mice that suggested a common genetic pathway of p19
ARF 
and p53 (223;322). p19
ARF protein induces cell-cycle arrest or apoptosis, in part either via 
stabilization of the p53 tumour suppressor protein by sequestering murine double minute 
(MDM) 2 oncogene in  the nucleolus, thereby inhibiting its E3 ubiquitin ligase  activity 
(324) or without p53 stabilization and MDM2 relocalization (325). Additionally p19
ARF can 
induce cell-cycle arrest in mouse embryo fibroblasts lacking p21
CIP1 or p53 indicating that 
the protein has p53-independent functions (326). 
 
1.4.5.2. Gene ablation in melanoma 
CDKN2A, as a candidate tumour suppressor gene, was pinpointed to chromosome 9p21 in 
1994 because of deletions in melanoma cell lines and was later identified as a candidate for 
the  chromosome  9p  melanoma  susceptibility  locus  (93;311;313).  Since  then,  genetic 
analysis in ethnically diverse populations have reported a variety of germline mutations in 
melanoma-prone families, in melanoma cases diagnosed at a  young age, or in multiple 
primary  tumours  (reviewed  in  (327)  and  (208)).  In  sporadic  cutaneous  melanoma, 
INK4a/ARF mutations are a less frequent event than reported in those familial melanoma  
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and additionally, its functional loss can also occur through epigenetic mechanisms such as 
promoter  hypermethylation  (328-330).  The  importance  of  p16
INK4a  has  been  further 
reinforced by finding of alterations that target its biochemical partners, that is, CDK4 point 
mutations  inhibit  binding  to  p16
INK4a  or  overexpression  of  CDK6  (331).  In  early  onset 
melanoma cases or a strong familial association with melanoma, the CDKN2A locus was 
found to be ablated in 25–40% of melanoma families (332-337). Analysis of melanoma 
families  in  Scotland  revealed  that  22%  possessed  CDKN2A  mutations,  with  one  new 
mutation of H83N reported (338). Through analysis of 2137 patients from 466 melanoma 
families,  CDKN2A  mutations  were  identified  in  41%  of  families,  of  which  most  were 
p16
INK4a (95%). A strong association between CDKN2A mutations and pancreatic cancer, 
but not neural system tumours, was also revealed (339). Studies of multiple-case families 
have indicated that the lifetime risk of melanoma in CDKN2A mutation carriers is very 
high, ranging from 58% in Europe to 91% in Australia by age of 80 years (340). The risk of 
melanoma in CDKN2A mutation carriers was approximately 14% by age 50 years, 24% by 
age 70 years and 28% by age 80 years in USA (341).  In addition, 75% of melanoma 
samples were found to have CDKN2A methylation to result in CDKN2A function loss at 
the transcriptional level (342). 
 
Cell lines generated from UVB/H-Ras induced mouse melanomas showed chromosomal 
abnormalities of homozygous or partial allelic deletions in the region of chromosome 4 
where the CDKN2A gene resides (221;222) which confirmed that the familial melanoma 
gene CDKN2A  encodes potent tumour suppressor activity, whose loss is necessary for 
melanoma formation. In human melanoma cells, inactivation of CDKN2A locus can lead to 
abrogation  of  both  Rb  and  p53  functionality  through  loss  of  p16
INK4a  and  p19
ARF 
respectively (343). The transfection of UV-damaged DNA into normal mouse fibroblast 
cells revealed that loss of function of either p16
INK4a or p19
ARF reduced the cells ability to 
repair DNA damaged by UV exposure and furthermore, loss of DNA repair ability was  
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independent of the cell-cycle (108). 
 
1.4.5.3. Transgenic melanoma mouse model and CDKN2A 
Interestingly,  although  INK4a/ARF  null  mice  did  not  exhibit  melanoma  susceptibility 
(316), p16
INK4a specific gene targeting can facilitate melanomagenesis, particularly after 
exposure to DMBA, but the majority of tumours were SCC (343-345). Mice expressing 
CDK4 mutation R24C that renders the CDK4 protein insensitive to inhibition by p16
INK4a, 
are  highly  susceptible  to  melanoma  development  following  DMBA  initiation,  which 
mutates Ras and significantly increases penetrance of melanoma in a H-Ras expressing 
model following UV induction (346-348). On a genetic background devoid of CDKN2A 
(INK4a/ARF), a role for CDKN2A in UV-induced melanomagenesis was directly assessed 
by expressing HGF/SF transgene, demonstrating that CDKN2A plays a critical role in UV-
induced melanomagenesis and confirming that sunburn is a highly significant risk factor, 
particularly  in  families  harbouring  abnormal  CDKN2A  gene  (349),  although  loss  of 
heterozygosity of 9p is not confined to melanoma but also detected in other melanocytic 
lesions and other genetic changes (e.g., loss of 10q, 6q, and 18q) may play an important 
role in development of malignant melanoma (14). Employing a p16
INK4a deficient mouse 
model, components of the Rb pathway were identified as being critical biological targets of 
UV-induced mutagenesis in the development of melanoma (224), whilst loss of vascular 
integrity  upon  inactivation  of  Ras  was  revealed  as  an  active  process  rather  than  a 
consequence of loss of cell viability in CDKN2A deficient mouse melanomas (350). 
 
By expressing activated H-Ras (V12G) on a p16
INK4a deficient background a high incidence 
of melanoma was produced within a relatively short latency (217), although in an earlier 
model, activated H-Ras alone failed to produce melanoma resulting in hyperpigmentation 
and/or melanocytic hyperplasia in the skin, eyes and  inner ear (216). Significantly, based 
on previous studies and the data presented in this thesis, all activated  Ras (H- and N- 
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alleles) induced mouse melanoma models (see above 1.4.2.5. Transgenic mouse models of 
Ras and melanoma) to date appear to require an INK4a/ARF deficient background and 
specifically, all Ras induced melanomas were shown to be p16
INK4a null/heterozygous or 
possessed of p19
ARF deficient background (217;224), indicating that a strong synergism 
exists  between  dysregulations  of  MAP  kinase  signallings  which  includes  B-Raf, 
PTEN/PI3K/AKT and p16/p19 mediated.   
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1.4.6. Other genes in melanoma 
Apart from those genes described above, there are many other genes involved in melanoma 
development, such as p53, B-Raf, MC1R, MITF. 
 
The tumour suppressor protein p53 plays a critical role in the orchestration of the cellular 
responses to a variety of genotoxic and cytotoxic stresses. The abrogation of the function of 
p53 is the most prevalent molecular alteration in solid human tumours. However its causal 
involvement in melanoma is still controversial to date. p53 mutation frequency is very high 
in human non-melanoma skin cancers (NMSC) (reviewed in (351)) but relative very low in 
melanoma (352-354). Although the low p53 mutation rate in uncultured specimens may 
indicate that inactivation of p53 is not a critical event in the progression of melanoma 
(reviewed in (355)), UVB induces p53 elevation, although not at mRNA level, in human 
skin (69) presumably in its attempt at a protective role. Results from one study, showed 
UVA  and  UVB-induced  apoptosis  in  a  dose  dependent  manner,  where  wild  type  p53 
melanoma cell lines were much more vulnerable than the mutant cell lines and this result 
suggested that p53 plays a role in UV-induced apoptosis in melanoma cell lines. On the 
other hand, there was little difference in p53 expression patterns between the primary and 
matched metastatic melanomas, indicated that expression of p53 in vivo maybe insufficient 
to  induce  apoptosis  in  melanoma  as  it  does  in  cell  lines,  or  the  p53  pathway  is 
compromised by alternate event in vivo (356). Therefore, one or more genes involved in 
p53 regulation might be the preferred targets ((322;357) and reviewed in (223;355)) and in 
this respect, much attention has been paid to the tumour suppressor gene ARF. The tumour-
suppressor activity of ARF regulates p53 in response to oncogenic signalling or aberrant 
growth by binding and inactivating MDM2 (324;325;358;359). While the ARF-p53 axis is 
inactivated in the vast majority of melanoma cell lines by mutation of p53 or deletion of 
ARF, alterations in these genes are not always mutually exclusive (87;359). Although the 
concept  of  whether  ARF  and  p53  act  in  the  same  pathway  during  the  melanoma  
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development remains open to argument, there is sufficient  evidence to suggest that ARF 
plays its own role as an important melanoma suppressor (see 1.4.5 above; reviewed in 
(355)) via  inducing p53-independent senescence (357). 
 
Of the Raf family of protein kinases, B-Raf is the only member to be frequently activated 
by mutation in cancer. A single amino acid substitution (V600E) accounts for the vast 
majority of mutation and results in constitutive activation of B-Raf kinase function. The 
first evidence of a direct association between Raf gene mutations and human cancers was 
provided in 2002 by Davies H. et al (200). Following this report, more intensive studies 
were performed to detect the B-Raf mutation spectrum in both malignant melanomas and 
relevant pre-malignant lesions. Brose and co-workers identified activating B-Raf mutations 
in 66% of sporadic melanomas of which 90% mutations were V599E (360) (thereafter 
V599E was identified as V600E, reviewed in (361)). Additional research suggested that the 
V600E missense mutation by a single substitution (T→A) may play an important role for 
malignant melanoma development (208;362-367). However as there is no such mutation 
detectable in 42 familial melanoma patient samples, it suggested that this V600E mutation 
is  a  somatic  mutation  associated  with  melanoma  development  and/or  progression, 
occurring in only a proportion of affected individuals (368) an idea confirmed by other 
studies (369;370). A lack of V600E B-Raf mutation in uveal melanoma was first reported 
by Edwards and co-workers in 2003 (371) and later confirmed by other groups employing 
various number of uveal melanoma cases (266-269). Despite a similar high frequency (62-
72%)  of  B-Raf  mutations  identified  in  melanocytic  nevi,  VGP  melanomas,  metastatic 
melanomas and melanoma cell lines (200;360;372), there is only a 10% mutation frequency 
appeared in the earliest stage of RGP melanomas.  This striking contrast result to the high 
frequency  in  other  samples  suggested  that  B-Raf  oncogenic  mutation  correlated  with 
progression of the transition from RGP to VGP and/or metastatic melanoma rather than 
with initiation of human melanoma (373). Alternatively, when B-Raf mutation is an early  
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event  in  the  pathogenesis  of  some  melanomas  it  is  preserved  throughout  tumour 
progression once mutated (212;374), and  some studies suggested that B-Raf mutation in 
melanoma is most likely to occur prior to the development of metastatic disease (363). In 
many  cancer  cell  lines,  B-Raf  expression  is  necessary  to  ensure  tumour  growth  and 
proliferation.  B-Raf  also  leads  to  benign  tumour  growth  and  these  can  progress  to 
malignancy only with additional genetic mutations (review in (375)). Given the established 
involvement of UV exposure in melanoma development, an association between UVR and 
B-Raf  mutation  was  identified  by  mutation  analysis  of  primary  cutaneous  melanomas 
arising  from  UV  exposure  sites  versus  unexposed  sites,  and  revealed  a  high  frequency 
mutation rate (33% and 62% respectively) following UV exposure (73;371).  Conversely, a 
later study suggested that UV light is not necessary required for the acquisition of the B-
Raf(V600E) mutation (10). Although high frequency B-Raf mutation detected in melanoma 
is linked to UV exposure, it is still unclear why B-Raf mutations are preferentially selected 
in melanoma and the mechanism of acquisition of the B-Raf V600E mutation remains to be 
clarified (reviewed in (375)).  
 
MITF  regulates  melanocyte  development,  function  and  survival  by  modulating  various 
differentiation and cell-cycle progression genes. MITF mediates differentiation effect of a-
MSH  (376;377)  by  regulating  expression  of  TYR,  TYRP1  and  DCT  (378-380)  (the 
enzymes that are essential for melanin production), and by controlling genes involved in 
melanosome genesis or structure such as MART1, Silver and GPR143 (OA1) (reviewed in 
(381)). Rab27A has also recently been identified as a new direct transcriptional target of 
MITF,  linking  MITF  to  melanosome  transport  (382)  ─another  key  parameter  of 
melanocyte  differentiation  and  skin  pigmentation,  while  microRNA-137  (miR-137)  has 
been  revealed  to  act  as  a  regulator  of  MITF  expression  and  to  down  regulate  MITF 
expression  in  melanoma  cell  lines  (383).  MITF  is  important  for  the  initial  survival  of 
melanocyte progenitor cells in the proliferation and migration from the neural tube (384).  
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Its relevance in melanocyte stem cells has also been revealed by Nishimura (53), where it 
has been demonstrated that MITF amplification acts as an oncogene in a sub-set of human 
melanomas. Although MITF has been described as a highly sensitive immunohistochemical 
marker  for  melanoma  diagnosis  (385;386)  since  1999,  the  evidence  of  MITF  as  an 
oncogene  came  from  a  study  in  which  B-Raf  mutation  as  well  as  p16  inactivation 
accompanied MITF amplification in melanoma cell lines and ectopic MITF expression in 
conjunction  with  the  B-Raf  mutant  (V600E)  transformed  primary  human  melanocytes 
(387). MITF amplification was found in 12% of analysed melanoma cell lines in keeping 
with 10% in primary melanomas and 15-20% in metastatic melanomas (208;387). MITF 
amplification in metastatic melanoma is also associated with a decrease of five years in 
survival (387). MITF expression in melanoma biopsy is highly variable. In some cases, 
MITF levels are high (i.e. amplification), but in others MITF levels are low or decreased 
(388;389).  Thus,  why  are  MITF  expression  lost/reduced  during  progression  of  some 
melanomas  but  amplified  in  others?  A  reasonable  explanation  is  that  the  fundamental 
differences existed among classes of melanoma and such differences might account for 
such  an  opposite  effects  of  MITF  expression  during  melanoma  progression.  Although 
MITF has been directly implicated in melanoma oncogenesis, its oncogenic activities are 
still poorly understood and the studies of MITF roles in melanoma development have just 
begun (reviewed in (381)). 
 
Different colour of skin and hair are genetically determined by variation in the amount, 
type  and  packaging  of  melanin  polymers  produced  by  melanocytes  and  secreted  into 
keratinocytes. Pigmentary phenotype is genetically complex but up to date, there is only 
one gene, the melanocortin 1 receptor (MC1R), has been identified to explain the variation 
of  skin  and  hair  in  a  normal  population  (reviewed  in  (390)).  MC1R  is  an  unique 
bifunctionally controlled receptor, activated by a-MSH and antagonized by agouti, both 
contributing to the variability of mammalian coat colour (review in (391)). The human  
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MC1R was cloned and located at 16q24.3 (392-394), with most red hair people harbouring  
homozygous diminished-function alleles at the MC1R (33), and not necessarily the null 
phenotype  of  MC1R  (395). a-MSH  protects  UV  radiation-induced  DNA  damage  and 
apoptosis  (66)  and  has  immunosuppressive  effects  in  human  acting  via  MC1R  on 
monocytes and B lymphocytes but not the antigen-induced lymphocyte proliferation (31). 
A recent mapping study in dogs identified another locus, termed K, encodes a member of 
the β-defensin family of antimicrobial peptides (396) and surprisingly,  the product of the K 
locus  promotes  eumelanin  production  by  binding  directly  to  MC1R  and  acting  as  a 
competitive inhibitor of Agouti (397).  
 
The  MC1R  gene  is  remarkably  polymorphic  in  white  populations  (398-400)  and  an 
association of MC1R variants and cutaneous melanoma was revealed in 2000 by Palmer et 
al (401). A relationship between CDKN2A and MC1R in melanoma was established in 
2001  (402;403)  due  to  MC1R  variants  in  addition  to  a  CDKN2A  mutation  that 
significantly  increased  the  melanoma  penetrance.  By  analysis  of  extensive  clinical  and 
epidemiologic data, Goldstein et al., also evaluated the relationship between MC1R and 
melanoma  risk  in  CDKN2A  melanoma-prone  families,  finding  that  multiple  MC1R 
variants are associated with the development of multiple melanoma tumours in patients 
with CDKN2A mutations (404), consistent with previous studies (405-407). An association 
between MC1R and sporadic melanomas was also revealed (406-408), but the study failed 
to establish the relationship of MC1R and ocular melanoma (409). A recent study failed to 
show an association between MC1R variant and melanoma in Italy (410) but it conflicts 
with the previous studies (406;408) which indicated that the differences in melanoma risk 
across geographic regions justify the need for individual studies. The effect of MC1R is 
not solely accounted through hair or skin colour (400) and therefore, additional molecular 
events downstream of MC1R activation, and their effects on melanoma risk need to be 
further studied to understand the causal pathways (e.g.MC1R) of melanoma.  
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There  are  many  genes  involved  in  melanoma  tumourigenesis  and  the  genes  described 
above represent some of the extensively studied. Others including E-cadherin, MDM2, 
VEGF, NF-kappab etc have also been well studied and many other genes (e.g. XPF, GSH, 
BCL-2,  PTPRD,  Apaf1,  Rb  etc)  have  also  been  identified  in  melanoma  cell  lines  and 
primary  melanomas.  To  describe  all  genes  and  their  pathways  involved  in  melanoma 
development is an impossible task, beyond the scope of this thesis. Also, as melanoma 
research progresses, more genes and their functions involved in melanoma development 
will be discovered and elucidated.   
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1.5. Transgenic mouse models for melanoma 
During the past decades, significant progress has been achieved on the investigation of the 
causes  of  many  human  diseases,  which  benefited  from  the  development  of  new 
biotechnologies —one of them being the transgenic animal approach that permits scientists 
to identify and test the causality of specific gene(s) that are involved in certain human 
disease. Identification of an important role for the suspected specific gene in a particular 
disease creates a new dimension of bio-research to understand the molecular mechanism 
that underlies the cause of that disorder. The development of an animal model specific for a 
disease and mimicking the in vivo situation is often a crucial step in this process and recent 
transgenic technology advances have made such an animal model generation easier, more 
rapid and more accurate. Technologies that allow for the addition, alteration or elimination 
of  individual  genes  from  the  genome  to  create  a  transgenic  animal  are  now  widely 
employed in bio-research. Moreover, the advanced inducible gene-switch system allows 
induction of highly localized disease by controlling of the target gene expression under a 
specific  promoter  (e.g.  tyrosinase  in  melanocyte).  Employing  such  an  inducible  gene-
switch system, animals remained disease free until treatment that increases viability and 
minimizes  unnecessary  suffering  as  well  as  to  minimize  the  number  usage  of  animals 
involved in the experiment (3Rs). 
 
Melanoma, one of the most morbid human cancers, is rising steadily and faster than any 
other  neoplasmas,  but  compared  to  other  cancers  there  are  still  relatively  few  useful  
models  available  that  are  able  to  directly  assess  relevant  genetic  causality  and  the 
underlying molecular mechanisms in vivo. To understand the molecular mechanisms of 
melanoma initiation and development, a transgenic mouse model designed to accurately 
mimic  human  melanoma  aetiology  is  highly  desirable  and  the  ultimate  goal  of  these 
studies. Moreover, by generating an in vivo model to mimic human melanoma aetiology it 
may potentially establish a test system to evaluate novel treatment modalities. To study  the  
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genes suspected to be causal in melanoma development, such as CDKN2A, Ras, B-Raf, 
PTEN,  MITF,  MC1R  and  p53,  a  TSG  much  less  mutated  in  melanoma  than  in  non-
melanoma  skin  cancers  (reviewed  in  (411;412)),  transgenic  mice  may  generate  useful 
models  to  elucidate  their  mechanisms  of  melanoma  development.  By  introducing  one 
(215;221)  or  more  (40;215;223;413)  insults  via  breeding  these  models  can  assess 
melanoma  development  as  a  multistage  process  and  take  into  account  melanocyte 
physiology as well. Further, the latest conditional gene switch approaches, which leaves 
animals disease free until inducer treatment activates regulatory transgenes to subsequently 
switch  target  genes  on  (detailed  below)  or  inactivate  TSGs,  will  allow  investigators  to 
explore the temporal causal role(s) in each stage of melanoma development. 
 
1.5.1. General introduction of melanoma transgenic model 
Many  studies  on  the  pathology,  epidemiology  and  genetics  of  melanoma  have  been 
performed and thus, we now know that genetic factors are the most important of the known 
risk factors. The most important epigenetic factor, overexposure to UVR in sunlight, is 
believed to be a contributing factor to at least many cases, even if not all, of melanoma. 
Indeed, even short periods of intensive exposure specifically episodic exposure during the 
childhood, such as sunbathing is associated with a two-fold increase in melanoma risk (25). 
In  mouse  melanoma  models,  either  HGF/SF  over-expressing  or  active  form  H-Ras 
expressing new born pups (2-3 days old) exposed to a single low dosage of UV radiation 
developed  melanoma  in  later  life  (12  months)  (39;40).  However,  the  molecular 
mechanisms of melanoma progression remain relatively unknown despite the fact that the 
worldwide incidence of melanoma is increasing more than any other neoplastic disease 
(1;83-85;414).  
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1.5.2. Advantages of transgenic models 
The development of techniques for the production of genetically engineered mammals was 
initiated by the pioneering microinjection efforts of Lin back in 1966 (415). Since the first 
transgenic animal produced more than two decades ago, many transgenic animal models 
such  as  pig,  sheep,  goat  and  cattle  have  been  generated  to  understand  molecular 
mechanism(s)  of  major  diseases  that  afflict  humanity  and  to  investigate  their  potential 
application  on  agriculture  and  pharmaceutical  industries  beside  the  factor  of  basic 
biomedical  research.  Such  'new'  technologies  that  allow  the  investigators  to  introduce 
specific-disease  related  gene(s)  of  interest  primarily  into  the  mouse  genome  exploiting 
microinjection of DNA into pro-nuclear stage embryos (416;417), or delete gene(s), for 
example TSGs from the genome by homologous recombination in pluripotent embryonic 
stem cells (418), have facilitated the generation of a host of experimental models of human 
disease (review in (419)). The transgenic mouse technology has already had a reverberating 
effect on studies of the aetiology of cancer, skin disease, motor neuron disease, diabetes, 
cardiovasculogy  and  hepatology  etc.  Often,  transgenic  animal  models  have  not  only 
clarified existing hypotheses, but have also implied new insights on disease progression 
and  provided  an  invaluable  starting  point  in  the  search  for  effective  therapies  and 
pharmaceutical production (review in (420)).  
 
To investigate the molecular mechanism of human disease before the advent of transgenic 
mice, previous rodent models were only produced fortuitously as a result of a spontaneous 
genetic mutation. Indeed, phenotypic observation in non-transgenic models sometimes does 
approximate pathological conditions associated with human diseases. However, a major 
caveat has to be mentioned is that the phenotypes obtained from the non-transgenic animal 
models do not often share the same underlying molecular/genetic mechanisms of diseases 
because  such  phenotypes  are  spontaneously  derived  or  disease  has  been  generated  in 
immunodeficient mice where mutated gene did not really mimic the genetic basis. The  
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huge benefit of ability of transgenic technology to add or delete defined human disease 
related genes in animals, has the potential to produce models that accurately reflect genetic 
mechanism of human diseases by defining its genetic basis. In addition, the generation of 
such models enable studies to mimic the in vivo condition of the human diseases more 
accurately than previous non-transgenic models. 
  
The advantages of a transgenic model are many. A main point is that this model can dissect 
downstream processes of the initial genetic event —e.g. the addition or deletion of specific 
defined gene(s) and which ultimately leads to the disease state. Therefore, the model
 can 
provide  strong  evidence  that  a  particular  gene  is  responsible  for  certain  disease 
development. Thus, once identified, events downstream of the specific gene(s) provide a 
wider range of targets for therapeutic intervention.  
 
The  applicability  of  a  transgenic  system  to  molecular  pathology  is  not  limited  to 
recapitulating  a  genetically  well  characterized  malady  but  often  raises  new  concepts 
relating  to  gene  expression  and  gene
  function  in  disease,  which  may  open  up  a  new 
research  direction  of  a  defined  gene  associated  human  disease.  Although  the  versatile 
aspect of a transgenic model is most employed to serve as a proving ground for testing 
hypotheses regarding the genetic mechanism of disease currently (review in (420)).  
 
Moreover,  in  the  most  advanced  inducible  conditional  gene  switch  systems,  where  an 
inducible  tissue/cell  specific  promoter  drives  the  gene(s)  of  interest  (target),  normal 
conditions are maintained until trigged by an active regulator and therefore, the tissue/cell 
specific target gene expression can be controlled on/off by application/removal of inducer 
at specific times, dependant on the  goals of  experimental design. Thus, the genetically 
modified animal remains disease free due to the inducible expression of the causative target 
gene which increases their viability and provides an ability to study multiple insults in vivo.  
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To study the molecular mechanism of multistep-development melanoma (14;19;421;422), 
the conditional gene switch approach provides investigators with a powerful tool to search 
the disease related genetic ablation spectrum in every stage during melanoma development.  
 
1.5.3. Inducible conditional gene switch systems 
Annotating the specific functions and the cooperation of individual genes during cancer 
development in vivo has become the primary task of cancer studies in the postgenome era, 
geared to search for potential novel therapeutic methods and to improve the life quality of 
the cancer patients. In addition to conventional approaches of transgenic and gene targeting 
technologies, the recent development of conditional gene modification technologies has 
provided a real opportunity for elucidating specific gene function and their cooperation at 
the level of genome. To understand the cancer aetiology at the molecular level, tissue/cell 
specific gene modifications in the mouse have been made possible by using site-specific 
DNA recombinases, conditional alleles and tissue/cell specific promoters to tightly control 
the timing and location of individual gene or gene co-expression. The studies have revealed 
novel basic insights for exploitation by the pharmaceutical industry. 
 
The creation of a  conditional gene switch system is based on the SSRs (Site-Specific-
Recombinases)  technologies.  The  most  used  this  kind  recombinases  are  Cre  (causes 
recombination of the bacteriophage P1 genome) and Flp (named for its ability to invert or 
“flip”  a  DNA  segment  in  S.  cerevisiae)  which  are  able  to  recombine  defined  DNA 
sequences with high fidelity without the need of cofactors (reviewed in (423))(424). These 
two  recombinases  have  been  used  widely  and  effectively  to  generate  gene  deletions, 
insertions,  inversions  and  exchanges  in  exogenous  systems  such  as  flies  (425;426), 
mammalian cell culture (427;428) and mice (429;430). Both Cre and Flp can recombine 
DNA at defined target sites, termed loxP (locus of crossover (x) in P1) (431) and FRT (Flp 
recombinase recognition target) (432) respectively, at a very high efficiency (99.98% and 
100% respectively) (427;433) (note:  with 34bp in both recognized sequences, there is only  
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1/4
34 chance to find a same sequences which is far lower than 1/number of genetic base 
pairs of a mouse genome) in both actively dividing and postmitotic cells in most tissue 
types. 
 
A  more  recently  established  Streptomyces  phage-derived  fC31  SSR  is  also  been 
employing for the use to generate genomic recombined mouse model. Unlike Cre and Flp, 
fC31 SSR mediates recombination only between the heterotypic sites attB (34bp length: 
CGCGCCCGGGGAGCCCAAGGGCACGCCCTGGCAC)  and  attP  (39  bp  length: 
CCCCCAACTGAGAGAACTCAAAGGTTACCCCAGTTGGGG),  named  for  the 
attachment sites for the phage integrase on the bacterial and phage genomes respectively, 
each containing an imperfect inverted repeats that are likely bound by fC31 homodimers. 
The  fC31-mediated  recombination  occurs  in  a  core  triplets  CAA  sequence  (underline 
indicated in the sequences) within each sites (434). 
 
1.5.4. Mechanism of Cre-and Flp- based gene switches 
Cre and Flp, members of the l integrase superfamily of SSRs, share a common mechanism 
of DNA recombination that involves strand cleavage, exchange and ligation (435). Both 
Cre  and  Flp  catalyze  DNA  recombination  at  the  specific  target  sites,  loxP  and  FRT 
respectively, which are distinguishable at the nucleotide level (below) 
 
loxP: ATAACTTCGTATAATGTATGCTATACGAAGTTAT 
  FRT: GAAGTTCCTA TTCTCTAGAAAGTATAGGAACTTC 
 
However, both loxP and FRT share an overall structure which includes two 13-bp unique 
inverted  repeats  sequences  (one  base  pair  exception  not  inverted  in  FRT,  bold  red 
indicated), separated by a 8-bp asymmetric core sequence (or called spacer). Cre and Flp 
recombinases defined DNA with the same catalytic mechanism in a gene-switch model. In  
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the presence of two target sites, recombinase monomers bound to the inverted repeats to 
promote DNA synaptic complex formation and recombination between two sites (436), 
whereas strand cleavage, exchange and ligation occur within the spacers (437). Because of 
spacer asymmetry, strand exchange is possible only when target sites are connected by 
synapsis in one orientation (438). Consequently, the relative orientation of target sites with 
respect to one another determines the outcome of recombination: Cre/Flp either excises a 
circular  molecule  from  between  two  directly  repeated  target  sites  and  accompanied  to 
integrate a circular molecule into a linear molecule each possessing a target site; or inverts 
the DNA between two inverted sites (Fig 4).  
 
Unlike  gene  inversion,  because  of  the  loss  of  a  circular  reaction  product,  the  excision 
reaction  (Fig4,  left)  effectively  results  in  gene  activation  or  silence  and  therefore,  this 
technique has been employed in mouse models in which either TSG (Conditional Knock 
Out –Cko, e.g. (439) and PTEN function loss in this study) inactivation or activation of 
oncogene preceded by loxP-stop-loxP flank (Conditional Knock In –Cki, e.g. (347) and N-
Ras
lys61  expression  in  this  study)  to  generate  tumourigenesis/developmental  models  of 
defined single/multiple gene(s) expression/silence for basic molecular and pharmaceutical 
studies. 
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Figure 4: Diagram of Cre recombinase to recombine flank DNA. Recombinase reaction 
catalysed by Cre/Flp. Black triangles indicate recombinase recognition sites; black lines 
present chromosomal DNA, with orientation indicated by the letters a, b, c and d. Grey 
ovals  are  recombinase  monomers.  In  the  presence  of  two  target  sites,  recombinase 
(Cre/Flp)  monomers  bound  to  target  sequences  to  promote  DNA  synaptic  complex 
formation and recombination between two sites whereas strand cleavage, exchange and 
ligation occur to result in DNA excision (left panel) or inversion (right panel). Cre/Flp 
excises  a  circular  molecule  from  between  two  directly  repeated  target  sites  and 
accompanied to integrate a circular molecule into a linear molecule each possessing a loxP 
or FRT site to (in)activate the target gene between two target sites for the gene-targeting 
purpose (left panel, gene deletion); or only inverts the DNA between two inverted sites to 
fail to target gene expressing (right panel, gene inversion). 
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1.5.5. CrePR gene switch 
In this study, a gene switch has been employed based on the Ru486 inducible progesterone 
receptor couple to the Cre/loxP system described above. By fusing the Cre recombinase 
gene  with  a  truncated  progesterone  receptor  ligand-binding  domain,  Kellendonk  et  al, 
created  a  valuable  system  for  inducible  gene  targeting.  Here  the  CrePR  fusion  protein 
recombinase  recognises  and  binds  Ru486  (mefipristone),  an  analogue  of  progesterone, 
(440). The CrePR fusion protein, previously sequestered in the cytoplasm then translocates 
to the nucleus where the recombinase functions to either excise critical flank (loxP floxed) 
exon/promoter or whole gene sequences to ablate function, or to excise inhibitor sequences 
(e.g. 'Stop’ cassette) to induce target transgene expression. By using tissue/cell specific 
promoter to drive the regulator Cre half of the gene switch, the floxed target gene could be 
switched on/off only in specific tissue/cell and at a specific time(s) controlled by Ru486 
(inducer)  application.  Therefore,  animals  remained  disease(s)  free  before  inducer 
application and this ability to induce defined temporal and highly localised of target gene 
expression  presents  a  significant  advantage  over  straightforward  transgenic  models,  in 
terms  of  viability  and  the  ability  to  study  multiple  targets  in  tumourigenesis  and  of 
developmental biology. 
 
Thus in this study, with the goal of generation of an inducible Cre-based conditional gene-
switch mouse model for melanoma, two lines of transgenic mouse, regulator and target 
lines each containing half of the gene-switch components, are produced and mated to create 
the complete gene-switch system. The regulator CreP half was coupled to a melanocyte-
specific expression promoter (i.e. Tyrosinase or TRP2 for melanocyte expression) for the 
purpose of controlling the target gene expression in bigenic compound lines, with the target 
half  constructed  to  be  relatively  generic,  harbouring  genes  (i.e.  our  N-Ras  and  EGFP) 
driven by generic promoter such as the CMV promoter and thus be activated by any cell 
specific Cre transgene.  
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1.5.6. Gene (in)activation by Cre/loxP switch 
To conditionally activate a target gene in vivo, a DNA 'Stop' cassette sequence containing 
poly(A) signal is placed between two 'loxP' sites (floxed) and cloned upstream of the target 
gene to stop downstream target gene expression until Cre is activated. Ideally, the 'Stop' 
cassette and target gene should be designed under the control of a general promoter to 
allow the gene to be active in all of the cell types once the 'Stop' cassette has been removed 
by active Cre recombinase. Because of the cloning of upstream 'Stop' cassette,  target genes  
remained  inactive until the regulator Cre activity switches on its expression by excision of 
the ‘Stop’ silencer following application of the inducer, unless the promoter is leaky (e.g. 
Trp2Cre). In contrast, inactivation of a target gene in vivo is achieved by floxing functional 
exon(s),  the  gene  promoter/transcription  elements  or  the  whole  gene,  so  that  the  gene 
remained  functional  until  target  gene  excision  by  Cre  recombinase  following  inducer 
application. 
 
1.5.7. Requirement for transgenic melanoma models 
In  mice  unlike  humans,  inter-follicular  melanocytes  decline  at  birth  and  epidermal 
melanocytes are localised to the follicle where they increase after birth for about 2 weeks 
and decline as the hair growth ceased on progression from anagen to catagen. Thus, as most 
proliferative murine melanocytes are located in the follicles, coupled to the fact that the 
adult mouse skin is almost devoid of melanocytes in the resting phase of the hair cycle until 
the occasional follicles enter anagen when melanocytes arise from their stem cells, it is 
very  difficult  to  induce  melanoma  by  chemical  carcinogenesis  or  UV  exposure  in  the 
mouse (57;76). Therefore, the mouse has not been a good model for studying melanoma in 
the past (2). But despite these limitations, transgenic approaches have been employed to 
generate melanoma mouse models by genetic modification of mouse genome in mouse 
embryo/stem  cells  to  express  customer-designed  oncogene(s)  or  to  ablate  the  certain 
chromosomes locus(es) which is(are) susceptible to melanoma development.  
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The  advantages  of  transgenic  and  conditional  knock-out/in  technologies  have  attracted 
many  researchers  to  put  their  effort  to  assess  the  in  vivo  mechanisms  of  the 
oncogenes/TSGs  during  the  tumour  development.  Thus,  the  first  transgenic  melanoma 
mouse  model  was  generated  by  expressing  simian  virus  40  early-region  transforming 
sequences driven by a tyrosinase, melanocyte-specific promoter in 1991 (441;442) with the 
idea of disrupting the then most famous TSGs p53 and Rb. The SV40 transforming gene, 
however, is not a human melanoma development related gene and therefore, melanoma 
related oncogene transgenic mouse model was developed by expression of activated H-Ras 
following  UV  exposure,  although  H-Ras  alone  failed  to  produce  melanoma  (221;222). 
Taking the advantage of inducible conditional gene-switch system, Chin et al developed 
another  H-Ras  induced  melanoma  model  by  controlling  H-Ras  expression  in  a  INK4a 
deficient  background  (223),  in  which  an  essential  role  of  Ras  expression  in  melanoma 
development was identified. To recapitulate the aetiology of UV causality on melanoma, 
mouse  models  either  over-expressing  HGF/SF  or  activated  H-Ras  were  generated  and 
results confirmed that neonatal UV exposure is critical on melanoma development (39;40). 
Surprisingly, only recently was a mouse model with melanotic and metastatic melanoma 
produced  that  recapitulated  genetic  lesions  frequently  found  in  human  melanoma  by 
crossing  activated N-Ras(Q61K), a hot spot N-Ras mutation in human melanoma, to a 
CDKN2A deficient mouse (215). In this model 90% mice developed melanomas within 6 
months compared to the 25% and 2 months in the previous H-Ras models respectively. 
Searching the literature, there remains few melanoma mouse models available to study the 
molecular mechanism and the causative factors of disease development. Melanoma is one 
of the deadliest diseases with an over-all 5-year survival rate less than 20% in the US and a 
higher survival rate reported in Europe (443-445), where the survival rate is related to the 
histology of tumour, given PDM (primary dermal melanoma) has remarkably prolonged 
survival  compared  with  patients  with  malignant  melanoma  or  PNM  (primary  nodular  
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melanoma) of similar thickness (446;447). Thus, to more accurately mimic the aetiology of 
human  melanoma,  additional  transgenic  models  (specifically  inducible  conditional  gene 
switch models for multi-stage investigation) production is necessary for the investigation of 
molecular mechanism and/or identification of any new biological mediators (new genes, 
new pathways) for drug development.  
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1.6. Aims of the study 
To create a model that avoids rapid melanoma development, mimic the early phases of nevi 
and to model epidermal/dermal junctional pathology of the RGP-VGP transition to mimic 
this vital development step in human melanoma, the inducible gene switch system provides 
a tool for these stage-related investigations whilst allowing the animal to develop normally. 
Therefore, the overall aim of this study was to create inducible transgenic melanoma mouse 
models to investigate the role of genes related to human melanoma development.  
 
1. Oncogenic N-Ras
lys61 was chosen to generate melanoma mouse model because it is the 
allele often mutated in human melanoma rather than H-allele which is less mutated in 
human melanoma but often used to generate mouse melanoma models by other groups.  
 
2. PTEN TSG was introduced into this model to test if this TSG was able to promote N-
Ras  triggered  tumourigenesis,  based  on  its  role  in  melanoma  progression  and  in 
pathological  development  revealed  by  the  other  studies.  PTEN  is  the  second  most 
abnormal TSG after CDKN2A in melanoma, yet its involvement in melanoma has not 
been relatively well studied in the few models to date nor its functional role(s) well 
detailed. 
 
3. The role(s) of inducible N-Ras
lys61 expression and/or PTEN function loss specifically in 
melanocyte during the melanoma development will be investigated. 
 
4. Technically  it  became  necessary  to  optimize  the  primary  mouse  melanocyte  culture 
method for the identification of transgenic expressers and ideally the method should 
allow melanocytes to grow for extended periods without spontaneous transformation, 
which was necessary for the development of an in vitro transformation analysis.  
 
5. Finally,  the  regulation  of  keratinocyte  disruption  on  melanoma  development  will  be 
studied  in  this  inducible  gene-switch  model  to  assess  whether  and  how  does  the 
microenvironment (keratinocytes) of melanocyte effects melanoma development.  
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Chapter 2: Materials and Methods 
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2.1. Materials 
 
2.1.1.   Cloning reagents 
2.1.1.1. Plasmids 
1.  Phagemid vector pBK-CMV to supply the CMV promoter and multiple cloning 
sites (MCS) was obtained from Stratagene Europe, Amsterdam, Netherlands. 
2.  pBS302  plasmid  supplied  ‘loxP-Stop-loxP’  cassette  was  obtained  from  Life 
Technologies, Inc. 
3.  Enhanced Green Fluorescent Protein (EGFP) DNA was cut from pEGFP-1 plasmid 
purchased from Clontech (Takara Bio), USA. 
4.  Plasmids  containing,  CrePR1  or  generic  intron  individually  were  generously 
supplied by Dennis Roop, Bayler College of Medicine, Houston, USA. 
5.  pSL1180 plasmid to provide extra MCS was purchased from Pharmacia (now G.E. 
Healthcare); 
6.  Tyrosinase, Trp2 and the tyrosinase enhancer, N-Ras
lys61 were generous gifts from 
Paul Overbeek, Baylor College and Frederich Beermann, Switzerland respectively. 
 
2.1.1.2. Restriction Endonuclease 
1.  Enzymes from New England Biolabs: Afl II, ApaL 1, Asc I, Eag I, Nde I, Nsi I 
2.  Enzymes from Promega, UK: Apa I, Ava I, BamH I, Bcl I, Cla I, Hpa II, Nhe I,  
Not I, Sal I, Sma I, Ssp I, Xba I 
3.  Enzymes from Invitrogen, Paisley, UK: Bgl II, EcoR I, EcoR V, Hind III, Kpn I, 
Pst I, Pvu II, Sca I, Spe I, Sph I, Sst I and Xho I 
 
2.1.1.3. Other Cloning Enzymes 
DNA  polymerase  I  large  (Klenow)  Fragment  and  Calf  Intestinal  Alkaline  Phosphate 
(CIAP) were from Promega, UK; T4 DNA Ligase and T4 DNA Polymerase were from  
  88 
Invitrogen, UK. 
 
2.1.1.4. Other cloning materials 
Ampicillin,  Kanamycin,  Select  peptone,  Yeast  Extract,  Select  Agar  and  Agarose  were 
purchased from Sigma, UK; 1Kb+ DNA marker; Stabl II and DH5a competent cells were 
from Invitrogen, UK. 
 
Gel electrophoresis tanks, tray, comb and power supplies were purchased from Bio-Rad, 
UK. 
 
2.1.2. Cell culture materials 
2.1.2.1. Reagents  
Fugene-6  transfection  reagent  obtained  from  Roche  (cat  #11815091001);  L-Glutamine, 
Penicillin/Streptomycin, Phosphate buffered saline (PBS) without Ca
2+ and 2.5% trypsin 
were from Invitrogen; basic fibroblast growth factor (b-FGF, F9786), alpha- Melanocyte 
Stimulating Hormone (a-MSH, M7909), Chelex 100 sodium form (C7901), Mefipristone 
(Ru486,  M8046),  G418  (A1720),  Sodium  orthovanadate  (Na3VO4,  S-6508),  N
6,2’-O-
dibutyryladenosine  3,5-cyclic  monophosphate  (dbcAMP,  D0627),  12-O-tetradecanoyl 
phorbol-13-acetate  (TPA,  P8139),  ethanol,  dimethyl  sulfoxide  (DMSO  )  were  obtained 
from Sigma. All other chemicals were purchased from Fisher Scientific. 
 
2.1.2.2. Tissue Culture Media  
1.   DMEM (Dulbecco’s Modified Eagle Medium) and Ham’s F12, foetal calf serum (FCS) 
and normal horse serum were purchased from Invitrogen.  
2.   KBM  without  Ca
2+  plus  component  additives  including:  0.5ml  Insulin  (cc-4021E), 
0.5ml  rhEGF  (cc-4015E),  0.5ml  GA-1000  (cc-4081E),  0.5ml  Hydrocortisone  (cc-
4031E) and 2.0ml BPE (cc-4002E) per 500ml KGM were purchased from Cambrex,  
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UK   
3.   The  in  house  designed  50/50  medium  for  primary  mouse  melanocyte  culture 
comprised:  50%  of  DMEM  supplemented  with  10%  chelexed  FCS  (prepared  by 
treating  FCS  with  Chelex  100  sodium  form  following  manufacture’s  instruction  to 
remove calcium) and 50% KGM with additions of calcium to 0.05mM Ca
2+, 10ng/ml 
TPA and 1ng/ml b-FGF.  
4.   Halaban’s medium for melanocytes culture comprised:  Ham’s F12, 7% horse serum 
plus 2% FCS, 50ng/ml TPA, 5.0x 10
-5M dbcAMP and 1.0mM Na3VO4. 
 
2.1.2.3. Cell lines 
The  B16F1  melanoma  cell  line  was  obtained  from  Ian  Hart,  London  and  originally 
established by Isaiah J. Fidler, MD Anderson Cancer Centre, Houston TX. 
 
2.1.3. Other molecular materials 
2.1.3.1. PCR and RT-PCR reagents 
Taq DNA polymerase ¾Cancer Research UK; 
dNTPs ¾Roche diagnostics; 
10x PCR buffer (500mM KCl, 100mM Tris pH 9.0, 1% Triton X-100, 15mM MgCl2) and 
6x DNA loading buffer (30% glycerol, 0.25% bromophenol blue, 0.25% xylene cyanol FF) 
were prepared in house. 
 
2.1.3.2. Molecular Biology Kits 
From Qiagen Ltd: DNeasy tissue kit (#69504), RNeasy mini kit (#74104), Qiaquick PCR 
purification kit (#28104), Qiaquick Gel extraction kit (#28704), QIAREP Spin miniprep kit 
(#27104),  QIAFILTER  Plasmid  max  kit  (#12262)  and  Endofree  plasmid  mega  kit 
(#12362). 
Stratagene: Absolute RNA mini (#400800)  
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Amersham Biosciences: First Strand cDNA synthesis kit ( #27-9261-01),  
 
2.1.4. Immunohistochemistry and histology reagents 
2.1.4.1. Antibodies 
Santa Cruz Biotechnology:  goat anti-Trp2, goat anti-Kit and goat anti-SCF. 
RDI Research Diagnostics Inc: rabbit anti-K1 and guinea pig anti-K14. 
Vector Laboratories: Biotinylated anti-goat IgG, biotinylated anti-rabbit IgG, biotinylated 
anti-guinea  pig  IgG,  Texas  red  avidin,  Fluorescein  avidin  D,  Texas  red  anti-goat  IgG, 
Texas  red  anti-rabbit  IgG,  Texas  red  anti-guinea  pig  IgG,  Fluorescein  anti-goat  IgG, 
Fluorescein anti-rabbit IgG and Fluorescein anti-guinea pig IgG. 
Cell signal technology: anti-caspase-3 and anti-caspase-9. 
 
2.4.1.2. Other reagents 
Normal horse/goat sera are from Invitrogen, Paisley, UK; 
PBS, Xylene, Ethanol, Haematoxylin, Eosin are from Fisher Sciences. 
PermaFlor, slides and cover slips are from BDH. 
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2.2. Methods 
 
2.2.1. Primary Cell Culture 
2.2.1.1 Primary melanocyte culture 
Mouse  melanocytes  were  isolated  from  neonates  no  later  than  48  hours  old  when 
melanoblasts  are  still  proliferative  prior  to  their  migration  to  the  hair  follicle  papillae 
because later the newly developing follicles make the dermis and epidermis difficult to 
separate leading to fibroblast contaminations. Newborn mice were killed by injection of 
urethane under PPL 60/2929, Schedule 1. The dead mice were soaked in 70% ethanol to 
sterilize  and  the  skin  was  carefully  separated  from  the  mouse  body  using  scissors  and 
tweezers. Following classical protocol, entire skin was stretched on the cover of a 60-mm 
dish to dry for a few minutes to prevent curling when floating on trypsin which inhibits 
separation  of  epidermis  and  dermis  resulting  in  increased  numbers  of  contaminating 
fibroblasts (448). The skin was taken off the dish lid and floated dermal side down on 5ml 
of  0.25%  sterile  trypsin,  overnight  at  4
0C.  The  following  day  the  epidermis  was  then 
stripped off the dermis and epidermal cells (keratinocytes and melanocytes) isolated from 
the cornified layer by gently rocking for approximately 15 minutes in 15ml Falcon tubes, 
containing 13ml DMEM medium with normal 10% FCS. To separate cornified layer debris 
from epidermal cells, the cell suspension was filtered through sterile gauze. Cells were then 
centrifuged for 3 minutes at 1000 rpm and cell pellets were gently resuspended in 5ml 
50/50 medium at 5 x 10
6 cells/60mm dish. Medium was changed 24 hours later to remove 
dead/differentiated cells and primary cells were kept in culture for 3-4 weeks by which 
time  keratinocytes  had  differentiated,  leaving  melanocytes  for  either  transfection  or 
required analysis, with medium changes every 3-4 days. 
 
2.2.1.2. Primary melanocyte culture in Halaban medium 
Epidermal  cell  pellets  isolated  from  new  born  mice  as  described  above  were  also  
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resuspended in Halaban medium (449) comprised of Ham’s F12, 7% horse serum plus 2% 
FCS, 50ng/ml TPA, 5.0 x 10
-5M dbcAMP and 1.0mM Na3VO4, and plated at 5 x 10
6  cell 
per dish as did for cells in 50/50 medium. Cells were washed with PBS at 24 hours post 
plating to remove any dead cells/debris and then replace medium twice weekly as above. 
 
2.2.1.3. Primary keratinocyte culture 
To isolate primary transgenic keratinocytes, newborn K14Cre/N-Ras
lys61 skin was prepared 
as described above and following successful genotyping, which had been performed within 
24 hours by PCR (see below), appropriate transgenic epidermis were pooled and primary 
keratinocytes plated at 5 x 10
6 cells per 60mm dish in low Ca
2+ medium (DMEM, 10% 
chelexed FCS, 0.05mM Ca
2+). The following day, cells were washed with PBS to remove 
dead and differentiating cells prior to adding fresh medium with or without 10
-9M Ru486. 
Cells were harvested 4 days later for analysis of K14Cre mediated N-Ras
lys61 transgene 
expression by RT-PCR. 
 
  
  93 
2.2.2 Cloning of the transgenes 
2.2.2.1. Restriction endonuclease digestion 
For general DNA purification purposes, 5mg DNA was digested in a 50ml total volume 
including:  1-2ml  of  enzyme  and  1x  buffer  (diluted  from  10x  stock)  specified  by  the 
manufacture for each enzyme for 2 hours at 37
0C (except: Sfi 1 at 50
0C, Sma1 at 25
0C and 
Sml  1  at  55
0C  according  to  the  manufacture’s  protocol),  followed  by  agarose  gel 
electrophoresis  and  Qiaquick  gel  purification  to  isolate  the  required  DNA  fragments. 
Where  a  second  digestion  was  necessary,  the  salt  concentration  of  reaction  buffer  was 
adjusted by adding more sodium (or potassium) chloride to create the working conditions 
for the second endonuclease enzyme or the DNA sample was purified using Qiaquick PCR 
purification kit following the manufacture’s instructions followed by the second restriction 
endonuclease digestion. 
 
For  general  diagnostic  cloning  purposes,  1ml  of  Qiaquick  miniprep  kit  isolated  DNA 
solution, together with 2ml of 10x specific enzyme buffer and 0.5ml enzyme was diluted 
with dH2O to 20ml total volume and incubated at 37
0C (occasionally at other temperatures) 
for  one  hour  followed  by  running  a  0.8%  agarose  gel  and  the  DNA  migration  pattern 
analysed to identify correct colonies. 
 
2.2.2.2. Blunt end DNA digestion 
3’ overhanging DNA was blunt ended by T4 DNA polymerase following the manufacture’s 
protocol. Briefly, 2mg restriction endonuclease digested DNA, 5ml buffer, 1.0ml T4 DNA 
polymerase, 0.2ml of 25mM dNTPs (to make 100mM final concentration) was diluted with 
dH2O to 50ml and incubated at 37
0C for 5 minutes to blunt the ends, the reaction stopped by 
adding 2ml of 0.5M EDTA and then DNA purified using Qiaquick PCR purification kit (as 
above). The eluted blunt end DNA fragment was then ready for further digestion or ligation 
as required.  
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To generate blunt ends from a 5’ overhanging DNA, DNA polymerase I large (Klenow) 
fragment was employed following the manufacture’s instructions. Briefly, 1-4mg restriction 
endonuclease  digested  5’  overhanging  DNA,  5ml  reaction  buffer  and  1  unit  Klenow 
fragment per microgram of DNA were incubated in a total volume of 50ml for 10 minutes 
at room temperature, followed by heating at 75
0C for 10 minutes to stop the reaction and 
DNA fragments purified as described above for the subsequent experiments. 
 
2.2.2.3. Dephosphorylation of DNA fragment 
To significantly reduce the ligation background by stopping the self-ligation of the vector, 
DNA dephosphorylation was occasionally necessary. Following manufacture's instructions, 
up to 10pmol of DNA (1mg of 10-Kb DNA = 0.152pmol), 5ml of 10x CIAP reaction buffer, 
0.05 unit CIAP and dH2O added to 50ml, was incubated for 15 min at 37
0C and then 56
0C 
for another 15 min. A second aliquot of CIAP was added into the reaction mixture and 
incubation repeated at both temperatures. To stop the reaction, 300ml CIAP stop buffer 
(10mM Tris-Cl, pH 7.5; 1mM EDTA, pH 7.5; 200mM NaCl and 0.5% SDS) was added 
and followed by DNA purification as described above. DNA is ready for ligation or further 
digestion as required. 
 
2.2.2.4. Ligation and transformation 
Following successful isolation and preparation of both insert and vector, the two fragments 
were ligated using T4 DNA ligase following manufacture’s instructions. A total of 100 
femtomol (fmol) of DNA at 3:1 (molar) ratio of insert: vector,  2ml of 5x ligation buffer, 
0.2 ml T4 DNA ligase (1 unit) and dH2O was added to 10ml, mixed and incubated overnight 
at 16
0C to obtain maximum ligation efficiency. 
 
Plasmid DNA was prepared and screened for correct recombination, via transformation of 
the  ligated  DNA  into  competent  bacterial  cells.  2ml  overnight  ligation  mixture  was  
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transferred into 50-100ml of Stabl II cells for enhanced tyrosinase (Stabl II was developed 
to stabilize DNA sequences containing many single repeats, which exist in the tyrosinase 
enhancer) or more generally into DH5a comptent cells. The mixture incubated on ice for 
30  minutes  followed  by  a  42
0C  shock  for  45  second  and  immediate  transfer  to  ice  to 
incubate  for  a  further  2  minutes.  Following  addition  of  0.9ml  SOC  medium,  the 
transformed cells were incubated at 37
0C for 1 hour in a shaking bath and 0.1ml culture 
medium was spread onto LB-agar plates containing 100mg/ml Ampicillin or Kanamycin 
depending on the antibiotic selection gene in the plasmid construct. Plates were incubated 
overnight at 37
0C for production of colonies. 
 
2.2.2.5. Colony screening 
Single  colonies  obtained  above  were  picked  and  transferred  into  5ml  LB  medium 
containing  either  100mg/ml  Ampicillin  or  Kanamycin  and  grown  overnight  for  DNA 
preparation using a Qiaquick Miniprep kit. Briefly, cells were harvested by centrifugation 
at 1000 rpm for 10 minutes, and resuspended in buffer P1 followed by alkaline lysis in 
buffer  P2  and  neutralized  by  adding  buffer  P3  which  precipitated  protein.  Precipitated 
protein was removed by centrifugation for 10 minutes at 13000 rpm, and the suspension 
containing  plasmid  DNA  was  loaded  onto  columns  and  centrifuged  for  1  minute  at 
maximum  speed  to  combine  DNA  with  silica  membrane.  Filtrate  was  discarded  and 
washing  buffer  was  loaded  into  the  column  to  remove  salts  and  endonucleases  by 
centrifugation  at  maximum  speed.  Plasmid  DNA  was  finally  eluted  from  column 
membrane by adding 50ml dH2O and centrifugation at maximum speed for 1 minute. 
 
Eluted  purified  DNA  was  digested  by  a  series  of  diagnostic  endonuclease  restriction 
enzymes. Following agarose gel electrophoresis, correct recombinants were identified by 
comparing  patterns  of  DNA  gel  migration  with  the  theoretical  map  of  vector  DNA 
fragments with correct insertion. The colonies were confirmed by sequencing to prove that  
  96 
no mutations had occurred during the cloning process. 
 
2.2.2.6. Melanocyte-specific regulator transgene construction 
The regulator is based on the backbone of plasmid pCrePR1 which was generous supplied 
by Professor Dennis Roop (Bayler College of Medicine, Houston, USA) in which fusion 
protein  CrePR1  expression  is  driven  by  the  HSV  TK  promoter  (440).  To  express  the 
CrePR1 fusion protein exclusively in melanocytes, an enhanced tyrosinase promoter (Etyr) 
replaced  the  generic  HSV  TK  promoter.  This  Etyr  promoter  had  been  previously 
constructed in the creation of Etyr.p65, a non–Cre based regulator transgene (Forrow, S et 
al; unpublished) by cloning a 200 bp SSP1 fragment of an upstream enhancer located at 
12kb upstream of the mouse tyrosinase gene (450) into a plasmid vector containing a 1.3kb 
fragment of 5’ mouse tyrosinase promoter sequence (451). The Etyr was released from 
Etyr.p65 and subcloned into pCrePR1 at the Pst1 and Bgl II sites via shuttling through a 
pSL1180 plasmid to create the EtyrCrePR1 regulator transgene (See results section 3.1.1). 
 
To further increase gene expression in transgenic mice, a final version of this tyrosinase 
vector was designed to include a generic intron, which was not in the EtyrCrePR1 (ECre) 
and increases message stability and efficient processing (452;453). To amplify this generic 
intron from pCrePR1 for multiple cloning purposes, two primers were designed: 
 
Fwd: 5'-CTCCTCTAACTAGTAGCTTTAAATTTGC-3' 
   Spe I 
 
Rev: 5'-TTAACAACTGGTACCTCTTGAACTATAG-3' 
     Kpn I 
 
to produce 5' Spe I and 3’Kpn I sites to facilitate cloning into ECre, as the 5’ Spe I site of 
generic intron was compatible to the Nhe I site of the ECre transgene; whilst a Kpn I 
digested generic intron was blunt ended at 3’ by T4 DNA polymerase and ligated to Bgl II 
digested and polymerase I fragment blunt ended ECre plasmid DNA. This final version  
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was named EICre and released for microinjection by  Not  I  digestion of plasmid DNA 
followed by recovery of a 5.6-kb DNA fragment. 
 
Tyrosinase  related  protein  2  (TRP2),  a  promoter  which  is  cited  to  be  stronger  than 
tyrosinase  and  possibly  expressed  in  melanoblast  stem  cells  (53),  was  also  cloned  by 
replacing  the  Etyr  promoter  of  EICre  vector  to  produce  another  melanocyte  specific 
regulator TRP2Cre. It was envisaged that CrePRI driven by the TRP2 promoter would give 
a stronger and wider window of CrePRI expression in transgenic mouse melanocyte. The 
TRP2Cre  regulator  was  cloned  by  cutting  plasmid  TRP2-p(A)  (Paul  Overbeek,  Baylor 
College of Medicine, Houston, USA) (454) with EcoR V and Not I to discard the vector 
p(A). The discarded vector p(A) in TRP2-p(A) was then replaced by the Intron-CrePR1-
p(A) fragment excised from EICre (described above) following digestion of Kpn1/blunt 
ending and Not I (they are compatible to the EcoR V and Not I sites of TRP2 fragment 
obtained from TRP2-p(A) respectively). As described above for EICre, successful colonies 
were  identified  by  diagnostic  restriction  enzyme  analysis  and  the  transgene  DNA 
sequenced to assure no additional mutations had arisen. 
 
2.2.2.7. Construction of transgenic target vectors 
To test the flox-Cre based conditional gene-switch system in cultured melanocytes prior to 
transgenic production, a Cre responsive target vector containing EGFP report sequence was 
created by excising the 'loxP-Stop-loxP' cassette from plasmid pBS302 (Gibco, NCBI data 
base U51223/GI: 1277147), which contained serial stop codes flanked by two ‘loxP’ sites 
(428;429), via digestion of Spe I and EcoR I. This 'Flx-Stop' fragment was then cloned into 
plasmid  pEGFP-N1  (Clontech,  US:  Gene  Bank  access  number  U55762/GI:  1377911), 
which  expresses  EGFP  downstream  of  the  CMV  promoter  by  ligating  with  double 
digestion of Nhe I and EcoR I to make ends compatible with the ‘Flx-Stop’ fragment (Nhe 
I to Spe I at 5’ and EcoR I at 3’ respectively).  
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The resulting vector was further modified by insertion of the generic intron between 'Flx-
Stop'  cassette  and  EGFP  protein  via  digestion  of  Spe  I(5')  and  Kpn  I(3')  to  create 
cmv.stop.EGFP. This target gene remains silent until Ru486 activation of a Cre regulator to 
evict the floxed ‘Stop’ cassette between CMV promoter and EGFP gene. The successful 
cloning  was  screened  and  identified  as  described  above  via  diagnostic  digestion  and 
sequencing. 
 
To construct the oncogenic target transgene cmv.stop.N-Ras
lys61, the mutant form of N-Ras
 
was released from a tk-N-Ras
lys61 plasmid (originally constructed by replacing the CAT 
report sequence from tk.CAT (455) with human N-Ras
lys61 cDNA cloned from the HT1080 
fibrosarcoma cell line (160)), via sequential digestions by Spe I, blunt ending using DNA 
polymerase  I  large  fragment  (Klenow)  and  Apa  I.  In  parallel,  report  target  vector 
cmv.stop.EGFP was sequentially cut with Not  I, blunt ended by  Klenow fragment  and 
digestion of Apa I to remove the EGFP sequence. The two fragments, N-Ras
lys61 (blunt Spe 
I/Apa I) and cmv-stop-intron (blunt Not I/Apa I) were ligated overnight at 16
0C followed 
by transformation, cell amplification and colony mini preparation. To identify successful 
construction,  cmv.stop.N-Ras
lys61  vector  DNA  was  analysed  by  diagnostic  restriction 
enzyme digestions and sequencing as above. 
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2.2.3. Transgenic line production 
2.2.3.1. Transgene DNA preparation 
Following successful construction of the regulator and target vector, endotoxin free DNA 
was prepared to minimize the potential toxicity of DNA and maximise surviving embryos 
following  pro-nucleus  microinjection,  employing  the  Qiagen  Endofree  plasmid  kit 
following manufacture’s instructions. 
 
To  obtain  the  EICre  transgene  regulator  sequence,  a  5.6-kb  band  was  recovered  from 
agarose  gel following  Not  I digestion of the EICre regulator vector  and purified using 
QiaQuick  gel purification kit following manufacture’s instructions. Similarly,  following 
Nsi I and partial Afl II digestions, a 3.5kb oncogenic target cmv.stop.N-Ras
lys61 transgene 
was cut from the agarose gel and purified. Transgene DNA was eluted into embryo transfer 
water (Sigma, #W1503). 
 
Transgene  DNA  concentrations  were  determined  by  running  various  volumes  of  gel 
purified transgene DNA through a 0.8% agarose gel against a series amount of certain 
DNA  marker  rather  than  quantification  by  UV  spectrophotometer  given  the  low 
concentrations  of  DNA  employed.  Transgene  DNA  was  then  diluted  to  the  optimal 
concentration of 1-2ng/ml in  microinjection buffer (5mM Tris, pH7.4 and 0.1mM EDTA) 
and was further purified to remove any possible particles which may interfere with pro-
nucleus microinjection by spinning centrifugation at 13000 rpm through a Ultra free-MC 
0.1mM filter (Millipore, USA). Following this additional purification step, a second agarose 
gel was run to confirm the concentration and quality, i.e. no DNA degradation of transgene 
for pro-nucleus microinjection. 
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2.2.3.2 Transgenic mouse production 
The  transgenic  lines  were  produced  following  the  typical  transgenic  mice  production 
procedures (456) and all procedures were performed in central research facility (CRF) in 
the Glasgow University under Project licence 60/2929 and personnel licence 60/8633. 
 
Briefly, following the preparation of regulator EICre and target stop.N-Ras
lys61 transgene 
DNAs  as  described  above,  1-2ml  transgene  DNA  solution  was  microinjected  into  one 
pronuclei  cell  harvested  from  mice  22-23  hours  after  superovulation.  To  induce 
superovulation, 5 IU PMS (pregnant mare’s serum to mimic follicle-stimulating hormone 
(FSH)), was intraperitoneally injected into a B6/D2/F1 mouse followed by injection of 5 IU 
hCG (human chorionic gonadotropin to mimic luteinizing hormone (LH)), with an interval 
of 46-47 hours. The female was placed in cage with a stud mouse after the injection of hCG 
and was checked for a copulation plug the next morning before harvesting. Microinjected 
embryos were implanted into pseudopregnant mice generated by mating of an ICR females 
and  a  sterile  male  (vasectomized),  which  was  set  while  a  mating  was  setting  for 
superovulating as described above. 
 
Following the birth of transgenic pups, tail tips were removed from 5-6 weeks old mice to 
isolate DNA for PCR genotyping (described below), and positive founders were bred with 
normal C57BL mouse to identify germline transmitters and transgenic expressers. 
 
Following identification of germline transmitters, transgenic neonates were produced by 
crossing transgenic founders with normal C57BL to obtain primary cultured melanocytes to 
be  used  for  identification  of  transgenic  expressers.  To  identify  regulator  expressers, 
primary  cultured  pure  transgenic  melanocytes  were  harvested  directly  and  assessed  for 
regulator activity, cmv.stop.EGFP DNA was transfected and cells were treated with 10
-9M 
Ru486  and  RNA  isolated  using  an  absolutely  RNA  kit  (cat  #400800,  Stratagene  UK)  
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followed by RT-PCR analysis or assessment for positive green cells, as described below. 
The  target  line  (cmv.stop.N-Ras
lys61)  expresser  identification  was  assessed  in  bigenic 
K14Cre/N-Ras
lys61  keratinocyte  via  RNA  isolation  and  RT-PCR  employing  well 
characterized  K14Cre  regulator  to  avoid  difficulties  of  primary  melanocyte  culture  and 
transfection. 
 
2.2.3.3. Tail cutting and genomic DNA isolation 
5-6 week-old weaned mice were briefly anaesthetized to remove approximately 3-4mm of 
tail tip and the wound was cauterised. Tissue was digested in 400ml of DNA extraction 
buffer  (50mM  Tris/HCl  pH  8.0,  100mM  EDTA  pH  8.0,  100mM  NaCl,  1%  SDS  and 
200mg/ml  fresh  proteinase  K)  in  an  eppendorf  tube  at  55
0C  overnight.  To  isolate  tail 
genomic DNA, tail lysates were centrifuged for 10 minutes at maximum speed  to remove 
tissue  debris  and  degraded  protein  and  the  supernatant  was  transferred  into  a  new 
eppendorf  tube  containing  an  equal  volume  of  absolute  ethanol  to  precipitate  genomic 
DNA. Cluster DNA was picked by gently stirring a pipette tip and DNA was left dry in air 
for 1-2 minutes to evaporate any residual ethanol which may interfere in the following 
reaction. Tail DNA was then transferred into a new eppendorf tube containing 400ml dH2O 
to  dissolve.  To  ensure  DNA  was  dissolved  properly,  DNA  solution  was  left  at  room 
temperature or at 55
0C overnight. 
 
2.2.4. Genotyping and identification of excised “floxed” sequences in target transgenes 
Generally, 1ml of tail DNA solution was used as a template in a 25ml reaction volume 
containing 0.5mM reverse and forward primers specific for each transgene (Table 1), 2mM 
Mg
2+, 0.25mM dNTPs and 1 unit Taq polymerase in a 200ml PCR tube. PCR programmes 
for each transgene were pre-optimized by gradient PCR using plasmid DNA (equal to 1 
copy  of  transgene  in  100ng  mouse  genomic  DNA)  to  determine  suitable  annealing 
temperature  for  each  individual  primer  pairs.  The  programmes  for  each  transgene  are:   
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initial DNA denature for 2 minutes at 95
0C, 30 cycles of 30 second at 95
0C denature, 30 
second annealing at 60
0C (K14Cre, EICre), or 45 second at 63
0C (cmv.stop.N-Ras
lys61), or 
60  second  at  64
0C  (PTEN)  and  extension  for  45  second  (K14Cre,  EICre  and 
cmv.stop.NRas
lys61) or 90 second (PTEN) at 72
0C, with a final extension cycle at 72
0C for 
10  minutes.  This  gave  the  following  transgene  specific  bands:  410-bp  K14Cre,  500-bp 
EICre, 850-bp N-Ras
lys61 and PTEN products were 1.1-kb (floxed), 0.9-kb (wild type) or 
1.1-kb plus 0.9-kb (heterozygote) respectively. 
 
To PCR DNA from tissues to identify excision of floxed sequence following application of 
Ru486 and resultant activation of CrePRI fusion protein, DNA was isolated using Qiagen 
DNeasy tissue kit following the manufacture’s instructions and a hot start PCR programme 
was employed given the difficulty of the product detection. PCR programme was run at 
59
0C for 60 seconds annealing, 72
0C for 60 seconds extension. 
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   Table 1: Oligos used in PCR analysis 
Name  Genotyping for  Sequences 
K14Cre.fwd  K14CrePR1  TCATTTGGAACGCCCACT 
K14Cre.rev  K14CrePR1  GATCCGAATAACTACCTGTTTTG 
PTEN.fwd  PTEN knockout  ACTCAAGGCAGGGATGAGC 
PTEN.rev  PTEN knockout  GTCATCTTCACTTAGCCATTGG 
Rosa.fwd  Rosa26  AAAGTCGCTCTGAGTTGTTAT 
Rosa.rev  Rosa26  CGAAGAGTTTGTCCTCAAC 
P1 and P76  N-Ras
lys61 forward  CTAGAATTCCATCAAGCTTAGGA 
P2  N-Ras
lys61 forward  CTAGAATTCGCTGTCTGCG 
P3 and P 28  N-Ras
lys61reverse  TCGCCTGTCCTCATGTATTG 
ECre.fwd  ECre (p29)  ATTGGTGCAGATTTTGTATG 
ECre.rev  ECre(p72)  CATCTTCAGGTTCTGCGG 
P42  cmv.stop.N-Ras  ACACCACAGAAGTAAGGTTCCT 
P61  cmv.stop.N-Ras  CAGAAAACAAGTGGTTATAGATGG 
P62  cmv.stop.N-Ras  TCCCACTAGCACCATAGGTAC 
P66  cmv.stop.N-Ras  TAAATCTGTCCAAAGCAGAGG 
P67  cmv.stop.N-Ras  AAATGTGGTATGGCTGATTATG 
P75  cmv.stop.N-Ras  GTTTAGTGAACCGTCAGATCC 
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2.2.5. RNA isolation and RT-PCR to confirm transgene
 expression 
RNA was isolated from cells and tissue using an absolute RNA mini kit following the 
manufacturer’s  instructions.  Transfected  cells  were  harvested  by  trypsinisation  and 
centrifugation for 5 minutes at 1000 rpm to obtain cell pellet and tissues were homogenised 
using motor-pestle. Briefly, harvested cell pellet or homogenised tissues were resuspended 
in 350ml lysis buffer containing fresh 7ml/ml b-mercaptoethanol. Lysate was spun down 
through a pre-filter column to remove debris, filtrate was recovered to precipitate RNA by 
adding an equal volume of absolute ethanol and the solution was gently mixed by inverting 
the tube. The mixture was loaded onto an RNA-binding column followed by pre-washing, 
DNase digestion and final-washing steps. RNA was finally eluted in a various volumes of 
RNase-free water depending on the number of cells (normally 20-50ml for 2x10
5-1x10
6 
cells) to obtain about 1mg/ml concentration of RNA. 
 
Reverse Transcription (RT) was carried out immediately after RNA isolation to avoid any 
degradation using a First-strand cDNA synthesis kit following manufacture’s instructions 
(#27-9261-01,  Amersham-Pharmacia  Biotech,  UK).  Briefly,  8ml  eluted  RNA  was 
denatured at 65
0C for 10 minutes, chilled in ice for 2 minutes. 1ml of 0.2mg/ml of oligo-
d(T)n, 1ml DTT and 5ml Bulk buffer (reverse transcriptase, dNTPs  and reaction buffer 
mixture) were added followed by one hour incubation at 37
0C creating the cDNA for the 
following PCR amplification. 
 
In a 200ml PCR tube, 1ml of RT product from above was used. Each PCR reaction mixture 
contained 2mM Mg
2+, 0.5mM reverse and forward primers, 0.25mM dNTPs and 1 unit Taq 
DNA polymerase and total volume was adjusted to 25ml using dH2O. PCR was run 35 
cycles at annealing temperature of 62
0C, 57
0C and 51
0C for N-Ras
lys61, EGFP and regulator 
EICre expression analysis respectively.  
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2.2.6. Transfection 
The B16 melanoma cell line and regulator primary transgenic melanocytes were employed 
to confirm biological activity of regulators and target vectors following successful cloning 
and  to  identify  transgenic  expressing  founders  in  transfection  experiments.  Regulators 
and/or target constructs were (co-)transfected into B16 cells to identify functional gene 
switch prior to transgenic production. To confirm regulator transgene expression in vitro 
prior to the breeding to produce oncogenic phenomenon, regulator primary melanocytes 
from  transgenic  mice  were  transfected  with  the  report  DNA  employing  Fugene-6 
transfection reagent. This carrier was identified as the best transfection reagent for both 
melanocyte cell line and primary cells in experiments that compared other DNA delivery 
vehicles (Lipofectin, Lipofectamine, Transit, calcium phosphate) which gave either higher 
toxicity and/or lower transfection efficiency. 
 
2.2.6.1 Transfection of B16 cells 
Routinely, B16 melanoma cells were cultured in minimal essential medium (MEM)/10% 
FCS and medium changed every 3-4 days. These cells were split weekly and plated at 1:50 
approximately  2x10
5  cells/60mm  dish
  in  normal  culture  to  avoid  confluence  as,  once 
confluent, B16 cells die quickly. 
 
Employing cmv-EGFP plasmid DNA as a transfection efficiency positive control and co-
transfection of pCrePRI DNA (CrePRI expression under control of the generic HSV tk 
promoter to allow CrePRI to express in all cells) together with cmv.stop.EGFP plasmid as 
gene switch positive controls, 24 hours prior to transfection, B16 cells were trypsinized and 
seeded at 1 x 10
5/per 60mm dish. Fugene-6 transfection reagent was employed following 
the  manufacturer’s  instructions,  finding  the  ratio  of  3:1  or  3:2  (for  co-transfection)  of 
Fugene-6 reagent to DNA (6ml Fugene-6:2 mg/or 2mg + 2mg DNA of cotransfection) as 
optimum.  
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The  transfection  was  carried  out  as  follows:  100ml  of  serum  free  MEM  medium  was 
aliquoted into a Nunc cryovial subsequently followed by adding 6ml of Fugene-6 reagent, 
tapping the tube briefly to mix the solutions and adding up to 4mg endotoxin free plasmid 
DNA (e.g. 2mg of each for EICre and cmv.stop.EGFP for co-transfection). The mixture was 
incubated at room temperature for 30 minutes to form reagent-DNA complex and added 
dropwise onto dish and the dish swirled slowly to allow an even mix of the reagent-DNA 
complex on the cells.  Following overnight incubation, cells were  washed and  fed  with 
medium  containing  10
-9M  Ru486  to  activate  the  CrePRI  fusion  recombinase  to 
subsequently excise the ‘Stop’ cassette of the target vector to express target genes or the 
medium without Ru486 in control dishes. For report assays, transfected cells were assessed 
for  fluorescent  green  cells  48-72  hours  after  transfection  of  cmv.stop.EGFP  or  96-120 
hours after co-transfection of regulator and target transgenes DNA under a fluorescence 
microscope, counted and photographed. 
 
2.2.6.2. Primary melanocytes transfection 
Primary melanocytes cultured in 50/50 or Halaban medium were washed twice with PBS to 
remove dead cells and fed with fresh medium 24 hours prior to transfection. Employing 
cmv-EGFP as a positive transfection control and pCrePR1 as a regulator positive control, 
regulator  (EICre  or  TRP2Cre)  or  target  (cmv.stop.EGFP  or  cmv.stop.N-Ras
lys61)  DNAs 
were (co)transfected with Fugene-6 as described above for B16 cells. The fluorescent green 
cells  (EGFP  transfection)  were  viewed  under  a  fluorescence  microscope  3  days  (cmv-
EGFP)  or  4-5  days  (regulator/target  cotransfection  and  cmv.stop.EGFP  transfected 
regulator  primary  melanocytes)  post  transfection  respectively  and  then  harvested  for 
confirmation  of  EGFP  expression  by  RT-PCR.  Parallel  transfected  target  (cmv.stop.N-
Ras
lys61, PTEN)
 cells were left in culture for EGFP cell proliferation or G418 selection in 
colony formation analysis. 
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2.2.7 Transformation of primary melanocytes and colony formation analysis 
Co-transfection of TRP2Cre with cmv.stop.EGFP or G418 resistant vector CMV-neo into 
target (D5PTEN
flx/flx and/or cmv.stop.NRas
lys61) transgenic primary melanocytes cultured in 
50/50 medium were carried out as described above. In these co-transfections, DNA ratio of 
3 (TRP2Cre) to 1 (cmv.stop.EGFP or CMV-neo) was used to ensure all green cells (EGFP 
expression  following  ‘Stop’  excision  by  active  TRP2Cre)  or  G418  resistant  N-Ras
lys61 
expressing cells (neomycin expression) transfectants containing TRP2Cre regulator. 
 
In the “green” colony formation assay, transfected melanocytes were left for continuous 
culture until the colony formed and cells were checked daily 4 days post-transfection under 
a fluorescence microscope for EGFP expression. In G418 resistant experiment, initially 
various  concentrations  of  G418  (20-600mg/ml)  were  tested  to  optimize  the  G418 
concentration for primary melanocyte colony selection prior to transfection and 200 mg/ml 
of G418 was optimized to select colonies due to the minimum toxicity for cell growth and 
selective pressure for colony formation. G418 was added 24 hours after transfection and 
then routinely employed until the end of experiment. 
 
2.2.8. Importation of K14CrePR1 and D D D D5PTEN
flx/flx  mice    
K14CrePR1  positive  control  mice  (developed  by  Dennis  Roop,  Bayler  College  of 
Medicine,    Houston,  TX  )  and  mice  expressing  PTEN  exon  5  flanked  by  ‘loxP’  sites 
(floxed)  (Hong  Wu,  UCLA  School  of  Medicine,  CA)  were  imported  from  USA  under 
licence and strict Home Office regulations. Following rabies quarantine and re-derivation 
by embryo transfer in class II hoods, and screening of sentinel mice to prevent import of 
diseases, quarantined transgenic mouse tails were cut in class II hoods following regulate 
procedures and genotyped via PCR. Using PCR positive mice, a typical mating was set to 
establish  the  colonies.  Generally,  the  male  was  removed  from  the  breeding  cage  once 
pregnancy was confirmed and pregnant females were separated, and neonates checked for  
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phenotype (if any). Mice were weaned at 4-5 weeks, ear tagged and the tails were cut for 
genotyping 1-2 weeks after weaning depending on the size. Negative mice were recorded 
and culled under PPL schedule 1 and positive progenies were kept for breeding or source of 
melanocytes or keratinocytes. 
 
2.2.9. Immunofluorescence staining 
2.2.9.1. Preparation of Samples 
(i)  Induction of adult melanocyte growth in vivo: Mice were briefly anaesthetized and back 
hair  was  plucked  with  tweezers  to  start  the  anagen  phase  of  the  hair  cycle  and  begin 
melanocyte proliferation. At this time (day 0) gene induction procedure was commenced by 
topical application of 10
-9M Ru486 in ethanol. Skin biopsies (5 x 3mm) were taken at each 
required time point from the mice on procedure and small wound sealed by wound clips 
which were taken off within 1-2 weeks. Biopsy samples were immediately fixed in 10% 
buffered formalin for 24 hours at 4
0C, embedded in paraffin and 4mm thickness sections 
were cut for immunofluorescence analysis. 
 
(ii)  Phenotypic  samples:  Phenotypic  mice  were  killed  by  Schedule  1  methods  and 
immediately post-mortem, phenotypic site(s) were biopsied, a portion was frozen in liquid 
nitrogen and the other was placed into formalin fix solution immediately for 24 hours at 
4
0C, embedded in paraffin and 4-6mm thickness sections were cut for immunofluorescence 
analysis. 
 
2.2.9.2. Immunofluorescence analysis 
Paraffin  sections  were  incubated  for  30  min  at  60
0C  and  subsequently  followed  by 
immersion in xylene to remove paraffin wax, immersion in a series of decreasing ethanol 
concentrations for 3 min to rehydrate. Antigen retrieval was performed as follows: pre-
warm 1 litre citrate buffer (18ml of solution A: 9.6g citric acid in 500ml dH2O and 82 ml of  
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solution B: 14.7g Tris-sodium citrate in 500ml dH2O and made up to one litre with dH2O) 
for  4  minutes  at  full  power  of  800W  microwave.  The  sections  were  immersed  in  this 
solution and transferred to a pressure cooker and once pressurised, the sections were boiled 
for further 7 minutes. 
 
After  20  minutes  cooling,  slides  were  removed  and  immersed  in  PBS.  Sections  were 
blocked in 20% normal horse serum for 15 minutes followed by incubation overnight at 
4
0C  with  primary  antibodies  which  were  diluted  to  the  manufacture  recommended 
concentration in 10% normal horse serum. To highlight the epidermis and follicles when 
staining for melanocytes via endogenous TRP2 expression, a K14 primary antibody was 
normally  added.  The  following  day,  sections  were  incubated  for  45  minutes  with 
biotinylated horse anti-species of the primary antibody (1: 100 diluted in 10% normal horse 
serum) and then by incubating in FITC or Texas red conjugated avidin at room temperature 
for  a  further  1  hour  followed  by  3x  washes  in  PBS.  For  double  immunofluorescence 
staining, biotinylated anti-species first antibody was employed for additional amplification 
followed by Texas Red-conjugated avidin and followed by incubation of FITC conjugated 
the anti-second primary antibody before being mounted with PermaFlor mountant. 
 
2.2.10. Induction of melanocyte specific transgene expression in vivo 
Prior to Ru486 treatment procedure, bigenic mice were checked for the lack of spontaneous 
phenotypes due to transgene insertion. To induce target transgene expression, anagen was 
initiated by hair plucking using tweezers followed by topical painting and intraperitoneally 
injection at day 0. Typically, mice were painted twice a week with 10
-9M Ru486 in ethanol 
and injected with 0.4mg/kg Ru486 in sesame seed oil due to its insolubility in water. The 
mice on procedure were treated continuously until biopsy samples were taken or the mice 
were culled because of the phenotypes affecting eyes and harderian glands. Treated mice 
were monitored weekly for checking of health conditions and phenotype development.  
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3.1. Cloning of the constructs 
The  creation  of  a  conditional  gene  switch  mouse  model  requires  generation  of  two 
transgenic lines containing the regulator and target halves, which are produced by micro-
injection of transgene DNA into pronucleus of one cell embryos. Typically the regulator 
transgene is expressed from cell/tissue specific promoters giving the specificity necessary 
for  gene  expression  in  vivo,  while  the  target  transgene  is  expressed  from  a  generic 
promoter. A regulator can express any one of specific recombinases (see introduction) and 
this approach employs the Cre recombinase, which remains inactive in the cytoplasm until 
application of inducer. The Cre recombinase was translocated to the nucleus to switch on 
the target transgene or eliminate a loxP flanked sequence following inducer application. 
 
In this project, Cre recombinase (regulator) was fused with progesterone ligand binding 
domain to create fusion protein CrePR1 which is responsible to application of Ru486 (an 
analogue of natural progesterone) but not to endogenous progesterone. By cloning of a 
melanocyte-specific  promoter  (enhanced  tyrosinase  or  Trp2)  in  front  of  CrePR1  fusion 
recombinase,  the  regulator  should  specifically  express  in  melanocytes  but  Cre  remains 
inactive until application of inducer Ru486. The target half was constructed by cloning 
report gene (EGFP) or oncogene (N-Ras
lys61) under the control of generic promoter CMV 
which lies downstream was followed by a floxed ‘Stop’ cassette, a Cre responsive element, 
to  silence  target  gene  (EGFP,  N-Ras
lys61)  under  normal,  untreated  conditions.  In  the 
imported D5PTEN
flx/flx mouse, floxed exon 5 of PTEN gene was responsive to CrePR1 to 
be ablated as ‘Stop’ cassette in our constructed target genes in bigenic mouse (crossing of 
regulator and target lines) by application of inducer Ru486  (Fig 5). 
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Cre-PLBD Tyrosinase/TRP2 promoter SV40-p(A)
NUCLEAR 
LOCALISATION Cre-PLBD
Ru486 Ru486
Cre-PLBD
Melanocyte-specific gene switch system 
CMV EGFP or N-Raslys61 Stop
Stop + loxP loxP CMV Active GFP or N-Raslys61
Exon Exon  Exon or Genome
Exon or Genome + Function lost gene loxP loxP
loxP loxP
loxP loxP
 
Figure 5: Scheme of the melanocyte-specific, progesterone receptor-based Cre/loxP gene 
switch.  To  achieve  inducible  melanocyte-specific  transgene  expression  following 
application  of  inducer  Ru486,  the  PLBD  (progesterone  ligand  binding  domain)  of  the 
progesterone  receptor  was  fused  to  Cre  recombinase  (Cre-PLBD)  and  this  regulator 
construct  was  expressed  from  an  enhanced  melanocyte-specific  Tyrosinase  promoter 
(EICre) or TRP2 (TRP2Cre). Thus following application of inducer Ru486, the Cre-PLBD 
fusion  protein  binds  Ru486,  dimerizes  and  translocates  to  the  nucleus  where  Cre 
recombinase is activated and subsequently acts to evict sequences flanked by loxP sites 
(floxed). Thus regulator and target lines are bred to create complete gene switch. In the 
resulting bigenic (trigenic/compound) mice, cellular specificity is provided by the regulator 
promoter and the cell/tissue specific active Cre recombinase either evicts a ‘Stop’ sequence 
(stop- EGFP or stop-N-Ras) to activate target transgene expression or inactivate target gene 
activity via loss of functional exons (e.g. PTEN) in designed cell/tissue depending on the 
‘floxed’ sequences within the target vector. Please also see Fig 4. 
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3.1.1. Regulators 
As outlined in the methods, plasmid pEtyr-P65 containing Etyr promoter, an enhanced 
tyrosinase promoter, was cut with Asc I and Kpn I to obtain Etyr promoter for cloning into 
pSL1180, a vector harbouring multiple cloning sites, which was linearized by digestion 
with the same enzymes AscI and KpnI to produce vector pSL1180-Etyr (Fig 6) following 
typical precedures for gene cloning as described in material and methods. The pSL1180-
Etyr construct therefore contains the cloning sites for the next step construction to result in 
the regulator ECre (Fig 7). 
 
 
Pst1
Bgl II
Kpn1
pSL1180-Etyr
5866 bp
Enhancer
Tyr. Pro.
Asc1
Kpn1
pEtyr-P65
6471 bp
Enhancer
Tyr. Pro.
Asc1
Figure  6:  Construction  of  intermediate  plasmid  pSL1180-Etyr.  Intermediate  vector 
pSL1180-Etyr was constructed to give convenience MCS (specific Pst 1 at 5’ and Bgl II at 
3’ for this purpose) for further cloning of Etyr promoter into pCrePR1. 
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Shuttle cloning of pSL1180-Etyr provided the Bgl II site essential for insertion of the Etyr 
promoter into pCrePR1 vector. To create the melanocyte-specific regulator construct where 
CrePR1 fusion protein was under the control of Etyr promoter, a fragment was cut from 
pSL1180-Etyr  by  Pst  I  and  Bgl  II  enzymes  which  were  also  employed  to  recover  the 
CrePR1  fusion  gene  from  pCrePR1  and  thus  discard  the  HSV-tk  general  promoter. 
Through ligation of Etyr and CrePR1 fragments and screening of positive colonies, the  
regulator plasmid ECre was generated in which CrePR1 fusion gene was controlled by 
melanocytes  specific  expression  promoter  Etyr  (Fig  7)  to  limit  target  gene  expression 
exclusively in melanocytes. 
 
Pst1
Bgl II
Kpn1
pSL1180-Etyr
5866 bp
Enhancer
Tyr. Pro.
+
Pst1
Pst1
Bgl II
pCrePR1
6300 bp
NLS-Cre
PR981
HSV-tk SV40-p(A)
ECre
7944 bp
NLS-Cre
PR981
SV40-p(A)
Enhancer
ETyr Pro
BglII
NheI
PstI
 
 
Figure 7: ECre plasmid creation. ECre regulator without generic intron was cloned via 
intermediate  vector  pSL1180-Etyr  and  pCrePR1.  The  CrePR1  fusion  gene  was  under 
control of Etyr in the resulting vector ECre.   
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To further increase gene expression, a final version of the enhanced tyrosinase vector was 
designed  to  include  a  generic  intron,  which  increases  message  stability  and  efficient 
processing  thereby  accumulating  cytoplasmic  RNA  to  elevate  gene  expression  in 
transgenic mice (452;453). Thus, a generic intron cut from K14CrePR1 vector was inserted 
into ECre between Etyr promoter and CrePR1 gene via ligation of Nhe1/Spe1 at 5’ and 
Kpn1 (blunt)/Bgl II (blunt) at 3’ from ECre/generic intron respectively. The final version of 
this regulator construct was named EICre. A 5.6-kb transgene fragment can be obtained 
following digestion of Not I (Fig 8). 
 
Generic Intron
Spe1 Bgl II
ECre
7944 bp
NLS-Cre
PR981
SV40-p(A)
Enhancer
ETyr Pro
BglII
NheI
PstI
EICre
8238 bp
NLS-Cre
PR981
SV40-p(A)
Enhancer
ETyr Pro
Generic Intron
BglII
PstI
PstI
 
Figure 8: Construction of regulator EICre. Final version of regulator EICre was cloned by 
insertion of generic intron into ECre. 
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Another regulator was also constructed based on the tyrosinase related protein 2 (TRP2) 
promoter, which is cited to be a stronger promoter and possibly expressed in melanoblast 
stem cells (288;454). The TRP2Cre regulator was cloned by cutting plasmid TRP2-p(A) 
with EcoRV and Not I to discard the vector’s p(A) which to be replaced by Intron-CrePR1-
p(A)  fragment  excised  from  EICre  by  Kpn1/blunt  and  Not  I.  Following  ligation, 
transformation and screening of colonies as described in material and methods, successful 
clones were sequenced to confirm the absence of mutation within the junction of TRP2 
promoter and Intron–CrePR1. A 4.62-kb fragment of transgene was released following Afl 
II partial cut and Not I digestion for microinjection into pro-nucleus (Fig 9) 
 
 
TRP2-p(A)
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SV40-p(A)
MCS
TRP2 Pro
Eco RV
Not I
EICre
8238 bp
NLS-Cre
PR981
SV40-p(A)
Enhancer ETyr Pro
Generic Intron
KpnI
Not1
TRP2Cre
7950 bp
NLS-Cre
PR981
SV40-p(A)
TRP2 Pro
Generic Intron
Not1
 
 
Figure 9: TRP2Cre construction. TRP2Cre regulator was constructed via replacement of 
the Etyr in regulator EICre with TRP2 promoter which was isolated from CrePR-p(A).  
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3.1.2. Target construction 
3.1.2.1. Report target 
To produce an easy analysis method to confirm functional regulator and successful target 
switch  in  vitro,  a  report  target  was  constructed  in  which  report  gene  EGFP  allowed 
successful  target  gene  switch  activity  to  be  easily  visualized  by  immunofluorescence 
microscopy. 
 
In  this  construct,  the  'Stop'  cassette  flanked  by  two  ‘loxP’  sites  at  5’  and  3’  ends 
respectively was employed and excised from pBS302 (NCBI data base: U51223, gene bank 
identification number: 1277147) by Spe 1/blunt and EcoR 1 digestion. In parallel, CMV 
driven EGFP in plasmid vector pEGFP-N1 (NCBI data base: U55762, gene bank identify 
number:  1377911)  was  linearized  between  CMV  promoter  and  EGFP  gene  employing 
Nhe1 digestion, followed by blunt-end with DNA polymerase I large fragment (Klenow) 
and further  EcoR 1 digestion. These two fragments, 'Stop' cassette and linearized 'VMC-
PFGE' fragments were ligated to produce the CMV-Stop-EGFP report construct in which 
EGFP expression was silenced by ‘Stop’ insertion between promoter (CMV) and target 
gene (EGFP) under normal conditions until the excision of ‘loxP-Stop-loxP’ sequences by 
active CrePR1 recombinase. To further increase gene expression (452;453), a final version 
of target vector was designed to include a generic intron as for regulator. Thus, the generic 
intron was cut from K14CrePRI vector and inserted between ‘Stop’ cassette and EGFP 
gene to generate final version of construct cmv.stop.EGFP (Fig 10). This report vector was 
employed  as  a  positive  control  in  tests  of  the  gene  switch  and  also  to  visualize 
‘transformed’ melanocytes in in vitro analysis. 
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Figure  10:  Construction  of  report  target  vector  cmv.stop.EGFP.  Report  target  vector 
cmv.stop.EGFP was cloned by insertion of a ‘generic intron’, obtained from K14CrePR1, 
and ‘loxP-Stop-loxP’ which was released from plasmid pBS302 into plasmid CMV-EGFP 
between CMV promoter and EGFP report gene.  
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3.1.2.2. Construction of N-Ras
lys61 target transgene 
Following  the  construction  of  the  report  target  vector  cmv.stop.EGFP,  a  target  gene 
containing a codon 61 mutant N-Ras oncogene (GAA (Gln, Q) ® AAA (lys, K)) was 
obtained by excising N-Ras
lys61 from tk-N-Ras
lys61 via digestion of Spe1, blunt-ended with 
DNA  polymerase  I  large  fragment  (Klenow)  and  the  following  Apa1  digestion.  The 
resulting  600-bp  N-Ras
lys61  fragment  was  ligated  with  linearized  CMV-Stop-Intron,  a 
fragment obtained from cmv.stop.EGFP by discarding EGFP gene following blunt-ended 
Not1 and Apa1 digestion, to create cmv.stop.N-Ras
lys61. The final construct was diagnosed 
by a panel of restriction endonucleases digestion followed by sequencing of the junction 
area to confirm the accurate sequence (Fig 11). 
Spe I
Apa I
Not I
Apa I
CMV-Stop-Intron-EGFP
HSV TK poly A
KanR/NeoR
SV40 ori, Pro SV40e
Pro. of Kana.
f1 ori
pUC ori
LoxP
Lox P
Generic Intron
EGFP
SV40 poly A
CMV IE
tk-Ras
tk promoter
N-Ras(lys61)
cmv.stop.NRaslys61
HSV TK poly A
KanR/NeoR
Generic Intron
SV40 poly A
f1 ori
SV40 ori, Pro SV40e
Pro. of Kana.
pUC ori
CMV IE
LoxP
Lox P
N-Ras(lys61)
 
Figure 11: Construction of oncogenic target cmv.stop.N-Ras
lys61. cmv.stop.N-Ras
lys61 was 
constructed by replacing EGFP gene in report target vector cmv.stop.EGFP with oncogene 
N-Ras
lys61 which was released from plasmid tk-Ras  
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3.2. Establishment of optimum primary mouse melanocyte culture  
3.2.1 Design and test of mouse melanocytes culture medium 
In order to be able to rapidly screen transgenic expressers prior to expensive breeding 
typically,  following  successful  genotyping,  cells  were  isolated  from  new-born  skin. 
Separated  epidermis  was  plated  in  an  appropriate  medium  and  cells  were  grown  for 
expression analysis or in this case to perform transfections to ensure biological and cell 
specific  (data  not  shown)  activities  of  the  gene  switch.  This  occurs  ideally  in  primary 
melanocyte culture from F1 germline transmitters without contaminating cells, however, 
unlike  human  primary  melanocyte,  it  turned  out  that  such  culture  of  primary  murine 
melanocyte was difficult (457;458). Also optimum culture conditions had to be defined that 
avoid  the  use  of  feeders  which  would  complicate  the  in  vitro  expression  analysis 
experiments  and  avoid  conditions  where  melanocytes  quickly  transformed  and  lost 
pigmentation.  Thus  it  was  necessary  to  test  several  experimental  regimes  where  after 
typically plating at 5 x 10
6, epidermal cells comprised mainly of keratinocytes (57;76), 
primary  murine  melanocytes  could  be  grown  in  various  media  to  define  optimum 
conditions. 
 
Initially, a method expounded by Prof D Bennett’s group was tried (459;460). Cells were 
grown  in  MEM  with  additive  cholera  toxin,  200mM  TPA  to  promote  melanocytes 
proliferation. In being a high-calcium medium, murine keratinocytes differentiated very 
quickly and failed to support melanocyte growth despite the presence of TPA. Typically, 
the cells grew poorly and quickly senesced (Fig 12). 
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Figure 12: Primary melanocyte growth in Bennett’s medium. Poor melanocytes obtained 
from the culture that murine epidermal cells were grown in Bennett’s recipe comprised of 
MEM, cholera toxin and TPA. Picture shows only very low density and poor melanocytes 
grow in the medium tried first. Photo was taken at 100x.   
 
Due to the poor melanocyte growth in the medium developed by Bennett et al, mouse 
melanocytes were grown in a commercial melanocyte growth medium designed primarily 
for  optimum  growth  of  human  melanocytes  (cc-4435,  Cambrex,  UK).  In  this  medium, 
basal  growth  medium  KBM  (cc-3112,  Cambrex,  UK)  was  supplemented  with  1ng/ml 
b-FGF,  TPA,  insulin,  hydrocortisone  and  2%  serum  for  melanocyte  growth.  Again, 
keratinocytes  differentiated  due  to  the  higher  calcium  condition  (0.09mM)  than  mouse 
keratinocytes needed (0.05mM). Indeed, melanocytes did grow and could be passaged over 
4 –5 weeks but senesced at passages 3 or 4 because this medium was primarily for human 
melanocyte but sub-optimum for mouse melanocyte growth and was very expensive. 
 
Other groups (57;460) have reported success with employing feeder layers. Murine primary 
keratinocytes  have  also  been  employed  as  an  initial  feeder  layer  grown  in  DMEM 
supplemented with 10% chelex FCS and 0.05mM Ca
2+ which then differentiate over a 
period of 2-3 weeks (461;462). On addition of TPA (10ng/ml) and b-FGF, melanocytes 
grow well enough to supply sufficient number of cells for expression analysis and provide 
cells for transfection. Melanocytes/melanoblasts become dendritic at subculture but cells 
can be kept for till passage 4 (6 weeks).  
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In  a  final  modification,  using  the  most  optimum  medium,  it  was  discovered  that  the 
keratinocytes feeder layer grew better and was maintained for longer in a medium which 
consists of 50% low calcium (0.05mM Ca
2+) DMEM and 50% commercial serum free 
KGM medium, containing epidermal growth factor (EGF), hydrocortisone and transferrin. 
Addition of TPA and b-FGF to this final version of optimum primary murine melanocyte 
growth medium defined as 50/50 medium induced the greatest melanocyte growth. 
 
Keratinocytes cultured in 50/50 medium grew quickly for first a few days as a confluent 
feeder  layer  and  gradually  terminal  differentiated  to  die  out  after  2-3  weeks  while  the 
melanocytes continued to grow and to proliferate, presumably due to the matrix provided 
by  the  keratinocytes.  In  this  optimum  50/50  medium,  the  first  presence  of  pigmented 
melanocytes can be observed at as early as day 3 after plating. At day 6, melanocytes are 
obviously  prominent  following  keratinocytes  differentiation.  The  reversed  trends  of 
increasing number of melanocytes and decreasing number of keratinocytes will last for 
approximately two weeks, although most of keratinocytes disappeared following in culture 
for 9-10 days (Fig 13). This increased melanocytes growth was more than sufficient for 
protein  analysis,  RNA  isolation  and  transfection  experiments  to  identify  transgenic 
expressers and supplied sufficient cells up to passage 5 without spontaneous transformation 
or  loss  of  melanin  production  by  active  tyrosinase.  By  passage  6  melanocytes  ceased 
proliferation but if plated in sufficient numbers, could be maintained for several weeks 
longer  (>10)  without  spontaneous  transformation.  On  occasion  e.g.  to  help  assess  for 
cellular immortality, the keratinoyte papilloma cell line, SP-1 (463), was used as a feeder 
layer (457) (data not shown).  
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Figure 13: Growth of murine melanocytes in low calcium 50/50 medium. Primary murine 
melanocytes grew in 50/50 medium which contained 0.05mM Ca
2+, 1ng/ml b-FGF and 
10ng/ml TPA. (A) Primary new born murine keratinocytes/melanocytes were plated where 
keratinocytes  grow  as  a  feeder  layer  for  melanocyte  growth  at  24hrs,  cells  attach  in 
colonies then differentiated to disappear gradually whilst melanocytes grow and proliferate. 
(B), Although pigmented melanoblasts/melanocytes are distinguishable from keratinocytes 
as early at day 2, (C) obvious melanoblasts/melanocytes presented at day 6 or 7 and (D) 
dominate the dish at day 9 or 10. A-D: photographs were taken at 1, 2, 7 and 10 days 
respectively after plating. A, B were taken at 50x and C, D were taken at 100x 
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3.2.2. Comparison of mouse melanocytes growth media 
To verify our murine primary melanocyte growth medium (50/50), primary cells isolated 
from new born skin were cultured in this house-made medium and in medium exploited by 
Dr Halaban (a quite popular recipe used in many laboratories, thereafter termed as Halaban 
medium)  (449)  respectively.  Melanocyte  growth  behaviour  and  the  changes  of  cell 
morphology following long term continuous culture were recorded for comparison. 
 
Fig  14  shows  that  melanocytes  grow  well  in  both  media  but  with  different  growth 
characteristics. Although the presence of sodium orthovanadate (Na3VO4) which inhibits 
tyrosine phosphatases to prolong the activity of endogenous tyrosine kinases in Halaban 
medium,  possible  due  to  the  higher  TPA  concentration  to  result  earlier  melanocytes 
appearance and high calcium caused quick differentiation of keratinocytes which involved 
in regulation of pigmentation (464) therefore, melanocytes grow as colourless and thus, 
melanocytes are visible mainly because of the light reflection on their 3-D dimension but 
hardly visible once the cells became flat after the transfection (see below 3.3.2) (449). 
Melanoblasts/melanocytes in 50/50 medium present as brown colour and various shapes 
including round (majority), triangle and spindle, in contrast to the cells in Halaban medium 
are mostly colourless and single spindle shape in the first a few days, although there do 
have a few pigmented melanocytes. Furthermore, melanocytes in Halaban medium are not 
distinguishable  from  keratinocytes  as  easy  as  in  50/50  medium  because  of  the  non-
pigmentation of most melanocytes appeared.  
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Figure 14: Comparison of mouse primary melanocytes cultured in different media. Mouse 
primary melanocytes cultured in 50/50 medium (A, B) and in Halaban medium (C, D) were 
compared  and,  50/50  medium  was  verified  as  optimum  for  mouse  melanocyte  culture 
conditions. Significant differences in melanocytes morphologies were observed by day 6 in 
culture (A in 50/50  &  C in Halaban). (A  &  B), all melanocytes in 50/50 medium are 
pigmented  and  grow  on  the  keratinocytes  feeder  layer.  (C  &  D),  however,  in  Halaban 
medium  there  are  few  pigmented  cells  set  amongst  vast  majority  of  non-pigmented 
melanocytes and residual differentiated keratinocytes. A & C photographs were taken at 
day 6 and B & D at day 9 in culture. All pictures were taken at 100x  
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Most  primary  keratinocytes  in  50/50  medium  totally  disappeared  by  2-3  weeks  time 
leaving a relatively pure pigmented melanocytes population (Fig 15, A). By which time in 
Halaban  medium  the  cells  comprised  numerous  non-pigmentation  cells  (Fig  15,  D). 
Furthermore, Halaban melanocytes had significantly changed morphology becoming more 
transformed and forming visible spontaneous colonies because of the gradual increase in 
the few melanocytes which had retained pigmentation (E), whereas cells in 50/50 medium 
grew in monolayer without morphological change (B) up to passage 6. 
 
Under  microscope  at  high  magnification  (200x),  significant  differences  were  revealed 
between cells cultured in these two mediums. Cells in 50/50 medium remained normal 
monolayer growth by  retaining the contact-inhibition character (C) while some became 
pigmented in Halaban medium and most cells became more dendritic and lost their contact-
inhibition character to pile up which resulted in impossible distinguish of any single cell 
(F) and thus would compromise any in vitro modelling of tumourigenesis. 
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Figure 15: Different melanocyte morphologies displayed in different media. Melanocytes 
were cultured in 50/50 medium (left panel) and in Halaban medium (right panel) in primary 
culture (A, D) and sub-culture following long time continuous growth either in macro- (B, 
E) or micrographs (C, F). Primary cells in 50/50 (A) and in Halaban media (D) displayed 
different melanocyte morphologies (100x), approximately two weeks following the first 
culture with pure brown and various shaped (mainly round and oval) melanocytes in 50/50 
medium (A) and with a few pigmented melanocytes amongst majority of non-pigmented 
spindle shape cells in Halaban medium (D). Spontaneous transformation-like melanocytes 
colonies formed in Halaban medium within 4 weeks of the first subculture (E) in contrast to 
cells in 50/50 medium remained a confluent, contact inhibited monolayer (B). (C) and (F) 
show the morphology of normal confluent melanocyte monolayer in 50/50 medium and 
transformed (some pigmented) melanocytes in Halaban medium respectively (200x).  
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3.3. Transfection 
Following the successful cloning of both regulator and target vectors, biological activity 
and response to Ru486 treatment was confirmed by transfection prior to the transgenic line 
production.  By  comparison  of  several  commercial  transfection  reagents,  Fugene-6  was 
defined as the best transfection reagent for transfection of murine primary melanocytes. 
Regulator and/or target constructs were (co)-transfected into B16 melanoma cells initially 
due to the lack of report of primary mouse melanocyte transfection and later into primary 
melanocytes once delivery parameters had been defined. Comparison of the transfection 
efficiency between cultured primary melanocytes in 50/50 and Halaban media confirmed 
50/50 as an optimum primary culture method for murine melanocytes in addition to the 
factor of growth and lack of morphological transformation during melanocyte culture. 
 
3.3.1. Transfection of B16 cells 
To  confirm  successful  cloning,  transfections  were  performed  initially  into  B16  cells 
employing Fugene-6 transfection reagent and cmv.EGFP DNA as a positive control for 
transfection  efficiency  and  co-transfection  of  pCrePR1  with  cmv.stop.EGFP  DNA  as 
positive control for gene switch activity. 
 
Following co-transfection of regulator and report target vectors into B16 cells and Ru486 
treatment, EGFP expressing cells were detected by immunofluorescence microscopy 5 days 
after transfection (Fig 16, Table 2). Co-transfection of either EICre or TRP2Cre employing 
cmv.stop.EGFP  as  the  Cre  responsive  target,  demonstrated  the  successful  cloning  of 
biologically active constructs in terms of the functional activation of regulator protein by 
Ru486 and target gene switch specificity in B16 melanoma cell. It was noted that TRP2Cre 
transfected  dishes  produced  more  green  cells  than  EICre  although  detectable  EGFP 
expressing  green  cells  were  recorded  in  TRP2Cre  transfection  without  Ru486  addition 
indicating whilst a stronger promoter, it possessed some gene switch leakage in vitro.  
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Figure 16: EGFP expressed in B16 following cotransfection. Detection of green fluorescent 
cells following cotransfection of regulator and report target vectors cmv.stop.EGFP into 
B16  melanoma  cells  demonstrated  successful  transgene  construction  and  gene  switch 
activity. B16 melanoma cells were cotransfected with regulator EICre (A) or TRP2Cre (B) 
and  report  target  vector  cmv.stop.EGFP  DNA.  Transfection  of  cmv.EGFP  (C)  and 
cotransfection of pCrePR1 together with cmv.stop.EGFP (D) were employed as a positive 
control  of  transfection  efficiency  and  of  gene  switch  activity  respectively.  Cells  were 
photographed (40x) under immuno-fluorescence microscope 3 days (C) or 5 days (A, B, D) 
post  transfection  respectively.  An  approximately  1:3  ration  of  target  gene  switch  was 
exploited between regulators EICre (A) and TRP2Cre (B). All pictures were taken at 50x. 
As the primary purpose of the experiment was to simply confirm gene switch function, the 
numbers of transfected cells were not counted while expression in the cells was relatively 
uniform, although was often stronger in the nucleus. Transmitted light photo was not taken 
for B16 cell transfections but was for primary melanocyte transfections (below). 
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3.3.2. Transfection of primary cultured melanocytes 
As  each  transgenic  founder  was  produced,  to  quickly  confirm  regulator  transgene 
expression  without  excessive,  expensive  breeding  of  unnecessary  bigenic  cohorts,  as 
required  by  the  Animal  licence,  it  became  necessary  to  establish  primary  melanocyte 
culture conditions prior to defining transfection parameters. 
 
Following  successful  transfection  of  B16  cells  to  identify  functional  gene  switch 
components, co-transfection of regulator EICre (picture not show) or TRP2Cre and report 
target cmv.stop.EGFP was carried out in primary cultured melanocytes as outlined for B16 
melanoma cells. This verified their transfectable capacity in 50/50 medium and confirmed 
functional  gene  switch  exclusively  in  melanocyte.  Detection  of  EGFP  expressed  green 
fluorescence cells in Fig 17 demonstrated the transfectable capacity (A) and functional 
gene switch in primary melanocytes employing our melanocyte-specific regulator TRP2Cre 
(C); although the reduced number of green cells indicated low transfection efficiency as 
determined by positive controls indicating the difficulty of primary melanocyte transfection 
(Table 2). 
 
As with results obtained from transfection of  B16 melanoma  cells, the cmv.stop.EGFP 
target vector was totally silenced until the EICre regulator was activated following ligand 
Ru486  application.  Furthermore,  regulator  EICre  was  again  confirmed  to  be  the  less 
powerful activator of target gene than TRP2Cre in primary melanocytes as revealed in B16 
melanoma  cells,  given  the  factor  of  less  green  fluorescence  cells  counted  in  EICre 
transfected dishes compared to TRP2Cre transfected dishes under the same transfection 
conditions.  However,  the  leakage  of  TRP2Cre  regulator  was  again  detected  in  primary 
melanocytes as observed in B16 cells (Table 2).  
  131 
             
A B
C D
 
Figure  17:  Target  gene  expressed  in  cotransfected  primary  melanocytes.  To  define  the 
transfectable ability of cultured melanocytes and confirm melanocyte specificity, cells were 
cotransfected with regulator and report target 10 days post epidermal cells plating. (A) 
transfection positive control cmv.EGFP DNA and (C) TRP2Cre/cmv.stop.EGFP DNAs.  
‘B’ and ‘D’ are light micrograph versions of ‘A’ and ‘C’ respectively to show the location 
and  ideal  morphology  of  transfected  melanocytes  and  the  arrows  show  the  EGFP 
expressing melanocytes location. Photos were taken at 100x. 
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Table 2: Transfection efficiency comparison of two versions of regulator in B16 melanoma 
cells and primary culture melanocytes. GFP –positive (3.3.1 and 3.3.2) cells were counted 
under’ fluorescence microscope and presented as the average number of positive cells per 
dish  in  repeat  experiments.  Control  cells  transfected  with  cmv.stop.EGFP  report  DNA 
alone  possessed  no  green  cells,  which  eliminated  the  possibility  of  a  transfection 
background (target leakage) from this report gene. Cotransfection of TRP2/cmv.stop.EGFP 
DNAs in B16 or primary melanocytes gave higher numbers of positive cells both with and 
without  Ru486  induction  compared  to  regulator  EICre/cmv.stop.EGFP  DNAs.  This 
revealed that although stronger TRP2 it possessed leakage and thus a greater potential for 
non regulatory phenotypes in vivo.  
 
  
  B16 Cells   Primary melanocytes  
DNA Transfected  (-)Ru  (+)Ru  (-)Ru  (+)Ru 
CMV-EGFP  1600  NA  500  NA 
cmv.stop.EGFP  0  0  0  0 
EICre/ cmv.stop.EGFP  0  480  0  70 
TRP2Cre/cmv.stop.EGFP  300  620  120  310 
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3.3.3. Comparison of transfection efficiency in 50/50 and Halaban media 
As  mentioned  above,  murine  melanocytes  can  be  cultured  in  both  50/50  medium  and 
Halaban medium and although Halaban possessed increased growth characteristics, 50/50 
medium did not give spontaneous transformation whereas in contrast melanocytes cultured 
in Halaban medium mainly gave non-pigmented cells until later passages in culture thus 
raising  concerns  on  their  use  to  test  Etyr  or  TRp2  regulated  genes,  and  quickly 
spontaneously transformed negating their use in transformation experiments. 
 
As  transfectable  capacity  and  transfection  efficiency  are  critical  factors  for  the 
identification of successful transgenes construction and functional gene switch analysis, 
primary and secondary melanocytes were thus cultured in both Halaban medium and 50/50 
medium to test transfection efficiency with cmv.EGFP DNA. The results (Fig 18) revealed 
that  melanocytes  in  50/50  medium  gave  approximately  3  times  higher  transfection 
efficiency than cells in Halaban medium under the same transfection conditions. Moreover, 
an approximately 3 times higher transfection efficiency in 50/50 vs. Halaban medium was 
also found for secondary melanocytes (confluent primary melanocytes were trypsinized 
and seeded at 1:3 for the next day transfection), although the numbers of transfected cells 
in both media was reduced compared to primary cells. Interestingly, all transfected cells in 
Halaban  medium  were  not  pigmented  and  thus,  the  transfected  cells  are  hardly  visible 
under normal light because of the loss of their 3-D dimension as mentioned above (3.2.2). 
This  observation  suggested  that  melanocytes  cultured  in  Halaban  medium  may  not  be 
transfectable once they became pigmented or that transfected Halaban cells lose ability to 
pigment.  
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Figure  18:  Photomicrographs  of  expressed  target  cells  in  different  media. 
Photomicrographs (100x) of green cells (upper panel) and their localisation (lower panel) 
following  transfection  of  cmv.EGFP  into  primary  melanocytes  cultured  in  (A)  50/50 
medium and (B) Halaban medium. The table 3 below shows the average numbers of EGFP 
expressing green cells from duplicate or independent transfections (a). 
 
Note: transfected cells are hardly visible in lower panel in Halaban medium under normal 
light version as mentioned.  
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Table  3:  Transfection  efficiency  comparison  in  different  media  by  counting  of  green 
(EGFP  expressing)  cells  after  transfection  of  cmv.EGFP.  All  GFP  –positive  cells  were 
counted  from  transfection  of  approximately  10
6  primary  cells/60-mm  dish  and  5  x  10
5 
secondary  melanocytes  at  50x  magnification.  Numbers  for  primary  transfection  are  the 
average  of  2  dishes  whilst  numbers  for  secondary  melanocyte  transfections  (a)  are  the 
average of 3 independent experiments. 
 
 
 
 
 
  
  50/50  Halaban 
Primary  1029  497 
Secondary  97
a  39
a  
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3.4 Transgenic line production 
3.4.1. Identification of the transgenic founders and germline transmitters 
The transgenic EICre and cmv.stop.N-Ras
lys61 DNAs were isolated, purified, quantified and 
1-2ng/ml  transgene  DNA  solution  was  microinjected  into  pronuclei  harvested  from 
B6/D2/F1  superovulated  females  as  described  in  chapter  2  (material  and  methods). 
Successfully  injected  one-cell  embryos  were  transplanted  into  pseudopregnant  females, 
produced by mating ICR females with vasectomized males, and normal gestation allowed 
to produce pups for screening transgenic founders. 
 
To identify potential transgenic founders, as no phenotype was expected, 5-6 week old 
mouse progenies were tail tipped and genomic DNA was isolated for PCR analysis. Using 
specific primers for each transgenic line (EICre forward: ATTGGTGCAGATTTTGTATG 
and  reverse:  CATCTTCAGGTTCTGCGG;  N-Ras
lys61  forward: 
ACACCACAGAAGTAAGGTTCCT  and  reverse:  GCGGTACCTCTTGAACTATAGC, 
see table 1), a 436-bp EICre or 888-bp N-Ras
lys61 fragment indicated positive transgenic 
mice respectively.  Over a period of time, ten  EICre and four N-Ras
lys61 founders were 
produced. Seven EICre and two N-Ras
lys61 lines were identified to be germline transmitters 
by  breeding  with  C57BL6  and  PCR  analysis  of  F1  progenies  (Fig  19  &  Fig  20).  All 
germline transmitters displayed the transgenes in a Mendelian fashion in their progenies 
and were employed to produce primary melanocytes for transgene expression analysis in 
vitro.  
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A
B
+ - 4118* 4119  4120  4121 4311 4312 4313 4314* 4316* 4317  4318 
4697 4698  4699  4710  4711 4712  4713 4714* 4735* 4736   +  -
4235  4236   4237  4238   4239 4240  4241  4242  4243  4244  4117*  4118* 4245  4246  4247  4248  4249  4230  4231  4232  4233
4453  4454  4455  4456  4457  4458  4459  4460  4461  4462  4463 4464            4313* 4314* 4465  4466  4467  4468  4469  4470  4471 
 
 
Figure 19: PCR product represents EICre transgenic founders 4314 etc. (A) A 436-bp PCR 
product represents EICre positive transgenic founders 4314 etc and (B) shows founders 
4118 (top row) and 4314 (bottom row) are germline transmitters as their F1 progenies 
displayed the transgenes in an expected Mendelian fashion. (+), PCR from transgene DNA 
as positive control and (-), PCR from wild type C57BL6 DNA as negative control for ‘A’ 
while the parental negative and positive DNAs (red indicated) as controls for ‘B’. DNA 
marker is Invitrogen 1kb plus DNA ladder (#10787-026).  
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4733  4734* 5275*  5276   5277  5278  5279  5280 
7153   7154   7155   7156* 8260   8261*           8262  8263
4912  4913 4914 4915 4916 4917 4918 4919 4920           4921 4922  4923 4924  4925 4926 4927 4928 4929
7725  7726  7727  7728 7729 7730 7731 7732 7733  7734 7735  7736 7737 7738  7739 7740 
 
 
Figure 20: PCR of tail genomic DNA identified four cmv.stop.N-Ras
lys61 founders. The 
888-bp PCR product was identified in four cmv.stop.N-Ras
lys61 founders 4734, 5275, 7156, 
and 8261 (A) and only two of them (4734 and 7156) proved to be germline transmitters  
(B: 4734 top row ; 7156, bottom row ). (+), PCR from transgene DNA as positive control 
and (-), PCR from wild type C57BL6 DNA as negative control for ‘A’ while parental 
genomic DNA (4733, 4734 & 7156, 7157) as positive and negative controls for ‘B’. DNA 
marker is Invitrogen 1kb plus DNA ladder (#10787-026).  
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3.4.2. Importation of K14CrePR1 and D D D D5PTEN
flx/flx  mice 
K14CrePR1, a line well characterised Ru486-based regulator expressed in keratinocytes, 
was imported from the USA under the Home Office regulations and was used as positive 
regulator  control  genotype  to  induce  target  transgene  expression  in  keratinocytes. 
K14CrePR1 was successfully identified to switch N-Ras
lys61 expression in primary bigenic 
K14CrePR1/cmv.stop.N-Ras
lys61  keratinocytes  and  N-Ras
lys61  expression  in  melanocytes 
was  subsequently  confirmed  in  EICre/cmv.stop.N-Ras
lys61  bigenic  mice  in  vivo. 
K14CrePR1  mice  were  also  utilised  in  experiments  to  investigate  the  tumour 
microenvironment contribution to the oncogenic process given that melanomagenesis is not 
a process involved of only melanocyte mutation but a complex issue involved of multiple 
partners in the neighbourhood (e.g. keratinocytes) (465;466). Therefore, K14CrePR1 mice 
were employed to allow N-Ras
lys61 expression and PTEN ablation in keratinocytes (246) to 
induce hyperplasia (in soil). Together with intrinsic N-Ras
lys61 expression in melanocytes 
(seed),  the  induction  of  K14CrePR1  mice  also  give  us  permission  to  assess  effects  on 
promoting melanomagenesis. 
 
PTEN  loss  is  the  second  most  common  tumour  suppressor  gene  deletion  after  p16  in 
melanoma (250;252). PTEN co-operated with p16 and H-Ras in melanoma both in vivo and 
in  vitro  experiments  implicated  that  PTEN  involved  in  mouse  melanoma  development 
(262).  Therefore  in  collaboration  with  Hong  Wu,  UCLA  in  US,  PTEN  floxed  mice 
(D5PTEN
flx/flx), expressing an exon 5 flanked by loxP sites to ablate functional PTEN TSG, 
were also imported from US under the home office regulations to cooperate with N-Ras
lys61 
expression in melanocyte/keratinocyte and to investigate their potential cooperation during 
melanomagenesis. 
 
Following importation, rabies quarantine and re-derivation via embryo transfer, the mice 
were  ear  tagged  and  tail  cut  for  genotyping  via  PCR  using  primers  K14Cre.fwd  
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(TCATTTGGAAC GCCCACT), K14Cre.rev (GATCCGAATAACTACCTGTTTTG) and 
PTEN.fwd (ACTCAAGGCAGGGATGAGC), PTEN.rev (GTCATCTTCACTTAGCCAT 
TGG) as described in methods. Following identification of K14CrePR1 and floxed PTEN 
PCR  positives,  their  progenies  were  produced  in  a  C57BL6  background  (Fig  21,  22) 
through seven back cross with wild type C57BL6 to ensure a genetically identical inbred 
C57  background.  To  produce  floxed  PTEN  homozygotes  (D5PTEN
flx/flx)  for  complete 
PTEN  ablation,  a  brother-sister  mating  of  F1  heterozygous  (Fig  23)  was  set  and 
D5PTEN
flx/flx mice were obtained (Fig 24). 
 
                     
+    - a13      a14      a15                  a16     a17      a18       a19      a20 
a21 a22       a23      a24      a25                  a26      a27      a28     a29      a30 
            
 
Figure 21: K14CrePR1 positive progenies were identified. K14CrePR1 positive progenies 
were identified from F1 (a13-a30) of K14CrePR1 imported mice in C57BL6 using primers 
K14Cre.fwd  and  K14Cre.rev.  410-bp  PCR  product  represents  K14CrePR1  transgenic 
positive mice. (+), PCR from genomic DNA of imported K14Cre mice as positive control 
and (-) PCR from C57BL6 DNA as negative control. DNA marker is Invitrogen 1kb plus 
DNA ladder (#10787-026). 
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a42 a43  a44  a45 a46  a47 a48  a49  a50 a51
               
Figure 22: Heterozygous PTEN (+/-) obtained from F1 progenies. All are Heterozygous 
PTEN  (+/-)  obtained  from  F1  (a42-a51)  progenies  of  imported  floxed  PTEN 
(D5PTEN
flx/flx)  in  C57BL6/ICR  background.  Top  band  represents  floxed  PTEN  (+/+, 
D5PTEN
flx/flx)  allele  and  lower  band  indicates  wild  type  PTEN  allele  (-/-).  Wild  type 
control (-/-) and floxed PTEN control (+/+) are from C57BL6 and imported D5PTEN
flx/flx 
mice respectively. DNA marker is Invitrogen 1kb plus DNA ladder (#10787-026). 
 
 
a135 a136 a137 a138 a139 a140 a141 a142 a143 a144 a145 a146   a147 a148 a149 a150 a151 a152 a153 a154 a155 
a156 a157 a158          a159 a160 a161 a162 a163 a164 a165 
 
Figure 23: Expected Mendelian fashion (a135-a165) obtained from heterozygous breeding. 
Either wild type (1/4), heterozygous (2/4) or homozygous PTEN (D5PTEN
flx/flx)
 (1/4) were 
detected from progenies of F1 (heterozygous) sister-brother breeding (a42 x a46; a43 x 
a47; a44 x a50 and a45 x a51, see Figure 22) in the expected Mendelian fashion. Single 
small band (900-bp) presents wild type PTEN (-/-), single big band (1100-bp) presents 
D5PTEN
flx/flx (+/+) and double band samples are for PTEN heterozygous. Parental genomic 
DNAs used as wild type (-/-) and floxed (+/+) controls. DNA marker is Invitrogen 1kb plus 
DNA ladder (#10787-026).  
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a232 a233 a234 a235 a236 a237 a238           a239 a240 a241 a242
a243  a244 a245 a246  a247 a248 a249          a250  a251 a252 a253
 
Figure 24: Pure D5PTEN
flx/flx mice generated (a232-a253) from sister/brother homozygous 
breeding. Breeding of D5PTEN
flx/flx mice (a136 x a142; a128 x a147and a148; a151 x a164 
and a162 x a165 from Fig 23) produces pure D5PTEN
flx/flx mice (all progenies are single 
1100-bp band). -/- and +/+ are wild type and floxed PTEN control using parental genomic 
DNAs from a140 and a138 mouse respectively. DNA marker is Invitrogen 1kb plus DNA 
ladder (#10787-026).  
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3.4.3. Functional gene switch identification in vivo 
Although  Cre/loxP  gene  switch  system  has  been  well  characterized,  the  imported 
K14CrePR1 and D5PTEN
flx/flx were used to verify functional activity in vivo, to confirm the 
Ru486 Cre/loxP system and to obtain technical in vivo insights for the EICre melanoma 
model. Therefore, bigenic K14Cre/PTEN
flx/flx were put on procedure for topical painting of 
Ru486  to  activate  K14CrePR1  to  ablate  floxed  exon  5  of  PTEN  exclusively  in  the 
epidermis, resulting in keratinocyte hyperplasia and investigations on carcinogenesis (246)  
 
Using primers P1 (located at exon 4, PTEN.fwd), P2 (a primer located within exon 5 for 
PTEN genotyping, PTEN.rev) and P3 (a primer located within exon 6 after the second loxP 
site) (Fig 25), production of a new 400-bp PCR product was indicative of the truncated  5 
allele in either Ru486-treated heterozygous or homozygous skin, but not from untreated 
bigenic mice or treated/untreated wild type controls. This verified that the CrePR1 fusion 
recombinase protein was activated in vivo following Ru486 application and furthermore, 
the  activated  CrePR1  is  responsible  for  ablation  of  ‘floxed’  fragment  in  keratinocytes 
because of the K14 promoter.  
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Figure  25:  Scheme  of  gene-switch  identification  in  vivo.  Gene-switch  specificity  was 
identified  in  vivo  employing  K14CrePR1  and  floxed  PTEN  (D5PTEN
flx/flx)  mice.  D5 
fragment  obtained  from  either  homozygous  (+/+,  lane  3,8,9)  or  heterozygous  (+/-) 
PTEN/K14Cre (lane 2,6,7) bigenic mice skins via PCR of genomic DNA using primers P1, 
P2 and P3, but not from wild type (-/-) PTEN/K14Cre which also treated with Ru486 (lane 
1) and untreated either D5PTEN
flx/flx/K14Cre (lane 4) or wild type PTEN (lane 5) mice. 
0.9-kb,  1.1/0.9-kb  and  1.1-kb  pattern  of  PTEN  alleles  represent  wild  type  (-/-), 
heterozygous  (+/-)  and  homozygous  (+/+)  PTEN  respectively.  The  second  top  band 
(between homo and wild type) in lane 2, 6 and 7 (heterozygous) may be amplified from the 
wild type/floxed PTEN hybrid DNA (the fusion of 2 chromatids in chromosome) during 
the PCR annealing/extension steps, which also applies to Figs 22 and 23 above. DNA 
marker is Invitrogen 1kb plus DNA ladder (#10787-026). 
1      2       3      4      5     6      7      8      9  
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3.5. Identification  of  the transgenic  expressers of regulator  EICre  and 
target N-Ras
lys61 
3.5.1. Identification of regulator EICre expressers 
In  order  to  identify  transgene  expressers  following  identification  and  confirmation  of 
founder germline transmitters (above), primary melanocytes were isolated from the skin of 
F1 neonates and cultured in 50/50 medium. The following week, once sufficient number of 
melanocytes had grown, total RNA was isolated from trypsinized cells and expression of 
the EICre transgene analysed via RT-PCR. Exploiting primers that spanned the small intron 
cloned  within  the  SV-40  poly(A)  signal,  detection  of  a  smaller  PCR  product  from  RT 
samples than from tail DNA revealed that relatively a few of regulator EICre germline 
transmitters were expressers (Fig 26). 
 
DNA
RNA
4112  4118  4121  4314     4316  4714 4735
 
Figure  26:  Analysis  of  regulator  EICre  expression  in  primary  melanocytes.  Regulator 
EICre expression was detected in primary melanocyte cDNA prepared from F1 neonates 
RNA of transmitters (4112–4735) using primers crossing the small intron within the SV40 
p(A)  tail.  Lower  band  shows  EICre  expression  in  primary  melanocytes  and  top  band 
indicates DNA contamination from RNA samples. (+) with RT reaction, (-) without RT 
reaction. Lines 4118, 4121, 4314, 4316 and 4714 are EICre expressers, whereas lines 4112 
and 4735 are not EICre expressers although they were germline transmitters. DNA marker 
is Invitrogen 1kb plus DNA ladder (#10787-026).  
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As expression of RNA does not necessarily mean successful biological activity, primary 
melanocytes  of  expresser  lines  4118,  4121,  4314,  4316  and  4714  were  subjected  to 
transfection with the report target vector cmv.stop.EGFP to confirm successful gene switch 
function and their relative expression levels. Once the majority of primary keratinocytes 
died out and pure melanoblasts/melanocytes were present in dishes, cells were transfected 
and the following day incubated in 10
-9M Ru486 and 3 days later the different numbers of 
green cells assessed employing an immunofluorescence microscope. 
 
Controls included lack of Ru486 treatment to determine gene switch leakage and Ru486 
treated transfection of non-transgenic C57BL6 melanocytes both cohorts proving negative. 
By counting the number of green cells detectable in each line, the results revealed that lines 
4118,  4314  and  4714  displayed  reasonable  strong  and  numerous  EGFP  expressing 
melanocytes, while other two lines 4121 and 4316 have relative weaker and less EGFP 
expressing cells in dishes. Furthermore, 4314 was the strongest expresser amongst the five 
investigated lines giving the most numerous (approximately 200 vs. 80-120 green cells in 
each  transfected  dish)  and  most  intensively  green  cells  following  treatment  of  Ru486. 
Therefore, line 4314 was chosen for further analysis because the highest biological activity 
of Cre recombinase to result in highest level of target gene expression following Ru486 
treatment in primary melanocytes in vitro (Fig 27).  
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Figure  27:  EGFP  expression  in  report  target  transfected  regulator  melanocytes.  EGFP 
expression in primary melanocytes from regulator expresser lines 4314, 4118 and 4714 
were observed under fluorescent microscope following transfection of report target vector 
cmv.stop.EGFP and Ru486 treatment for 3 days. Untreated  controls were negative and 
transfected melanocytes of lines 4121 and 4316 have only very weak and few green cells 
detected which were not shown here. Cells were cultured in 50/50 medium and transfection 
carried out using Fugene-6 transfection reagent. Pictures were taken at 100x 
4314 
4118 
4714  
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The number of EGFP expressing cells from each transfected dish was not many, which 
indicated the targeting protein level may have been low. However, the protein level may 
not  exactly  mean  transcription  level.  Thus  RT-PCR  to  semi-quantify  targeting  gene 
transcription  level  was  carried  out  by  isolating  RNA  from  cmv.stop.EGFP  transfected 
primary melanocytes of lines 4118, 4314 and 4714 which showed relatively stronger EGFP 
expression in the above analysis. A primer pair which spanned across generic intron within 
the target vector was employed to distinguish PCR products of RNA from contaminant 
DNA. This detected a smaller band from RT-PCR than from transfected target vector DNA 
in  transgenic  regulator  melanocytes  following  Ru486  treatment,  whereas  no  such  band 
could be observed in without Ru486 treatment or Ru486 treated non-transgenic control 
melanocytes.  This verified Cre activation in melanocytes of regulator expresser lines 4314, 
4118 and 4714 following Ru486 treatment and the subsequent ablation of floxed ‘Stop’ 
sequences to result in the expression of target genes (Fig 28).  Furthermore, all of the 
targeting gene expression levels were consistent with their transcription levels, with 4314 
having both relative strongest protein activity and highest transcription level amongst the 
three lines analysed. 
 
 
Figure 28: RT-PCR of report target transfected melanocytes of regulator expressers. RT-
PCR  products  were  detected  from  cmv.stop.EGFP  transfected  primary  melanocytes  of 
regulator EICre expresser lines 4314 (sample 2), 4118 (sample 3) and 4714 (sample 4). 
Higher band (490-bp) indicates DNA contamination of samples and lower band (290-bp) 
reveals expression of target gene EGFP. Sample 1 is without Ru486 treatment control and 
sample 5 is non-transgenic melanocytes control. (+) is with RT reaction and (-) is without 
RT reaction. DNA marker is Invitrogen 1kb plus DNA ladder (#10787-026). 
 1                    2                     3                    4                    5  
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3.5.2. Identification of target N-Ras
lys61 expressers 
As described for identification of germline transmitters, to quickly identify target N-Ras
lys61 
expressers, yet avoid the difficulty of primary melanocytes culture and variable transfection 
of numerous melanocyte lines, F1 keratinocytes cultures were established from breeding N-
Ras founders with K14CrePR1 mice. This also had the advantage employing a known, well 
characterised  gene switch regulator, strongly expressed in keratinocytes from a Keratin 
K14  promoter  (467).  Primary  keratinocytes  of  K14Cre/N-Ras
lys61  bigenic  mice  were 
cultured  under  proliferative  low  calcium  conditions  and  treated  with  or  without  10
-9M 
Ru486,  followed  by  RNA  isolation  and  RT-PCR  reaction.  Using  primers  forward  one 
located in front of generic intron and reverse one within the N-Ras
lys61 gene, detection of a 
smaller  RT-PCR  product  of  line  4734  primary  keratinocytes  than  PCR  product  of 
contaminant DNA indicated correct splicing of the generic intron. These experiments also 
revealed that target gene expression in only 4734 (Fig 29a) not 7156 (data not shown) 
keratinocytes. Dishes were assessed in triplicate to ensure result in both transmitter lines. 
 
 
Figure 29a: Oncogenic target N-Ras
lys61 expressed in K14Cre/N-Ras
lys61 primary bigenic 
keratinocytes. N-Ras
lys61 expression (line 4734) was detected from primary keratinocytes of 
K14Cre/N-Ras
lys61 bigenic mice following Ru486 treatment for 3 days via RT-PCR using 
primers  crossing  over  generic  intron  within  target  gene.  Lower  band  shows  N-Ras
lys61 
expression while top one indicates DNA contamination. Samples 1-3 are Ru486 treated 
bigenic keratinocytes with (+) or without (-) RT reaction from triplicate dishes, far left lane 
and  sample  4  are  transgene  DNA  and  bigenic  keratinocytes  without  Ru486  treatment 
control respectively. DNA marker is Invitrogen 1kb plus DNA ladder (#10787-026). 
 
A 
1  1  1  2  3  4  1  
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Because line 4734 was the only N-Ras
lys61 target transgene expresser identified amongst 
few founders and thus its expression is uniquely important for this project, expression was 
further analysed employing a panel of primer pairs located at various positions (forward 
primers p76 sites within CMV promoter, p61 in front of generic intron and p66 locates at 
the 5’ end of N-Ras gene, reverse primers p62 and p67 site at the C-terminal of N-Ras gene 
and SV40 poly(A) signal respectively) within the construct employing target monogenic N-
Ras primary keratinocytes as control. Use of forward primers located either within the 
CMV promoter or the junction of 'Stop' cassette and intron, and reverse primers site at 
various positions within N-Ras
lys61 respectively, gave different sizes of PCR product in 
Ru486 treated bigenic keratinocytes but not in monogenic cells (Fig 29b).  
 
To  confirm  ablation  of  floxed  sequences  by  the  active  CrePR1  fusion  protein  and 
successful splicing of generic intron, two forward primers one located in front of intron 
(P2) and one situated at the end of promoter (P1), together with a reverse primer (P3) 
within N-Ras
lys61 gene were designed and employed for RT-PCR. Primers P2+P3 gave an 
only  slightly  smaller  RT-PCR  product  than  P1+P3  because  of  the  location  of  forward 
primer and ablation of floxed ‘Stop’ cassette. A bigger band was detected from transgene 
DNA than from RNA in P2+P3 reaction due to the generic intron, whereas no PCR product 
was  detectable  from  transgene  DNA  in  reaction  P1+P3  because  the  size  (>3kb)  of  the 
expected product was too large to be detected under these PCR conditions (Fig 29c).   
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Figure  29b:  Analysis  of  oncogenic  target  N-Ras
lys61  expression.  N-Ras
lys61  expression 
detected from primary keratinocytes of K14Cre/N-Ras
lys61 bigenic mice following Ru486 
treatment  for  3  days  via  RT-PCR  employing  additional  series  of  primers.  p61+p62; 
p66+p67; p76+p62; p66+p62 and p61+p67 represent lane 1 to 5 respectively, of which 
locate at various positions within target vector and the same order of primer pairs repeated 
for lane 7 to 11. Lane 1-5, K14Cre/N-Ras
lys61 bigenic primary keratinocytes treated with 
Ru486 have N-Ras
lys61 expression; lane 6, DNA marker (Invitrogen 1kb plus DNA ladder 
(#10787-026));  Lane  7-11,  no  N-Ras
lys61  expression  detectable  in  monogenic  mouse 
cmv.stop.N-Ras
lys61 control keratinocytes with Ru486 treatment. 
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Figure 29c: Scheme of confirmation of N-Ras
lys61 expresser. To confirm mouse 4734 as a 
germline expresser of the N-Ras
lys61 transgene, Ru486 treated bigenic K14Cre/N-Ras
lys61 
primary keratinocytes were analysed via in vitro RT-PCR. Employing primer pair P2+P3, 
successful N-Ras
lys61 expression in line 4734 was confirmed by detection of a ~450bp PCR 
product (DNA contamination produces a ~650bp band resulting from existence of intron). 
Employing  primer  pair  P1+P3,  successful  expression  of  correctly  spliced  N-Ras
lys61 
transcript produced a ~550bp band owing to excision of the ‘STOP’ cassette in genomic 
DNA by Ru486 activated K14Cre while DNA contamination (product is more than 3kb in 
size)  was  not  detectable  by  designing  PCR  programme  for  detection  of  less  than  1kb 
product.  DNA marker is Invitrogen 1kb plus DNA ladder (#10787-026) 
P2+P3  P1+P3  
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3.6. Generation of compound transgenic genotypes EICre/N-Ras
lys61 and 
EICre/N-Ras
lys61/D D D D5PTEN
flx/flx,  and  identification  of  gene-switch 
specificity  
 
Following the establishment of monogenic lines expressing both regulator EICre and target 
cmv.stop.N-Ras
lys61,  confirmation  of  functional  gene  switch  activity  in  melanocytes  by 
transfection of target vector into regulator primary melanocytes and confirmation of target 
in  vivo  expression  in  K14Cre/cmv.stop.N-Ras
lys61  bigenic  keratinocytes  (above),  
EICre/cmv.stop.N-Ras
lys61 bigenic cohorts were bred and topically treated with Ru486 to 
determine whether N-Ras
lys61 activation was an initiating event in this melanoma model.  
 
Therefore, bigenic adult EICre/cmv.stop.N-Ras
lys61 mice were put on procedure. In brief, 
plucking hair induces telogen phase follicles to re-enter into anagen and thus stimulates 
maximum melanocytes proliferation and expression of the tyrosinase promoter in vivo to 
produce cellular targets for topical Ru486 treatment whilst IP injection in addition ensured 
Ru486 delivery to the base of hair follicles. However, after 3-4 months of treatment these 
mice failed to produce melanoma unlike e.g. in the Chin’s model where melanoma was 
induced by H-Ras expression on a CDKN2A deficient background (223), or even elicit any 
overt melanocyte hyperplastic phenotype as when H-Ras was expressed in melanocytes by 
Powell via a similar but constitutive, not gene switched, Tyr-based vector (216). Therefore, 
experiments quickly progressed to show that gene switch specificity in vivo was confirmed 
by detection of N-Ras target gene expression in treated mice skin and in the meantime, 
giving the frequency of PTEN mutations in human melanoma, conditional knockout of 
tumour suppressor gene PTEN (D5PTEN
flx/flx) instead of constitutive deficient of CDKN2A 
gene, was introduced to assess whether melanoma would be elicited by  cooperation of 
PTEN function loss
 with N-Ras
lys61 expression.  
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3.6.1. Line production and induction of N-Ras
lys61 expression by treatment with Ru486 
EICre/N-Ras
lys61  bigenic  line  was  first  produced  by  crossing  EICre  with  cmv.stop.N-
Ras
lys61 mice following typical breading procedures and PCR screening of progenies. To 
generate trigenic line EICre/N-Ras
lys61/D5PTEN
flx/flx, floxed PTEN (D5PTEN
flx/flx) was bred 
with EICre/N-Ras
lys61 to obtain heterozygous D5PTEN in EICre/N-Ras
lys61 bigenic mice 
(D5PTEN
flx/-/EICre/N-Ras
lys61) initially followed by brother-sister mating to produce floxed 
PTEN
 trigenic mice (D5PTEN
flx/flx/EICre/N-Ras
lys61) as described at 3.4.2 for D5PTEN
flx/flx 
production. 6-8 week old transgenic mice with appropriate controls were then set for the 
experiments. Controls included ethanol treatment of compound transgenic mice and Ru486 
treatment of mono genotype littermate siblings. 
 
One  aspect  of  this  study  is  the  necessity  of  tyrosinase  expression  in  proliferative 
melanocytes  for  regulator  expression  and  gene  targeting.  Murine  melanocytes  ceased 
proliferation  and  undergo  apoptosis  at  catagen  and  thus,  during  telogen  few  epidermal 
melanocytes are apparent in adult epidermis. To initiate the hair cycle and obtain maximal 
target  melanocytes  for  Ru486  treatment  approximately  7-9  days  later  as  determined  in 
timed experiments (Fig 30), the mouse back hair was plucked at day zero of procedure and 
then approximately every 4 weeks as the hair grew back. Mice were topically painted with 
100ml of 100mg/ml Ru486 (468) twice a week together with once a week IP injection of 
0.4g Ru486/per kg mice weight to ensure efficient delivery of Ru486 to the hair follicle 
(469) (average weight 25g was considered).  
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Figure 30: Melanocytes growth following hair plucking. TRP2-stained melanocytes (green) 
of skin biopsies show maximal melanocytes exist in hair follicle 7-9 days after plucking. 
From top to bottom pictures represent staining of biopsies from 1, 3, 7 and 9 days post-
plucking respectively and K14 (red) used for counter staining. Pictures were taken at 100x.  
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3.6.2. Confirmation of N-Ras
lys61 expression in vivo 
Due to the failure of melanoma or any hyperplastic melanocyte production following mice 
on procedure for 3 months when the mice were expected to have produced phenotypes 
(216;223),  N-Ras
lys61  expressing  was  confirmed  by  in  vivo  detection  via  RT-PCR  by 
isolating RNA from those Ru486 treated, plucked mice skins. Controls included vehicle 
treated bigenic mice skin and Ru486 treated wild type skin (Fig 31).  
 
 
500bp
400bp
 
 
Figure  31:  Confirmation  of  melanocyte  specific  gene-switch  specificity  in  vivo.  Target 
gene N-Ras
lys61 expression was detected in Ru486 treated bigenic EICre/N-Ras
lys61 mice 
skins but not in Ru486 applied wild type C57BL6 or vehicle treated bigenic mouse A1136 
skins. As outlined above, primer pair P2+P3 used for Fig 29c were employed for RT-PCR 
here and a ~450bp fragment confirmed N-Ras
lys61 expression in vivo in EICre/N-Ras
lys61 
bigenic mice. DNA marker is Invitrogen 1kb plus DNA ladder (#10787-026) 
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Following identification of N-Ras
lys61 target gene expression and the identification of gene 
switch  functional  specificity  in  vivo,  the  mice  were  kept  on  procedure  for  longer  to 
investigate whether inducible N-Ras
 lys61 expression was sufficient to generate melanoma or 
any  phenotypes  with  longer  latency.  Recently  a  similar  but  constitutive  N-Ras(Q61K) 
expression model was shown to be able to generate melanoma although with a long latency 
of more than one year and following embryonic expression throughout development (215), 
whereas H-Ras expression gave simple melanocyte hyperplasia in the absence of UV or 
DMBA initiation (216;221).  
 
A  conditional  knockout  of  tumour  suppressor  gene  PTEN  instead  of  common  using 
CDKN2A gene, was introduced to promote eliciting of melanoma model by cooperation of 
PTEN function loss
 with N-Ras
lys61 expression which cooperated quite successfully with H-
Ras in a model of squamous cell carcinogenesis (246). However, again unexpectedly a lack 
of  melanoma  production  resulted  from  EICre/N-Ras
lys61/D5PTEN
flx/flx  trigenic  mouse, 
suggesting therefore a redundancy between these two insults in melanocytes in vivo and 
therefore, the investigation of whether PTEN function loss promoting N-Ras
lys61 initiated 
tumourigenesis  in  vitro  was  performed  employing  colony  formation  assay  in  primary 
melanocytes (below).  
 
Keratinocyte can secret numerous regulatory factors to control melanocyte development as 
well  as  to  play  potential  roles  in  melanoma  formation  (470).  K14Cre,  a  regulator 
controlling target gene expression in keratinocytes specifically, was introduced to induce 
epidermal hyperplasia by switching N-Ras
lys61 expression in keratinocytes at the same time 
in melanocytes by EICre regulator. Disruption of melanocytes microenvironment (mainly 
keratinocytes) could release melanocytes from enslavement by keratinocytes, a seed/soil 
hypothesis  (471)  was  therefore  added  to  this  model  (see  3.9)  to  investigate  PTEN 
functional loss promotion on N-Ras
lys61 expression for melanoma production.   
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3.7. Colony formation in PTEN loss and N-Ras
lys61 expressing melanocyte 
As mentioned above, PTEN function loss did not appear to have a synergistic effect on 
inducible N-Ras
lys61 initiation in the triple EICre/N-Ras
lys61/D5PTEN
flx/flx transgenic mouse 
and there was no obvious difference observed from EICre/N-Ras
lys61 mouse. Despite the 
successful expression of the gene switch in vivo and in vitro, serious concerns as to a lack 
of  phenotype  in  vivo  experiments  and  essential  role  of  PTEN  in  carcinogenesis  (245) 
prompted an in vitro analysis of whether N-Ras
lys61 and PTEN biological function loss 
would co-operate to transform melanocytes, whereas TSG PTEN function-loss promoted 
tumourigenesis  in  cooperation  with  H-Ras  in  keratinocytes  (246).  Furthermore,  whilst 
PTEN mutations, were often detected in melanoma cell lines but less often in short-term 
cell (STC) lines and solid melanomas (reviewed in (264)) implied that PTEN functions 
may play different roles between in vitro and in vivo.  Therefore, to investigate whether 
PTEN  function-loss  promote  N-Ras
lys61  initiated  tumourigenesis  in  melanocyte  in  vitro, 
colony formation assays were performed employing target transgenic melanocytes and the 
defined protocols of transfection. Here the relatively stronger (compare to EICre) TRP2Cre 
regulator was employed for transfection despite its previously discovered leakage (table 2, 
section 3.3.2) which would not interfere but actually enhance the analysis in vitro. 
 
The results demonstrated that N-Ras
lys61 expression or PTEN loss led to faster melanocyte 
proliferation and together PTEN promoted N-Ras
lys61 expression to initiate transformed cell 
colony morphology in tagged immunofluorescent protein expressing (EGFP) as well as in 
G418  selection  experiments.  However,  and  consistent  with  the  eventual  redundancy 
concluded  between  these  molecules  in  vivo  (see  below  3.8),  in  vitro  although 
morphologically  more  transformed,  N-Ras
lys61/D5PTEN
flx/flx  cell  co-expressers  were  not 
immortalized because cells in 50/50 medium still senesced by passage 5 or 6 but remained 
viable for some more months in culture.  
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3.7.1. EGFP immunofluorescence tagging 
The experiment to test the transforming ability of PTEN loss or/and N-Ras
lys61 expressing 
in melanocytes was performed in 50/50 medium to avoid any spontaneous transformation 
(melanocytes  in  Halaban  medium  spontaneously  transformed,  see  section  3.2.2).  To 
quickly and easily confirm that  transformation was induced by gene switch activities and 
produce colonies visible under immunofluorescence microscope, a cmv.stop.EGFP plasmid 
was co-transfected to tag melanocytes together with Trp2Cre at a ratio of 1:3 (to render all 
EGFP expressing cell are TRP2Cre transfected) into wild type, monogenic (D5PTEN
flx/flx 
or  N-Ras
lys61)  and  bigenic  D5PTEN
flx/flx/N-Ras
lys61  melanocytes.  Following  4-5  weeks 
continuous  culture  in  presence  of  10
-9M  Ru486,  green  colonies  expressing  EGFP  were 
formed in all transfected different genotypic cells (Fig 32 and Fig 33). The morphology of 
colony  cells,  however,  was  significantly  different  between  colonies  formed  from 
transfections of different genotypic cells. 
 
In wild type control dishes, green cells without orientation were often observed as separate 
events  (close  individual  transfected  cells)  rather  than  a  colony  proliferated  from  single 
transfected cells. Indeed, two likely colonies formed by single transfected cell amplification 
were  observed  among  three  C57BL6  dishes  but  cells  retained  a  normal  morphology. 
Moreover, there are only 3 and 4 cells comprised in each colony in contrast to the most of 
colonies formed in transgenic cells consisted of numerous cells (Fig 32, left panel). 
 
Following  biological  function  loss  of  TSG  PTEN  via  co-transfection  of  TRP2Cre  and 
cmv.stop.EGFP  into  D5PTEN
flx/flx  melanocytes,  greater  numbers  of  green  colonies  still 
without orientation were observed in transfected D5PTEN
flx/flx melanocytes dishes than in 
transfected C57BL6 wild type control dishes. These colonies were also bigger than control 
colonies, as PTEN loss promoted cell proliferation. However, the melanocytes in PTEN 
null colonies remained contact inhibition characteristic (Fig 32, right panel).  
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Figure 32: Colonies formed in wild type and D5PTEN
flx/flx melanocytes. Green colonies 
without  orientation  formed  in  TRP2Cre/cmv.stop.EGFP  cotransfected  primary  cultured 
melanocytes of wild type (left panel A, B) and of D5PTEN
flx/flx (right panel C, D) following 
4-5 weeks continuous culture in presence of Ru486. Photographs were taken at 200x. More 
and bigger green colonies obtained from D5PTEN
flx/flx melanocytes (right panel) due to loss 
of PTEN function switched by active Cre recombinase under control of TRP2 promoter, 
whilst single transfected melanocyte-clusters rather than formed colony (2 pictures of left 
panel show a few such clusters or ‘colonies’) occasionally observed from transfected wild 
type C57BL6 melanocytes. Arrows show colonies without orientation or may be just green 
cell clusters.  
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In contrast to the colonies formed in wild type and D5PTEN
flx/flx melanocytes, TRP2Cre 
transfected  cmv.stop.N-Ras
lys61  primary  melanocytes  formed  more  and  various  colonies 
due to the expression of oncogenic protein N-Ras
lys61 following Ru486 treatment (Fig 33, 
A-C).  N-Ras
lys61  expressing  colony  cells  presented  as  various  shapes  with  most  being 
spindle shaped consistent with a transformed nature. The green colony cells looked capable 
of a degree of migration/invasion either growing within another colony or grow on the top 
of another brown colony, which could be the result of non-EGFP transfection as TRP2Cre 
DNA was transfected at a higher 1:3 ration (EGFP : TRP2Cre applied) or possible result of 
EGFP expression turning off caused green immunofluorescent protein expression loss in 
some colony cells due to the toxicity of EGFP expression (A). 
 
In bigenic D5PTEN
flx/flx/N-Ras
lys61 melanocyte cells, loss of PTEN function in addition of 
N-Ras
lys61 expression following TRP2Cre transfection and Ru486 treatment induced a lager 
number of colonies with obviously more cells in each colony. However the area of green 
colonies (D-F) seemed smaller than of those colonies formed in cmv.stop.N-Ras
lys61 and 
D5PTEN
flx/flx monogenic dishes suggesting that theses melanocytes piled up on each other. 
Cells  in  these  colonies  lost  contact  inhibition  characteristic  of  normal  cell  to  become 
multiple piled up layers and thus it was impossible to distinguish individual cells, and 
colonies were smaller and more compact despite more cells than some of those formed in 
monogenic dishes. This suggested an increased invasive ability especially in colony F by 
growing on top of the surrounding melanocytes. However, even these colony cells senesced 
eventually  following  5-6  passage  sub-culture  suggesting  that  these  cells  were  not 
immortalized. Moreover, this may  have been the in vitro equivalent of the melanocyte 
cluster effect observed in pigmented papilloma aetiologies (Section 3.9).  
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Figure  33:  Colonies  formed  in  N-Ras
lys61  and  D5PTEN
flx/flx/N-Ras
lys61  melanocytes. 
Potential  transformed  colony  formed  in  N-Ras
lys61  (A-C,  100x)  monogenic  dishes  and 
migratory/invasive ability promoted by PTEN function loss in D5PTEN
flx/flx/N-Ras
lys61 (D-
F, 200x) bigenic melanocytes following co-transfection of TRP2Cre and cmv.stop.EGFP 
(3:1). Photos were taken after 4-5 weeks continuous culture in presence of Ru486 post 
transfection. 
A 
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3.7.2. G418 selection 
To verify in vitro results obtained by immunofluorescence marking of transformed colonies 
as  described  above,  CMV-neo  (a  plasmid  allowing  G418  selection  in  50/50  medium 
applicable to result in only transgene expressing cell growth) was employed instead of 
cmv.stop.EGFP  to  transfect  primary  melanocytes  and  this  provides  a  more  stringent 
assessment of transformation potential and avoids potential problems from EGFP toxicity. 
Following co-transfection of TRP2Cre and CMV-neo (3:1 of DNA concentration to allow 
TRP2Cre transfect all CMV-neo transfected melanocytes), 200mg/ml of G418 (optimized 
in titration experiments to kill untransfected cells within 3 days but not too toxic to prevent 
colony selection) was added into transfected dishes to select CMV-neo transfected cells 
and 10
-9M
 Ru486 was presented to activate TRP2Cre to allow N-Ras
lys61 expression and/or 
PTEN function loss. 
 
Fig  34  shows  different  numbers  of  the  colonies  formed  in  each  dish  per  transfected 
genotype following G418 selection. Possibly due to continuous G418 selection pressure 
and the slow growth of primary murine melanocytes without keratinocyte feeders, the time 
to obtain reasonable colony size took longer than expected. Tiny, visible colonies appeared 
at week 6-7 post transfection, with clear differences emerging between transfected colonies 
as  show  at  10-11  weeks  selection  of  G418.  In  this  figure,  colonies  appeared  in  all 
transfected  dishes  but  with  significant  different  number  and  size  of  colony  in  various 
genotypic  cells.  In  C57BL6  melanocytes,  very  few  cells  survived  G418  selection  to 
occasionally  form  a  very  tiny  spontaneous  colony,  normally  visible  only  under  the 
microscope,  in  contrast  to  big,  black  and  obvious  colonies  formed  in  D5PTEN
flx/flx,
 N-
Ras
lys61 and D5PTEN
flx/flx/N-Ras
lys61 melanocytes given function loss of PTEN or/and N-
Ras
lys61  expression.  Additionally,  N-Ras
lys61  expressing  dish  formed  more  colonies  than 
D5PTEN
flx/flx  dish.  Furthermore,  although  various  size  of  colonies  formed  in  both 
D5PTEN
flx/flx  and  N-Ras
lys61  dishes,  more  significant  size  difference  between  colonies  
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presented in D5PTEN
flx/flx dishes with some are extremely big while others are really tiny 
which are visible only under microscope, compared to colonies formed in D5PTEN
flx/flx/N-
Ras
lys61 that appeared almost similar sized. These results are consistent with the results 
obtained  from  the  previous  EGFP-based  immunofluorescence  transfection  observations. 
Again, there are more colonies presented in D5PTEN
flx/flx/N-Ras
lys61 than in D5PTEN
flx/flx 
and N-Ras
lys61dishes. 
 
 
 
Figure  34:  Colony  formation  in  TRP2Cre/CMV.neo  cotransfected  primary  melanocytes 
following  G418  selection.  Colonies  formed  in  different  genotypic  primary  melanocytes 
following cotransfection of regulator TRP2Cre together with selecting plasmid CMV-neo 
and G418 application. There are tiny and few difficult visible colonies in C57BL6 dishes 
(A), more and variable size colonies in monogenic melanocytes dishes D5PTEN
flx/flx (B) 
and N-Ras
lys61 (C)  while  D5PTEN
flx/flx/N-Ras
lys61 (D) gave most colonies. The results are 
consistent with the previous observation of green colonies using EGFP protein as a marker. 
C 
A  B 
D  
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By comparing (Fig 35) cell morphology between colonies formed in different genotypic 
melanocytes, identical results to the unselected experiments (3.7.1) were obtained. Again, 
selected C57BL6 cells grow very slowly eventually forming a few tiny colonies (A) with 
some  are  microscopic  (B).  Colonies  formed  in  D5PTEN
flx/flx  melanocytes  were  much 
bigger than those in C57BL6 dishes because the function loss of PTEN promoted cell 
proliferation. Cells in both colonies retained their contact-inhibition characteristic and grew 
as monolayer even in the dense colonies (C). Cells in colonies formed in PTEN function 
loss presented a relatively normal morphology as described above suggesting that PTEN 
loss promoted cell proliferation but not transformation, unlike cells in N-Ras
lys61 expressing 
colonies (3.7.1 and below) 
 
          
Figure 35: Colony cell morphologies in wild type and D5PTEN
flx/flx melanocytes. Colonies 
formed  in  TRP2Cre  transfected  D5PTEN
flx/flx  primary  melanocytes  following  200mg/ml 
G418 for 10-11 weeks selection. PTEN function loss promotes cell proliferation to form 
very  big  colonies  (C,  D)  compared  to  spontaneous  colonies  formed  in  wild  type 
melanocytes (A, B). Photographs were taken at 100x except B (400x).  
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Consistent with the results obtained from 3.7.1 using green fluorescent protein as a marker, 
in contrast to the colonies formed in wild type, N-Ras
lys61 expressing dishes form more 
colonies and furthermore, colony cells (Fig 36, A-B) presented different shapes from those 
cells in normal melanocytes dishes and in D5PTEN
flx/flx dishes. 
 
In addition to forming a greater number of colonies, than in monogenic and wild type cells 
(Fig 34), the morphology of bigenic melanocyte cells was significantly different from those 
monogenic and wild type colony cells (above 3.7.1). Addition of PTEN functional loss 
(D5PTEN
flx/flx) to N-Ras
lys61 expressing promoted a further change of cell morphology in 
D5PTEN
flx/flx/N-Ras
lys61  colonies  (Fig  36).  The  most  important  factor  among  these 
differences  is  that  cells  in  these  colonies  lost  contact  inhibition  characteristics  to  gain 
multilayer growth ability of the characteristic of transformed cells, thus it is impossible to 
distinguish any single cell in the centre of these colonies. Furthermore, these colonies have 
more spindle shape cells with disappearing of those round and oval shaped cells which 
mainly presented in normal cultured melanocytes (Fig 13) and thus, cells in these bigenic 
colonies  are  different  again  from  cells  in  those  colonies  formed  in  wild  type  and 
D5PTEN
flx/flx or N-Ras
lys61 monogenic melanocytes as presented in Fig 35. 
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Figure 36: Morphology of colonies formed in N-Ras
lys61 and D5PTEN
flx/flx/N-Ras
lys61. A 
number  of  different  colonies  formed  in  monogenic  N-Ras
lys61  (A,  B)  and  bigenic 
D5PTEN
flx/flx/N-Ras
lys61  (C-F)  melanocytes  following  regulator  TRP2Cre  co-transfection 
with  selective  vector  CMV-neo  and  continuous  G418  selection.  Cell  morphologies  in 
D5PTEN
flx/flx/N-Ras
lys61 colonies are significantly different from those in colonies formed 
spontaneously (wild type, Fig 35 A, B) or monogenic N-Ras
lys61 (and D5PTEN
flx/flx in Fig 
35 C, D) dishes due to promotion of PTEN function loss on N-Ras
lys61 oncogenic protein. 
All photos were taken at 50x. 
A  B 
C  D 
E  F  
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This colony formation analysis in vitro demonstrated that PTEN function loss promoted N-
Ras initiated tumourigenesis to form colonies with a transformed nature. In addition, the 
finding that D5PTEN
flx/flx/N-Ras
lys61 colony cells still senesced and were viable in dishes 
for months but were not immortalised, was consistent with the eventual conclusion to this 
study that an N-Ras/PTEN redundancy apparently exists in vivo (below). 
 
Collectively,  by  inventing  50/50  medium  where  primary  melanocytes  grow  without 
spontaneous  transformation,  unlike  cells  cultured  in  Halaban  medium,  and  optimising  
transfectable capacity (see 3.2.2), an in vitro inducible gene switch model was established 
able  to  select  colonies  without  contamination  from  keratinocytes  or  spontaneous 
transformation  or  spontaneous  progressing  to  an  immortalised  phenotype.  The  results 
verified PTEN promotion of N-Ras initiated tumourigenesis in vitro, which is consistent 
with the previous reports in cell lines, and the fact that these cells were viable for months 
but  senesced  eventually,  implied  a  redundancy  between  PTEN  loss  and  N-Ras  genes, 
which was also proven by the experiments in vivo where PTEN  and N-Ras were both 
revealed to induce melanocyte apoptosis but lacked the power to ablate this protective 
pathway without additional genetics events for cross-talk.   
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3.8.  Phenotypes  obtained  from  EICre/N-Ras
lys61  and  EICre/N-Ras
lys61 
/D D D D5PTEN
flx/flx 
Initially  no  immediate  phenotypes  were  obtained  from  EICre/N-Ras
lys61  nor  the  mouse 
lines, EICre/N-Ras
lys61/D5PTEN
flx/flx and
 EICre/D5PTEN
flx/flx, which were put on procedure 
later  for  the  testing  of  PTEN  loss  promotion  on  N-Ras
lys61  initiation,  whereas  H-Ras 
expression  in  a  CDKN2A  gene  deficient  background  successfully  produced  melanoma 
(223). However, all mice were kept on procedure to test whether N-Ras
lys61 expression 
and/or PTEN function loss would produce melanoma eventually or any other phenotypes. 
 
Following  more  than  one  year  on  procedure,  an  eye  phenotype,  very  similar  to  that  
presented in the recently published Ackermann model of constitutive N-Ras expression 
(215), was obtained in EICre/N-Ras
lys61 bigenic mice. Yet the addition of PTEN functional 
loss  in  EICre/N-Ras
lys61/D5PTEN
flx/flx  trigenic  mice  failed  to  produce  additional 
phenotypes,  nor  accelerate  appearance  of  the  N-Ras-associated  eye  phenotype,  which 
indicated that in this case biological function loss of the PTEN gene lacked an ability to 
promote  N-Ras
lys61  initiation  unlike  H-Ras/PTEN  synergism  in  keratinocytes  (246). 
However cutaneous N-Ras expression apparently initially failed to result in a phenotype, 
but as outlined below, this was revealed later to be due to induction of a caspase-dependant 
apoptosis  pathway  which  eliminated  the  melanocyte  population  resulting  in  white  hair. 
Here functional PTEN loss still resulted in this apoptotic response in melanocyte and thus 
again,  additional  PTEN  loss  did  not  provide  an  alternative  pathway  to  overcome  this 
surveillance mechanism which therefore, negated melanoma formation in this model. Also 
unique to the EICre model was the presentation of Harderian gland adenoma, which was 
absent in alternate models, and may have been a consequence of different promoters and/or 
different Ras alleles as discussed below.  
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3.8.1. Phenotype 1— enlarged eyes and harderian gland adenoma 
3.8.1.1 Enlarged eyes  
Ru486-treated mice were checked twice a week for any phenotypes when the Ru486 (or 
vehicle  control)  treatment  was  applied.  Although  neither  bigenic  EICre/N-Ras
lys61  nor 
trigenic  mice  EICre/N-Ras
lys61/D5PTEN
flx/flx  had  developed  melanoma,  an  unexpected 
phenotype of enlarged eye was displayed in both bigenic and trigenic mice following 12-15 
months of systemic Ru486 treatment, which was absent in either Ru486 treated monogenic 
mice or vehicle (ethanol) treated bigenic and trigenic controls (Fig 37). This somewhat 
alleviated concern that the gene switch was non-functional in vivo because the controls 
remained normal although following treatment target expression was confirmed both in 
cultured cells and in skin biopsies (see 3.5.2. and 3.6.2.). Biopsies were obtained from 
phenotypic  mice  for  further  analysis  although  these  phenotypes  were  unexpected 
particularly in Harderian glands ─but a site proved to express tyrosinase (472). 
 
H&E stained micrographs of formalin fixed phenotypic eyes displayed a much larger size 
and  a  predominance  of  melanin  (Fig  38  A-D),  possibly  indicative  of  melanocyte 
hyperplasia in the RPE rather than overt tumour at this stage, compared to control eye (Fig 
38 E, F) when micrographs taken at the same magnification (50x). Furthermore, it had been 
expected that the trigenic EICre/N-Ras
lys61/D5PTEN
flx/flx would elicit melanoma because 
given  oncogenic  N-Ras
lys61  expression  and  PTEN  tumour  suppressor  gene  deletion, 
however this trigenic mouse line did not generate any additional phenotypes compared to 
bigenic mice.  
 
This  result  coupled  to  the  failure  to  develop  melanoma  in  trigenic  mice  revealed  that 
tumour suppressor gene PTEN deletion appears to be somewhat redundant in cooperation 
with oncogenic N-Ras
lys61 expression in melanocytes in vivo and therefore, clearly PTEN 
loss functions differ from CDKN2A gene. Although when the role of whether PTEN loss  
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would  cooperate  with  N-Ras
lys61  was  investigated  further  in  vitro  (see  3.7),  the  data 
demonstrated  that  PTEN  and  N-Ras  would  cooperate  but  melanocytes  were  still  not 
immortalised. This would fit into a redundancy idea observed in vivo and the lack of a 
cutaneous  melanocyte  phenotype  also  prompted  a  test  of  whether  microenvironment 
disruption via keratinocyte hyperplasia would affect melanocyte fate in vivo in a synergism 
that  allowed  N-Ras
lys61  expressing  melanocyte  dysregulation  to  give  a  phenotype  that 
resulted in melanoma (see 3.10 below). 
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  Figure 37: Presence of enlarged phenotypic eyes. Phenotypic eyes obtained in EICre/N-
Ras
lys61  and  EICre/N-Ras
lys61/D5PTEN
flx/flx  mice  following  12-15  months  of  systemic 
treatment  of  Ru486  (twice  topical  painting  and  once  IP  injection  per  week).  Vehicle 
(ethanol painting and sesame seed oil injection) treated trigenic control mouse (mouse 1) 
remained normal while phenotypic eyes appeared in Ru486 treated bigenic and trigenic 
mice (left eyes of mice 2 and 3; right eye of mouse 4 which is mild compare to eyes of 
mice 2 and 3). The histology of formalin fixed phenotypic eyes was further assessed by 
pathologists  in  the  Veterinary  Pathology  Department,  Veterinary  School,  Glasgow 
University, who reported no evidence of melanoma, but the presence of corneal ulceration 
and mild hyperplasia in the RPE layer. However, the pathologists also reported harderian 
gland adenoma, an unexpected phenotype which turned out to be due to the expression 
characteristics of the EICre regulator transgene, which again relieved concerns over a lack 
of expression in vivo (468)(See below). 
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Figure 38: H & E staining of phenotypic EICre/N-Ras eyes (A-D) compared to normal 
controls (E, F) taken at the same magnification (50x). All phenotypic eyes displayed a 
larger size and a predominance of melanin (arrow) with a thicker RPE indicative of cellular 
hyperplasia.  Abnormal  folded  neuroretinal  and  enlarged  choroid  were  also  observed  in 
these phenotypic eyes (also see Fig 51 at section 4.4). The specimens were further checked 
by pathologists in Glasgow University who reported no evidence of melanoma, but the 
presence of corneal ulceration and mild hyperplasia in the RPE layer. The result simply 
exploited to confirm successful gene switch activity (N-Ras expression) following Ru486 
treatment in vivo and we assume that N-Ras induced RPE hyperplasia which was absent in 
untreated or vehicle treated controls. This phenotype was not studied in further detail as it 
is not uveal melanoma but relieved concerns over whether the gene switch system was 
working in vivo and whether N-Ras was sufficiently expressed in vivo to give a phenotype. 
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3.8.1.2. Harderian gland adenoma 
Employing similar tyrosinase transcriptional elements to express Cre and report alkaline 
phosphatase (AP) expression, Tonks et al,  determined  tissue specific Tyr-Cre transgene 
expression in embryonic cells and the fate maps revealed that the harderian  gland had 
report gene activity (468). Due to the obvious eye bulge, when we harvested the enlarged 
eyes from those Ru486 treated EICre/N-Ras
lys61 bigenic and EICre/N-Ras
lys61/D5PTEN
flx/flx 
trigenic
  phenotypic  mice,  further  dissection  displayed  another  surprise  unexpected 
phenotype  ─enlarged  harderian  glands  with  a  pathology  diagnosed  as  adenoma  by 
pathologists in Veterinary Pathology Department, Veterinary School, Glasgow University. 
The harderian glands obtained from the phenotypic mice were much bigger than the ones 
obtained from Ru486 treated wild type or vehicle treated transgenic mice, although the 
sizes of phenotypic harderian glands varied between individuals (Fig 39). H&E histological 
staining  of  both  phenotypic  and  normal  harderian  glands  also  revealed  that  transverse 
sections  of  the  phenotypic  glands  are  much  bigger  than  the  normal,  and  possessed  a 
significantly different histotype compared to normal under low magnification (Fig 40, 50x). 
Initially, under the low magnification, little histological difference was observed between 
normal  and  certain  parts  of  phenotypic  glands  (Fig  40  B,  50x),  but  under  the  high 
magnification (100x for left panel and 200x for right panel) the differences between normal 
(Fig 41, A, B) and phenotypic glands (C-F) became obvious. 
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Figure 39: The size comparison of harderian glands between phenotypic mice and normal 
control mice. Harderian glands adenoma from Ru486 treated phenotypic bigenic EICre/N-
Ras
lys61 or EICre/N-Ras
lys61/PTEN
flx/flx trigenic mice (left and middle in each panel) were of  
a much bigger size compared to  wild type or vehicle treated bigenic mouse control  (right 
in each panel).  
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Figure  40:  H&E  staining  of  normal  and  phenotypic  harderian  glands.  The  transverse 
sections  show  the  different  sizes  of  harderian  glands  obtained  from  normal  (A)  and 
phenotypic (B-D) mice. The adenoma histology of phenotypic glands was also revealed in 
the larger phenotypic harderian glands under the low magnification (50x). 
A  B 
C 
D  
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Figure 41: Higher magnification (100x for left panel A, C, E and 200x for right panel B, D, 
F) shows subtle differences between normal and phenotypic harderian glands. Compared to 
normal (A, B), significant structure difference was revealed in phenotypic glands (E, F). As 
shown on Fig 40 B, some parts of the phenotypic glands looked very similar to the normal 
gland  under  lower  magnification  (50x),  however,  an  adenoma  pathology  was  clearly 
indicated  at  higher  magnification  (C,  100x  and  D,  200x).  This  unexpected  phenotype 
turned out to be due to the expression characteristics of the EICre regulator transgene as 
cited in the text that other groups reported harderian expression of this promoter (468). 
Thus these phenotypes were not studied in further detail but again simply exploited to 
confirm successful gene switch activity following Ru486 treatment in vivo and relieved 
concerns over a lack of expression in vivo as we assume that N-Ras induced harderian 
gland adenomas which were absent in untreated or vehicle treated controls. 
A  B 
C  D 
E  F  
  178 
3.8.2. Phenotype II-white hair and hair loss: An unexpected apoptotic phenotype 
With time, collectively each logical stepwise analysis of the technical components of the 
model and troubleshooting both in vitro and in vivo began to clearly indicate that firstly 
transgene construction was correct; the transgenes eventually had biological activities in 
vivo and in vitro, N-Ras
lys61 expression and PTEN loss transformed but did not immortalise 
primary melanocytes. Thus, the in vivo model was more closely examined and it became 
clear that what was originally assumed to be an artifact of plucking C57BL6 mice was in 
fact a real, but very subtle phenotype; i.e. the production of white hairs following treatment 
giving a more grey appearance to the treated site, and a premature (slight) greying to the 
overall coat colour in the long-term treated bigenic mice.  
 
One aspect of activated Ras is that normal cells do not generally tolerate its expression 
well. Thus, deregulated or activated oncogenic Ras signalling can induce apoptosis in vitro 
through  a  caspase-independent  pathway  if  the  pro-apoptotic  pathway  overcomes  anti-
apoptotic  mechanisms  when  the  oncogenic  Ras  form  is  expressed  and  this  effects  the 
balance of cell fate determination (473;474). Following 12-15 months continuous systemic 
treatment, other than phenotypic eyes and harderian gland adenomas, it became clear that 
another phenotype of white hair and moderate hair loss was consistently observed in treated 
EICre/N-Ras
lys61, EICre/D5PTEN
flx/flx and EICre/N-Ras
lys61/D5PTEN
flx/flx mice separate to 
the  general  greying  of  the  fur  observed  in  older  mice,  such  that  younger  individuals 
appeared older.  
 
Given  the  well  characterise  apoptotic  response  to  Ras  activation  in  vitro,  this  result 
suggested that this subtle phenotype was due to the apoptosis of melanocytes induced in 
hair follicles by N-Ras
lys61 expression in EICre/N-Ras
lys61 mice. A very similar phenotype 
of white hair and hair loss was also observed following PTEN loss, and while TSG PTEN 
loss would suggest a reduction in apoptotic capacity via AKT up-regulation, this TSG plays  
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a multifunctional role in melanocyte and thus it appears that the loss of PTEN functions 
also resulted in melanocyte apoptosis in EICre/D5PTEN
flx/flx. Hence this apoptosis maybe a 
possible common pathway induced as a compensatory response to loss of D5PTEN
flx/flx 
function as well to expression of mutant N-Ras
lys61 in N-Ras
lys61/D5PTEN
flx/flx mice, their 
lack  of  cooperation  to  overcome  this  response  indicates  that  a  redundancy  may  exist 
between TSG PTEN loss and N-Ras
lys61 activation in melanocyte. If so this result would be 
an important finding, as it was known that Ras activation can induce an apoptotic response 
in vitro (473;474). 
  
In such phenotypic mice, the dorsal hairs at treated sites re-grew as white un-pigmented 
shafts, as did the hair on back, sides or belly  presumably due to Ru486 run off or  IP 
injection, while age matched control mice remained normal. In addition these mice also 
began to exhibit hair loss starting during the 5
th to 6
th hair plucking cycle. On the back, hair 
loss is limited within the painting area although hair loss on sides and belly where are not 
the Ru486 treatment areas ¾however, Ru486 could be delivered to these areas by mice 
themselves scratching and by IP injection. The white hair was initially observed at only a 
few independent sites which sat among mostly black hairs and started to appear as early as 
at the 2
nd hair plucking cycle (Fig 42) when the control cohorts remained normal. Indeed, 
control mice occasionally presented a few white hairs when at age of >6 months but they 
appeared randomly and the number of white hairs and the area they presented are markedly 
less than those presented in treated transgenic mice; as shown in Fig 42. To confirm this 
idea,  skin  biopsies  were  taken  from  white  hair  growth  areas  and  compared  with  skin 
samples  taken  from  hair  growth  normal  mice.  TRP2  staining,  to  identify  melanocyte, 
revealed that there were more melanocyte-containing follicles in normal skin than in skins 
taken from Ru486-treated transgenic mice, a result consistent with appearance of white hair 
areas (Fig 43).  
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Figure  42:  White  hair  or  hair  loss  appeared  in  N-Ras
lys61  expressing  and/or  PTEN 
functional  loss  transgenic  mice.  EICre/N-Ras
lys61,  EICre/D5PTEN
flx/flx  and  EICre/N-
Ras
lys61/D5PTEN
flx/flx  mice  gave  white  hair  or  lost  hair  (left  mouse  in  both  A  and  B) 
phenotypes following 7-8 month on procedure while the age-matched controls (right mouse 
in both A and B) hair growth remained quite normal. 
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Figure 43: Different number of melanocytes and melanocyte-containing follicles between 
normal skins (A-C)  and white hair/hair loss skins (D-F). Obvious melanocytes (green) 
reduction and melanocyte-containing follicles were observed in biopsies of skins taken 
from  white  hair/hair  loss  (D-F)  mice  while  more  melanocytes  and  a  larger  portion  of 
melanocyte-containing follicles detected in control skins (A-C) employing immunostaining 
of melanocyte specific marker TRP2. Skin biopsies were taken at day 10 post-plucking 
when maximum melanocytes obtained as previously revealed. As seen in the figure, either 
vertical cut (A vs. D) or horizontal cut (B, C vs. E, F) sections possessed more melanocytes 
and  more  melanocyte-containing  follicles  in  normal  skins  than  in  white  hair/hair  loss 
mouse skins. At least 5 separate fields from 5 separate transgenic biopsies taken 10 day 
post plucking and Ru486 or vehicle treatment presented these same features of reduced 
melanocytes as well reduced melanocyte-containing follicles in treated bigenic mice. See 
Fig 44 also.  
  182 
3.9. Melanocytes loss in EICre/N-Ras
lys61 and EICre/N-Ras
lys61/PTEN
flx/flx 
mice via caspase-3 mediated premature apoptosis 
Given  that  Ras  expression  can  induced  cell  apoptosis  in  vitro  (473;474),  N-Ras
lys61 
expression in melanocyte in vivo, specifically at the low level initially induced by the gene 
switch, may cause apoptosis via a shift in the balance of pro-apoptotic and anti-apoptotic 
pathways  in  anagen  and  catagen,  and  thus  negating  melanoma  formation.  Therefore  to 
investigate whether melanocyte apoptosis was induced by N-Ras
lys61 expression and played 
a  role  in  the  failure  of  melanoma  formation  in  EICre/N-Ras
lys61  and  whether  a 
compensatory  pathway  of  anti-PTEN  loss  resulted  in  the  failure  to  promote  N-Ras 
tumourigenesis  in  EICre/N-Ras
lys61/PTEN
flx/flx  mice,  melanocyte  growth  in  different 
genotypic mice were analysed in vivo. Anagen follicles were obtained by plucking back 
hair to initiate hair cycle followed by Ru486 treatment to induce N-Ras
lys61 expression and 
inactivate PTEN function. The numbers of anagen follicles was assessed for melanocytes 
as in Fig. 44 via TRP2 expression and apoptosis analysed via immunostaining for active 
caspase-3 expression patterns in the different genotypes. 
 
3.9.1. Reduced numbers of melanocytes 
Following hair plucking and Ru486 topical treatment, skin biopsies were taken at different 
time points to monitor melanocyte growth by immunofluorescence analysis of TRP2 as 
defined  before.  Skin  biopsy  samples  were  embedded  in  paraffin  and  sections  cut  and 
stained for TRP2 (green) and the numbers of TRP2 positive (melanocyte) hair follicles 
counted. The results (Table 4 and Fig 44) revealed that at the time of plucking among all of 
genotypes, few melanocyte positive follicles were in the telogen phase. As always, the 
follicles harbouring growing melanocytes increased gradually to reach a peak at day 7-10 
post plucking, which confirmed the results of experiments performed in Fig 26.  
 
However,  the  trend  of  melanocyte  disappearance  in  hair  follicles  following  Ru486  
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treatment was different between genotypes. In normal wild type C57BL6 and N-Ras
lys61 
monogenic  mice,  the  peak  of  the  number  of  follicles  which  express  Trp2  melanocyte 
extended  to  14  days  post-plucking  by  which  time  most,  if  not  all,  melanocytes  had 
disappeared  in  EICre/N-Ras
lys61,  EICre/D5PTEN
flx/flx  and  EICre/N-Ras
lys61/D5PTEN
flx/flx 
mice (pictures not shown because they are almost identical to that of
 EICre/N-Ras
lys61). 
There was no detectable melanocyte in any genotypes at the end time point (21 days post-
plucking) of the experiment.  
 
One interesting observation was that the peak time of melanocyte growth initiated by hair 
plucking appeared later in PTEN loss mice (EICre/D5PTEN
flx/flx) than in other genotypic 
mice (day 10 vs. day 7), although analysis was not carried at day 0 and day 3 due to the 
source shortage. Moreover, the percentage of melanocytes (1/3) stained follicles is less than 
others (1/2) when the maximum melanocytes obtained and the peak time is shorter (only at 
day 10) than others. 
 
These observations are not in agreement with the previous results in which PTEN loss 
enhanced stem cell growth rate and proliferation in vitro (reviewed in (475)). However it 
appears in this context that possibly being the compensatory pathway of anti-PTEN loss in 
melanocyte in vivo in the same pathway as N-Ras based on their redundancy, the same 
apoptosis happens to protect the individual from developing deadly melanoma. 
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Figure 44: In vivo melanocyte growth in different mouse genotypes. Anagen was induced 
by plucking, followed by Ru486 treatment to activate target gene expression. Skin biopsies 
from  plucked/Ru486  treated  areas  were  taken  at  different  time  points  and  subjected  to 
immunofluorescence analysis for melanocyte specific TRP2 expression (green). All 0 days 
photographs and the photograph of EICre/N-Ras
lys61 at 14 days were taken at 50x to show 
as many follicles as possible, while others were taken at 100x to show reduced numbers of 
melanocytes in treated vs. normal skin. These were quantitated in Table 4. Figures of 21 
days  post-plucking  are  not  shown  because  all  are  in  catagen  where  no  melanocyte  is 
detected.  
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Table  4:  Ratio  of  melanocyte-containing  follicles/total  follicles  at  different  time  points 
following hair plucking (days) and Ru486 treatment. As shown in IF micrograph (Fig 44) 
each  section  counted  was  oriented  and  cut  to  show  the  full  length  of  each  follicle, 
regardless of stage and not squint cut where the melanocyte-containing bulb regions may 
be lost. The data are the average numbers from 3 different mice where 3 separate fields of 3 
separate sections were observed via immunofluorescence microscope at magnification of 
50x (Fig 44).  
 
  0  1  3  7  10  14  21 
C57  7/43  5/53  3/45  29/59  40/72  33/72  0 
N-Ras
lys61  0/42  0/53  12/33  10/43  35/52  22/54  0 
EICre/ D5PTEN
flx/flx  na  2/43  na  3/44  17/61  4/62  0 
EICre/ N-Ras
lys61  1/44  0/58  58/91  29/61  27/71  0/78  0 
EICre/N-Ras
lys61/D5PTEN
flx/flx  0/35  6/58  24/54  32/78  1/64  0/65  0 
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3.9.2. Melanocytes under go a caspase-3 mediated apoptosis 
Investigations revealed that in treated N-Ras
lys61 and D5PTEN expressing mice there were 
fewer hair follicles bearing melanocytes than in age matched control mice. This suggested 
that expression of activated N-Ras
lys61 and/or PTEN loss induced an apoptotic response in 
melanocyte consistent with the growth of white hair and earlier in vitro studies where 
activated  Ras  was  shown  to  induce  apoptosis  (473;474).  To  address  this  question  and 
determine  whether  melanocyte  undergo  apoptosis  in  vivo  through  a  caspase-dependent 
pathway,  immuno-staining  for  the  cleaved,  active  form  of  caspase-3/9  was  performed, 
using K14 expression as a counterstain to delineate keratinocytes from melanocytes (Fig 
45). In control mice, 14 days post plucking, only a single caspase-3 positive melanocyte 
was observed  (Fig 45  A), whereas in all Ru486 treated bi- or tri-transgenic  genotypes 
analysed,  caspase-3  expressing  melanocytes  were  detected  in  numerous  follicles  (B: 
EICre/N-Ras
lys61;  C,  D:  EICre/D5PTEN
flx/flx  and  E,  F:  EICre/N-Ras
lys61/D5PTEN
flx/flx). 
Typically mice expressing N-Ras
lys61 and/or D5PTEN exhibited more than 10 hair follicles 
with various numbers of caspase-3 expressing melanocytes throughout a section. However, 
it was noted that while N-Ras
lys61 or D5PTEN expression gave more caspase-3 positive 
melanocytes than wild type controls, the number of caspase-3 expressing follicles was not 
additive  in  trigenic  EICre/N-Ras
lys61/D5PTEN
flx/flx  mice.  Hence,  PTEN  loss  apparently 
induced a similar mechanism of caspase-3 mediated apoptosis to that of N-Ras, which 
suggests a redundancy in their oncogenic functions despite the result in vitro co-expression 
was  synergistic  although  unable  to  achieve  immortality  (see  above  section  3.7  and 
Discussion).  
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Figure 45: Analysis of Caspase-3 expression in hair follicles. Double-label staining for 
caspase-3  (green)  and  K14  (red)  expression  in  skin  biopsies  to  investigate  potential 
melanocyte apoptosis at day 14 post plucking, shows increased caspase-3 expression in N-
Ras
lys61 and/or PTEN
null mouse skin vs. wild type skin at sites of melanocyte locations. 
Although  not  directly  labelled  for  melanocyte  markers,  this  location,  cell  shape  and 
dendrites as well the lack of K14 expression suggest that these cells were not keratinocytes 
but  melanocytes  under  going  apoptosis.  A:  C57BL6  mice;  B:  EICre/N-Ras
lys61;  C-D: 
EICre/D5PTEN
flx/flx;  E-F:  EICre/N-Ras
lys61/D5PTEN
flx/flx.  All  photographs  were  taken  at 
400x. 
A  B 
C  D 
E  F  
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3.10. Effects of the microenvironment on inducible melanoma model 
generation: Melanocyte survival during papillomagenesis 
Keratinocytes can secrete numerous regulatory factors to control melanocyte development 
as well as to play potential roles in melanoma formation (470). Thus, it is thought that 
keratinocytes exert significant control over the regulation of melanocyte physiology and 
failure  of  this  regulation  by  keratinocytes  may  contribute  to  melanoma  formation 
(465;476). Further, it is well known that the microenvironment can influence melanoma 
aetiology,  as observed in several models e.g. transgenic HGF/SF overexpression where 
melanoma formation was accompanied by epidermal hyperplasia in neonates (40). Indeed, 
many transgenic mouse models of melanoma are accompanied by keratinocyte hyperplasia 
at early stages (216;217;221). Therefore, to assess whether N-Ras
lys61 expression and PTEN 
functional loss would produce melanoma if the microenvironment was disrupted and to test 
this  seed/soil  hypothesis  (471),  a  K14Cre  regulator  was  introduced  into  the  model  to 
express these inducible mutations in keratinocytes. Previously this was employed to assess 
H-Ras cooperation with PTEN loss in carcinogenesis, which induced epidermal hyperplasia 
and  formation  of  benign  squamous  cell  papillomas  (246).  In  this  model,  induction  of 
epidermal  hyperplasia  by  N-Ras
lys61  and  PTEN  loss  in  keratinocytes  did  not  produce 
melanoma or melanocyte hyperplasia. Instead in a fascinating result, expression of mutant 
N-Ras  and  functional  loss  of  PTEN  in  both  melanocytes  and  keratinocytes  produced 
pigmented  papillomas.  Thus,  it  now  appears  that  in  the  hyperplastic  environment  of 
papillomagenesis, melanocytes did not undergo this N-Ras- or PTEN
null-induced apoptosis 
or the normal programmed apoptosis of catagen, but rather these melanocytes acquired a 
survival potential.   
 
The K14Cre transgenic regulator strain was introduced into EICre/N-Ras
lys61/D5PTEN
flx/flx 
mice  to  generate  a  tetragenic  line  K14Cre/EICre/N-Ras
lys61/D5PTEN
flx/flx  in  which  both 
keratinocytes and melanocytes expressed N-Ras
lys61 and functional PTEN loss following  
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Ru486  treatment.  K14Cre/N-Ras
lys61/D5PTEN
flx/flx  mice  produced  similar  hyperplasia 
results  to  H-Ras  cooperation  with  D5PTEN  (246),  e.g.  PTEN  loss  promoted  N-Ras
lys61 
initiated tumourigenesis to induce hyperplastic skin and given the disruption to follicular 
keratinocytes  alongside  N-Ras
lys61  activation  and  PTEN  ablation  in  melanocytes, 
pigmented  tumours  were  produced  (Fig  46a).  However  despite  their  overt  pigmented 
appearance, histological analysis (Fig 46b) confirmed that these lesions were pigmented 
papillomas,  not  melanomas  or  nevi.  These  tumours  possessed  typical  squamous  cell 
papilloma pathology, where in each case darkly staining melanocytes can be observed (Fig 
46b,  A-B)  with  occasional  clusters  (Fig  46b,  B  and  D).  The  majority  of  melanocytes 
appeared to be restricted in the proliferative basal layers at higher magnification (Fig 46, 
C), a result consistent with the requirement for proliferative keratinocytes as feeders in 
vitro melanocyte culture and with immunofluorescence analysis of TRP2 expression in Fig 
47.   
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Figure  46:  Macroscopic  and  histological  appearance  of  pigmented  papillomas.  (a)  
Following Ru486 treatment, tetragenic K14Cre/EICre/N-Ras
lys61/D5PTEN
flx/flx mice exhibit 
tiny pigmented tumours as on the media aspect of the carpus (arrow); (b) Histology of 
pigmented  tumours  from  Ru486  treated  K14Cre/EICre/N-Ras
lys61/PTEN
flx/flx  compound 
mice 9909 (A) and 9912 (B) possess a typical squamous cell papilloma pathology with the 
tumour  in  9912 exhibiting a  slightly  more  aggressive  histotype.  In  each  case,  darkly 
staining melanocytes can be observed and at higher magnification of the boxed areas, (C) 
shows  the  majority  of  melanocytes  appeared  in  the basal  layer,  whilst  (D)  shows  the 
occasional cluster of darkly staining melanocytes. These histotypes are consistent with the 
results of immunofluorescence analysis of TRP2 expression to detect melanocytes in these 
papillomas (Fig 47). 
 
 
a  b  
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As outlined above in melanocytes, N-Ras
lys61 expression and PTEN functional loss lacked 
the strength to overcome cell’s sentinel mechanism to initiate tumourigenesis. This failure 
to obtain a neoplastic phenotype may have derived from the inducible approach taken, 
where  the  skin  developed  normally  into  adulthood.  Whereas  in  previous  models 
developmental expression/deletion of transgene may prevent the retention of this kind of 
sentinel response in adults. 
 
However, in this new approach on incorporation of follicular keratinocyte hyperplasia, this 
did  not  occur  in these  compound  mice.  Thus  to  investigate  melanocyte  survival  in  the 
aetiology  of  these  pigmented  papillomas  further,  the  Kit/SCF  signalling  pathway  was 
analysed. The Kit/SCF signalling system has been shown to be very important for normal 
melanocyte development and proved to be a survival factor that defined the melanocyte 
stem cell niche (53). Further, the migration of melanoblast from murine epidermis to the 
hair follicle in neonates is controlled by SCF expression in follicular keratinocytes (60), 
and in the development of melanoma Kit expression was undetectable or was significant 
reduced,  allowing  for  overgrowth  and  invasion,  or  possibly  a  reversion  to  a  stem  cell 
phenotype (53;273;274;293;294). Thus Kit/SCF expression and co-localization of Kit with 
melanocytes  were  analysed  in  pigmented  papillomas  elicited  in  K14Cre/EICre/N-
Ras
lys61/D5PTEN
flx/flx  to  investigate  a  role  in  the  survival  of  pigmented  papilloma 
melanocytes.   
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3.10.1. Pigmented papilloma aetiology: Melanocyte localization 
In immuno-double staining, pigmented papillomas (Fig. 46) were analysed (Fig 47) for 
TRP2 (green) and K14 (red), together with differentiation marker keratin 1 (K1, red), as its 
super-basal  expression  pattern  helped  delineate  the  basal  from  suprabasal  layers  for 
melanocyte  location,  and  also  indicated  that  the  tumours  were  benign  papillomas,  as 
typically up to 100% of squamous cell carcinomas lose K1 expression on conversion to 
malignancy in many murine carcinogenesis studies (477;478), with the notable exception 
of  novel  K1  retention  in  TPA  promoted  c-Ras/PTEN
null  carcinomas  (246),  where 
progression proceeded independently of Ras expression. 
 
The patterns of TRP2 staining indicated that PTEN loss in addition to N-Ras
lys61 expression 
confirmed the histological analysis that the tumours were not melanomas but pigmented 
papillomas,  in  which  TRP2  expressing  melanocytes  survived  the  apoptosis  of  normal 
catagen  and  of  N-Ras  expression  as  well  PTEN  loss  induced  during  papillomagenesis. 
Comparing  the  patterns  of  TRP2  expression  (Fig  47)  in  pigmented  papillomas  and 
hyperplastic skins against normal skin with anagen stage follicles, the results demonstrated 
that  melanocytes  remained  detectable  and  restricted  to  the  hair  follicle  of  normal  and 
hyperplastic skins following hair plucking (A-C) until the papillomagenesis stage when the 
hair follicles degraded (D-F). In an untreated normal (A) and hyperplasia (B, C) skins of 
K14Cre/EICre/N-Ras
lys61/D5PTEN
flx/flx  mice,  melanocytes  were  still  confined  to  hair 
follicle in samples taken at the anagen (5-7 days after plucking), before the melanocytes 
disappeared  (7-10  days  in  Ru486  treated  EICre/N-Ras
lys61/D5PTEN
flx/flx  vs.  14-21  days 
post-plucking in normal, see table 4). In contrast, papillomas induced in K14Cre/EICre/N-
Ras
lys61/D5PTEN
flx/flx  mice  (D-F)  show  that  melanocytes  successfully  escaped  apoptosis 
induced  by  N-Ras
lys61  expression  and/or  PTEN  loss  in  melanoblasts/melanocytes,  to 
survive  and  proliferate  leading  to  a  sub-set  of  pigmented  papillomas  during  the 
papillomagenesis  resulting  from  N-Ras
lys61  expression  and  PTEN  function  loss  in  
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keratinocytes.  
 
Interestingly  two  most  common  patterns  of  melanocytes  were  detected  in  pigmented 
papillomas:  the  cluster  formation  (D)  and  the  more  common  streaks  of  melanocyte 
confined to the K1 negative (E)/K14 positive (F) basal layer. Thus, these results revealed 
that melanoblasts/melanocytes survived within the proliferative K14 stained basal cells, 
which proved to be consistent with the later finding of basal keratinocyte expression of 
SCF creating a paracrine survival loop with Kit (below).  
  194 
 
Figure  47:  Melanocytes  location  in  normal  skin,  hyperplastic  skin  and  pigmented 
papillomas. Localization of melanocytes via TRP2 (green) immunofluorescence in vehicle 
treated skin (A) or Ru486 treatment elicited hyperplastic skin (B, C) and papillomas (D-F) 
in K14Cre/EICre/N-Ras
lys61/PTEN
flx/flx mice. D-F are squamous cell papillomas because 
they express K1 (early differentiation maker which is lost on conversion to malignancy) 
nor  do  these  benign  tumours  express  K13  (a  simple  keratin  employed  as  a  marker  of 
progression which appears sporadically in benign papillomas and uniform in carcinomas 
(data not shown) (477;478)). K1 (red) was used for counterstain in A-E confirming their 
benign papilloma status in D & E, while K14 (red) was used in F for basal layer location 
purpose. Photographs were taken at 100x magnification except 400x for F. 
A 
B 
D 
E 
F  C  
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3.10.2.  Pigmented  papilloma  aetiology:  Immunofluorescence  analysis  indicates  a 
paracrine  melanocyte  survival  loop  established  by  intrinsic  Kit  expression  and 
extrinsic keratinocyte SCF secretion 
Given  melanocyte  survival  following  the  anagen  stage  and  proliferation  in  pigmented 
papillomas, coupled to the important roles of the Kit/SCF for melanocyte physiology and 
melanoma  development  (53),  Kit  and  SCF  expression  during  papillomagenesis 
development was determined via immunofluorescence. Initially, Kit (green) expression was 
performed (Fig 48) in pigmented papillomas against normal newborn and H-Ras expressing 
newborn hyperplastic skin (246), employing keratin K14 as a counterstain to delineate the 
epidermis and appendages. 
 
In normal newborn (24 hours) skin, Kit expression was mainly detected in the developing 
hair  follicle  with  sporadic  expression  in  a  subpopulation  of  basal  cells  (A).  In  H-Ras 
hyperplastic newborn skin, Kit expression was detectable in most layers of the epidermis 
and hair follicles, with interfollicular basal cells retaining an expression level as strong as 
in the follicles (B). In all pigmented papillomas (C-F), Kit expression levels was elevated 
significantly  even  compared  to  the  hyperplasia,  and  strongly  expressed  throughout  the 
proliferative epidermal areas of the expanded basal layers, and less so in the differentiated 
stratified layers although still detectable, as confirmed at higher magnification (E 100x; F, 
200x), where Kit expression in basal layer was higher than in other areas. 
 
The results  implied that if papillomagenesis occurred alongside the anagen stage of hair 
follicles,  the  proliferative  melanocytes  survived  by  expressing  Kit  (receptor)  to  receive 
survival signals (e.g. Kit ligand SCF) from disrupted microenvironmental keratinocytes and 
suggests  therefore,  that  a  Kit/SCF  related  cell  survival/proliferation  signalling  pathway 
overcome pro-apoptotic pathway of catagen or that induced by N-Ras
lys61 expression and/or 
PTEN loss in melanocytes, to result in melanocytes escaping from apoptosis. Surviving  
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melanocytes may further proliferate to produce more progeny due to this active Kit/SCF 
loop  and  this  idea  was  investigated  by  assessing  expression  of  the  SCF  (Kit  ligand) 
keratinocytes and melanocytes. 
 
Figure 48: Kit expression in normal skin, hyperplastic skin and papillomas. Kit expression 
(green)  levels  elevated  in  pigmented  papillomas  elicited  in  K14Cre/EICre/N-
Ras
lys61/D5PTEN
flx/flx  mice.  A:  normal  new  born  skin  (100x);  B:  transformed  (H-Ras) 
hyperplastic  new  born  skin  (100x)  and  C-F:  pigmented  papillomas  show  significant 
elevation of Kit expression (C and D, 50x) and stronger Kit expression in basal layer (E, 
100x; F, 200x) than other parts of epidermis. K14 (red) was used for counterstain. 
A 
F  E 
D  C 
B  
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3.10.3. SCF expression by basal cell keratinoyte acts as a survival loop 
TRP2  staining  suggests  that  melanocytes  survived  in  pigmented  papillomas  where/if 
tumourigenesis occurred at the anagen phase of hair follicles when a population of target 
melanocytes was available, and the elevated Kit expression in most cells of pigmented 
papillomas  suggested  that  melanocytes  survival  may  have  been  through  the  Kit/SCF 
paracrine loop. To investigate whether this was due to SCF secretion and released from 
keratinocytes because of the disruption of melanocytes microenvironment, which binds to 
Kit receptors on expressing melanocytes to allow survival, SCF (green) expression was 
performed in normal adult and normal newborn skin, which is naturally briefly hyperplastic 
for the first few days, as well as pigmented papillomas employing immuno-staining with 
K14 counterstain (red) (Fig 49). 
 
The SCF expression pattern was very similar to Kit expression patterns, being detected 
mainly in hair follicles of normal skin, and also sporadic expression was detectable in outer 
root sheath keratinocytes, but only very little interfollicular epidermis SCF expression was 
observed (A). Similarly in new born skin which possesses a normal, mild hyperplasia (B), 
SCF expression level was elevated and strongest in hair follicles, with a few interfollicular 
epidermal keratinocytes exhibiting a relative higher level of SCF expression which was in 
contrast  to  normal  skin.  In  papillomas  in  a  similar  fashion  to  melanocytes  localization 
described at 3.9.1 via TRP2 immunofluorescence, again, two categories of SCF expression 
were observed: clusters and streaks respectively were demonstrated in all papillomas. In a 
striking  result,  under  the  low  magnification  (C  and  D,  50x)  and  SCF  expression  in 
papillomas was mainly localized in basal layers under the higher magnification (E, 200x 
and F, 400x), which is in a direct repeat of localization of melanocytes via marker TRP2 
and the expression of Kit. 
 
These results are consistent with the idea that secreted SCF by disrupted keratinocytes  
  198 
supplied ligand to the Kit receptor expressed in melanoblasts/melanocytes at the anagen 
stage of hair follicles, and thus during subsequent papillomagenesis this Kit/SCF survival 
loop  overcome  pro-apoptotic  pathways  induced  by  N-Ras
lys61  expression  and/or  PTEN 
function loss in melanocytes to result in melanocytes survival and proliferation. To verify 
these  results,  co-localization  of  Kit  and  TRP2  in  melanocytes  in  those  pigmented 
papillomas was identified below.  
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Figure  49:  SCF  expression  in  normal  skin,  hyperplastic  skin  and  papillomas.  SCF 
expression  in  normal  adult  and  newborn  skin  and  pigmented  papillomas  via  double 
immunofluorescence staining of SCF (green) and K14 (red). SCF was detected in sporadic 
keratinocytes and in hair follicles of normal skin (A, 100x). In new born hyperplastic skin, 
focal SCF expression was detected in all layers, with the occasional streak in basal cells, 
whilst hair follicles retained the strongest expression (B, 100x). In contrast all papillomas 
investigated exhibited elevated strong expression (C-F) in two distinct categories. Under 
low  magnification  (50x),  SCF  expression  was  mostly  observed  in  streaks  (C)  but 
occasional clusters of expression were observed (D). Higher magnification (E, 200x; F, 
400x) demonstrates the localization of SCF in basal cell layer. 
A  B 
C  D 
E  F  
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3.10.4. Localization of Kit expression in melanocytes 
The results obtained from TRP2, Kit and SCF immuno-staining described above, suggested 
that melanoblasts/melanocytes survival in pigmented papillomas was a consequence event 
of  keratinocytes  disruption  which  secreted  and  released  SCF  signal  to  Kit  expressing 
anagen stage melanocytes during papillomagenesis. To confirm if this was true and that Kit 
expression in melanocytes was able to receive this signal from the disrupted keratinocytes, 
the localization of Kit expression in melanocytes was performed via double staining of Kit 
(green) and TRP2 (red) employing normal 9 days post-plucking C57BL6 skin as a positive 
control. 
 
The co-localisation of Kit and TRP2 is shown in Fig 50, which again demonstrates that the 
maximum melanocytes were presented at day 9 post-plucking, where both TRP2 and Kit 
were strongly detectable in plucked normal skin as melanocytes entered the cell cycle in 
anagen  (A).  Here  Kit  expression  was  detected  in  all  Trp2  positive  melanocytes.  This 
proved to be the case also in melanoblasts/melanocytes which survived and proliferated in 
all papillomas investigated. Consistent with the results described above, where TRP2, Kit 
and SCF exhibited stronger expression in the papilloma basal layers, here once again co-
localised Kit and TRP2 expression was mostly detectable in the basal cells of papillomas 
elicited by Ru486 treatment in K14Cre/EICre/N-Ras
lys61/D5PTEN
flx/flx mice either under 
low (B, 50x; C, 100x) or higher magnification (400x, D-F). 
 
This co-localisation of Kit and TRP2 expression in melanocytes confirmed the mechanism 
outlined above, that PTEN functional loss promoted N-Ras
lys61 initiation in keratinocytes 
and pigmented papillomas may result via disrupted keratinocytes secretion of SCF which 
provided the signal to Kit expressing melanocytes that lead to SCF/Kit survival loop which 
overcame Ru486-induced melanocyte apoptosis.  
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Figure 50: Kit and TRP2 co-expression in skin and pigmented papillomas. Kit expression 
was localized to melanocytes via double immunofluorescence staining of Kit (green) and 
TRP2 (red), a melanocyte specific marker. A, normal C57BL6 9-day post-plucking (100x); 
Papillomas B, 50x; C, 100x and D-F, 400x. 
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With the goal of development of an inducible gene-switch mouse melanoma model, both 
regulator (EICre) and target constructs (cmv.stop.N-Ras
lys61) were successfully constructed 
and functional gene switch specificity subsequently identified both in vitro and in vivo.  
With  the  time  however,  despite  induction  of  anagen  to  obtain  a  target  population  of 
proliferative adult melanocytes and confirmation of N-Ras expression in vivo, bigenic lines 
failed  to  produce  melanoma  following  systemic  application  of  Ru486  and  additional 
inducible  loss  of  PTEN  function  via  introduction  of  D5PTEN
flx/flx  in  this  model.  The 
repeated lack of melanoma production in trigenic mice (EICre/Ras
lys61/D5PTEN
flx/flx) drove 
the  experiments  that  established  in  vitro  assays  to  investigate  and  confirm  N-Ras  and 
PTEN  transformation  potential,  until  the  eventual  phenotypes  obtained  in  eyes  and 
harderian glands, whilst not melanoma, indicated that the switch approach was working in 
vivo, a result consistent with the in vitro N-Ras/PTEN cooperation data. This prompted a 
closer  and  careful  analysis  of  treated  skin  for  any  subtle  cutaneous  phenotype,  which 
discovered that one potential reason for lack of melanoma was due to a caspase-3 mediated 
apoptotic response to N-Ras
lys61 expression and/or compensation to PTEN function loss 
and therefore gene function redundancy in vivo.  
 
Even  so,  in  the  interim  experiments  had  progressed  to  asses  the  effects  of  seed/soil 
hypothesis on melanoma aetiology by incorporating follicular keratinocyte hyperplasia in 
the  model  to  affect  the  microenvironment.  Here  the  effect  was  to  overcome  this 
melanocyte apoptosis allowing their survival, but this resulted in a pigmented papilloma 
not melanoma. The aetiology of pigmented papillomas in this N-Ras/PTEN murine model 
suggests that such tumours arise when papilloma formation occurs alongside hair growth 
and  incorporates  anagen  melanocytes.  This  ideas  is  supported  by  the  facts  that  only  a 
subpopulation of papillomas were pigmented and  most papillomas containing melanocytes 
arose at approximately 4 weeks when the second  phase of synchronised hair cycle occurs. 
This may also happen in humans where seborrheic keratoses also contain melanocytes,  
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although in humans the melanocytes may also arise from the interfollicular melanin unit. 
Nonetheless, our data suggest that the SCF secreted by transformed, proliferative basal 
layer  keratinocytes  provides  a  survival  loop  for  Kit  expressing  melanocytes  during 
papillomagenesis. 
 
Although  this  model  failed  to  produce  melanoma,  due  to  compensatory  apoptotic 
mechanism, several other studies have provided valuable insight into melanoma aetiology 
in humans. Such models often require p16/p19 deficient mice (215;223;439) and exploit 
keratinocyte hyperplasia to develop melanoma in HGF expressing mice (40). Here in the 
latter models neonatal UV exposure directly led to melanoma in adults, thus mimicking 
human  pathology  (See  section  4.6)  whilst  in  adults  UV  exposure  promoted  Ras 
tumourigenesis (221), as did INK4a/ARF deficiency promotes (349).  Recently, oncogenic 
N-Ras was shown to collaborate with deficiency in ARF, but interestingly not p53, to fully 
transform  melanocytes  (357).  Indeed  for  murine  models,  the  introduction  of  p16/p19 
deficient  mice  and/or  other  melanocyte/melanoma  development  related  factors  in  this 
inducible gene-switch model will provide an up-to-date superior mouse model to mimic 
multi-stage human melanoma development.  
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4.1. Construction and identification of transgenes 
Through DNA recombination, a hetero DNA fragment forced into a mammalian cell can 
locate  and  recombine  with  the  endogenous  homologous  sequences.  Site-specific  gene 
targeting systems have made it possible to genetically manipulate embryonic stem cells 
and  the  mouse  germline.  Recent  advances  using  Cre-loxP  and  Flp-FRT  systems  give 
scientists the possibility to design and generate germline mutations following a single gene 
targeting  event,  as  well  as  inactivation  of  genes  in  a  conditional  manner  in  the  living 
mouse. In a Cre-loxP based conditional gene-switch system, Cre recombinase recognizes 
sequences  of  loxP  to  determine  whether  to  excise  DNA  fragment  between  2  directly 
orientated loxP sites or to invert the intervening DNA between 2 inverted loxP sites (Fig 4). 
Two inducible systems based on Cre recombinase have been independently developed by 
fusing a truncated progesterone ligand-binding domain (CrePR) which binds mefipristone 
(Ru486) but not progesterone (440;479;480);  and a mutant estrogen receptor (CreER) 
which is activated by binding 4-hydroxy (OH)-tamoxifen, but not to natural beta-estrodial 
(481-485) thus minimising interference with normal hormone physiology whilst providing 
temporal Cre recombinase activity for conditional gene expression/inactivation in vivo. 
 
To initiate a CrePR/loxP conditional gene-switch model, two components of a gene switch 
are required: the cell-specific regulator half incorporating CrePR and target transgene half 
containing loxP-gene-loxP or loxP-stop-loxP-gene, and followed by crossing of transgenic 
lines expressing these two halves. In this study, melanocyte specific EICre and TRP2Cre (a 
cited  stronger  and  earlier  expression  promoter  than  EICre)  regulator  were  successfully 
constructed.  To  further  increase  gene  expression  to  achieve  as  strong  expression  as 
possible, a generic intron, which increases message RNA stability and efficient processing 
was included, thereby elevating gene expression in transgenic mice (452;453). This generic 
intron was isolated from K14CrePR1 and inserted into constructs between promoter (Etyr 
or  TRP2)  and  CrePR  gene.  The  insertion  of  an  intron  into  the  transgenic  vector  also  
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provides a convenient protocol to distinguish gene expression from DNA contamination 
following RT-PCR as deletion of the intron during transcription process to give a smaller 
band than contaminating DNA (Fig 26, 28). 
 
The biological activities of cloned regulator vectors were subsequently identified through 
transfection of B16 melanoma cells (Fig 16) and of primary melanocytes (Fig 17). To 
enable the detection of target expression easier following regulator activation by Ru486 
treatment, a useful report target (cmv.stop.EGFP) which contains EGFP to render target 
expressing cells visible under microscope was constructed as well as the oncogenic target 
vector  cmv.stop.N-Ras
lys61.  Employing  a  Cre  responsive  report  target  plasmid  and  the 
newly defined transfection protocols, active function of regulators was revealed following 
Ru486 treatment on the cultured cells (Fig 16 & 17) and accordingly, the successful target 
gene switch was identified in vitro. This report vector supplied a very simple and helpful 
protocol  for  identification  of  targeting  gene  expression  and  therefore  for  gene-switch 
specificity confirmation in vitro prior to in vivo analysis in CrePR/loxP system.   
 
Although stronger expression levels were detected in TRP2Cre vs. EICre transfected B16 
melanoma cells and primary melanocytes (table 2), an obvious leakage was detected in 
TRP2Cre transfection and therefore EICre, in which CrePR fusion protein was under the 
control  of  an  enhanced  tyrosinase  promoter  (0.22kb/2.2kb),  was  chosen  to  produce 
transgenic lines despite its weaker expression levels compared to TRP2Cre constructor. 
The target gene EGFP expressing following transfection and Ru486 treatment indicated 
that primary melanocytes as well as B16 cells are transfectable whilst the number of EGFP 
expressing cells (table 2 & Figs 16, 17) implied a low transfection efficiency.   
 
Once  the  biological  activities  had  been  confirmed  in  vitro,  the  regulator  expression  in 
transgenic melanocytes was initially verified in the primary transgenic melanocytes by RT- 
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PCR (Fig 26) and its functional activity verification was followed by transfection of EGFP 
report target for microscopic analysis (Fig 27) and for RT-PCR detection (Fig 28).   
 
Interestingly,  the  EGFP  expressing  cells  were  not  as  numerous  as  expected  following 
transfection of report target vector cmv.stop.EGFP into regulator melanocytes and Ru486 
treatment, but it was cell specific, as no keratinocytes were positive and did not leak, both 
by microscope viewing and by RT-PCR when compared to the EICre expression at the 
RNA level (Fig 26). This may have been a consequence if transfection variability of EGFP 
toxicity.  However,  binding  sites  for  regulatory  proteins  and  RNAs  secondary  structure 
upstream of the open reading frame of  the untranslated regions (5’ and 3’) of mRNA, can 
determine gene expression level by influencing mRNA stability and translation efficiency 
(486) and thus, although insertion of a generic intron and the KOZAK sequences (487) that 
was cloned in front of start cordon ATG,  the translation level of EICre transgene may not 
be as high as we needed or expected. Another  possibility derived from comparing the 
morphology of EGFP expressing primary melanocytes in Fig 17 and Fig 27, where all 
EGFP positive cells in the latter were well differentiated melanocytes which had numerous 
dendrites. Brn-2 (its human homologue N-Oct3) is a class II POU domain factor and a 
melanoma-specific  octamer  binding  protein,  its  mRNA  expression  is  found  both  in 
melanoma cell lines and melanoblast but not in normal melanocyte. Its expression prevents 
activation of the tyrosinase promoter via displace factors required for tyrosinase expression 
(7). EICre regulator could be repressed by the Brn-2 expression in mouse melanoblasts but 
might  not  in  those  well  differentiated  melanocytes  by  loss  of  Brn-2  expression  and 
therefore  only  those  differentiated  melanocytes  but  not  melanoblasts  expressed  CrePR 
fusion protein to result in target gene (EGFP) activation.  
 
To achieve high expression level of fusion protein CrePR in mouse melanoblast as well as 
in melanocytes, a longer promoter in which more 5’ untranslated region (UTR) included  
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could  be  an  alternative  useful  approach  according  to  the  successful  Cre  expression  in 
mouse skin melanoblasts employing a 6.1-kb promoter (488), but this may not be critical 
since either short or long promoter was successfully employed in melanoma generation by 
H-Ras initiation in CDKN2A gene deficient mice (223;439) and also mouse hair cycle 
physiology  has  to  be  accounted  for  these  inducible  purposes.  Indeed,  TRP2,  a  cited 
stronger and in melanoblasts expressing promoter (288;454) which was also identified in 
this study (table 2), could be another alternative choice to replace this short version of 
tyrosinase enhancer/promoter to obtain stronger expression in melanoblasts as well as in 
melanocytes. However, the leakage of this promoter is another issue has to be carefully 
concerned and solved before application because the unexpected phenotype(s) may appear 
before inducer application to interfere the study of developmental stage related. 
 
The  same  cloning  strategy  of  report  target  vector  cmv.stop.EGFP  was  employed  for 
oncogenic cmv.stop.N-Ras
lys61 construction and as only two lines proved to be germline 
transmitters, K14Cre/N-Ras
lys61 primary
 keratinocytes were employed to rapidly confirm 
N-Ras
lys61 expressers. This confirmed successful cloning and target expression following 
regulator activation obtained from the in vivo primary keratinocytes cultured in vitro (Fig 
29 a-c) without the difficulties of primary melanocyte culture and transfection. It proved to 
be difficult to initial culture and later transfect mouse primary melanocytes, compared to 
their human counterparts or keratinocytes, but this was eventually achieved (below).  
 
Collectively, both regulators and report target constructions were confirmed successfully in 
vitro employing transfection in B16 melanoma cells and later in primary melanocytes and 
the  results  indicated  the  gene-switch  specificity  in  vitro.  N-Ras  expression  in  bigenic 
K14Cre/N-Ras primary keratinocytes following Ru486 treatment also indicated the gene-
switch specificity in vivo in keratinocytes and inferred in melanocytes in vivo.    
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4.2.  Optimisation  of  media  for  primary  melanocyte  culture  and 
transfection 
Murine melanocyte primary culture and transfection was not as easy as human melanocyte, 
although  the  other  groups  have  achieved  some  success  in  culture  of  primary  murine 
melanocyte  exploiting  ideally  the  requirement  for  feeder  (457;458).  Development  of 
murine melanocyte primary culture, however, was a very useful and necessary protocol for 
identification of transgene construction prior to in vivo breeding and helped to cut the 
experimental  running  cost  as  well  as  to  cut  the  animal  usage  to  meet  the  ethic  goals 
required by home office.  
 
In human skin, each melanocyte is surrounded by 50-60 keratinocytes in the epidermal 
melanin unit and 95% of epidermal cells are keratinocytes, thus keratinocytes regulation of 
melanocyte  proliferation  and  differentiation  is  as  indispensable  to  the  regulation  by 
intrinsic genetic factors in melanocytes themselves. To date, a-MSH, b-FGF, SCF, HGF 
amongst many others, have all been suggested to be the important keratinocyte-derived 
factors  which  regulate  the  proliferation  and/or  differentiation  of  mammalian  epidermal 
melanocytes through different signal pathways  (reviewed by (470)). The same can be said 
for mouse melanocytes with the distinction that murine melanocytes are mainly follicular 
and proliferate during anagen, and thus in vitro grow from residual follicles, hence why 
SP1 cells, a transformed papilloma line derived from hair follicle stems cells via two stage 
chemical carcinogenesis proved a very useful feeder layer, both in our hands (not shown) 
and Yoon et al (457).  
 
However, with the goal to produce a relatively pure population of tyrosinase expressing 
melanocytes,  without  the  degree  of  spontaneous  transformation  that  would  hamper 
development of any transformation assay, primary melanocytes isolated from new born 
mice were cultured in a variety of different recipes either developed by ourselves, other  
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laboratories or commercial sources, we concluded that the recipes which supported initial 
keratinocyte  growth  as  a  feeder  layer  gave  the  best  murine  primary  melanoblast/ 
melanocyte morphologies and highest transfection efficiency (Fig 12-15, 18 and table 3) 
but without spontaneous transformation. This observation was  consistent with previous 
results  employing  feeders  obtained  by  Bennett  et  al  (459;460),  but  did  not  agree  with 
another  popular  recipe  developed  by  Halaban  and  co-workers,  which  did  not  employ 
keratinocytes  as  a  feeder  layer,  but  exploited  horse  serum  and  sodium  orthovanadate 
(Na3VO4) as critical additives (449).  
 
In  the  50/50  culture  medium  of  this  system,  the  differentiation  status  of  keratinocyte,  
controlled  by  extracellular  calcium  concentration  (50)  was  exploited  to  maintain 
undifferentiated  proliferative  (e.g.  basal  layer)  keratinocytes  as  a  feed  layer  to  secrete 
melanoblast/melanocyte  growth-stimulation  factors  to  promote  melanoblast/melanocyte 
growth to obtain maximum number of pigmented cells. The effect of calcium in regulation 
of keratinocyte differentiation is well characterised in vitro and in vivo. Using particle 
probe methods (electron probe and proton probe X-ray microanalysis) and cytochemical 
methods  (oxalate-pyroantimonate  technique)  respectively,  the  investigation  of  the 
distribution  of  elements  and  water  in  the  different  layers  of  the  epidermis  revealed  a 
gradient of Ca
2+. In normal human and mouse skin, the concentration of Ca
2+ increased 
steadily  from  the  basal  region  to  the  stratum  granulosum  (489;490).  Changes  in 
intracellular  calcium  concentration,  which  result  from  both  the  intercellular  Ca
2+ 
accumulation in the mid granular layers and Ca
2+ influx from the upper granular layers, 
helped regulate epidermal differentiation (491) e.g. via Scarf and its binding target proteins 
(492).  In  vitro,  regulation  of  epidermal  differentiation  is  also  mediated  by  these  Ca
2+-
dependent  processes.  Mouse  keratinocytes  cultured  in  low  Ca
2+  medium  (0.05mM) 
proliferate  repeatedly,  and  begin  to  differentiate  once  the  Ca
2+  concentration  exceeds 
0.1mM  (50;493;494).  Thus  if  required  terminal  differentiation  can  be  induced  by  
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increasing the calcium concentration from 0.05mM to > 0.1mM and it is note worthy that 
in  experiments to  analyse  melanocyte  survival  in  pigmented  papillomas  (section  3.10), 
melanocytes mainly populated in the proliferative basal layers of papillomas. This result 
was consistent with in vitro observations where successful culture of melanocyte initially 
required low calcium culture conditions to maintain proliferative keratinocyte populations 
(NB:  In  alternate  studies,  secondary  melanocytes  grew  poorly  on  SP1  papilloma  cells 
cultured in high calcium media, which partially differentiated).  
 
Keratinocytes in 50/50 medium grow well for the first few days and then gradually lost 
their  proliferative  ability  and  either  spontaneously  or  were  induced  to  terminally 
differentiate over 2-3 weeks of culture (Fig 13-15), while the pigmented melanoblasts/ 
melanocytes gradually appeared in presence of TPA (459) and other factors, including the 
matrix  secreted  by  earlier  proliferative  keratinocytes.  Thus  once  developed  this  50/50 
media incorporated all the factors of lower calcium concentration (0.05mM in our 50/50 
medium vs. 1.802mM in Bennett and 0.278mM in Halaban recipes) as well as the lower 
concentrations of TPA (10ng/ml in 50/50 medium vs. 200ng/ml in Bennett and 50ng/ml in 
Halaban  medium  respectively)  to  maintain  and  promote  melanocytes  proliferation  yet 
minimise  spontaneous  keratinocytes  transformation  (495).  Whilst  compared  to  other 
media, pigmented melanoblasts/melanocytes presented later in dishes of 50/50 medium, 
use  of  this  optimised  primary  mouse  melanocyte  culture  medium  was  able  to  produce 
sufficient  number  of  cells  possessing  a  normal  morphology  for  identification  of  cell 
specific gene-switch activity in vitro, of transgene expression prior to in vivo breeding as 
well as of in vitro modelling of N-Ras and PTEN synergism. 
 
The recipe developed by Halaban has been wildly used for murine primary culture, thus  
the comparison of melanocytes cultured in Halaban medium and in our house optimised 
50/50 medium was performed to verify any (dis)advantages against each other. On culture  
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using exactly the same protocols, obvious differences were revealed between these two 
recipes. In Halaban medium, keratinocytes were not optimised to grow and then to support 
melanocytes/melanoblasts in contrast to our 50/50 medium in which keratinocytes were 
considered to be an important factor providing an initial feeder layer for residual primary 
(follicular) melanocyte growth and therefore a medium containing low Ca
2+ was chosen.  
 
Addition  of  TPA  in  the  medium  was  essential  for  murine  melanoblasts/melanocytes 
growth (459) and thus, TPA was included in both media. In Halaban medium, although 
Na3VO4  was  included  to  inhibit  tyrosine  phosphatases  to  prolong  the  activity  of 
endogenous tyrosine kinases (449), the vast majority of melanocytes are not pigmented 
which  indicated  the  little  tyrosinase  activity  in  these  cells  and  therefore  they  are  not 
suitable  for  our  purpose  where  regulator  expression  relies  on  the  tyrosinase  activity. 
Indeed,  the  proportion  of  pigmented  cells  in  Halaban  medium  gradually  increased 
following long term culture with a very slow speed and moreover, pigmented cells had 
spontaneously transformed very quickly as had pigmentation within 1 or 2 passages (Fig 
15) and thus, again melanocytes grown in Halaban medium were not consistent with our 
goals to investigate Ras roles in transformation and its synergism with PTEN gene deletion 
in vitro.  
 
Despite the advantages being demonstrated by 50/50 medium, melanoblasts/melanocytes 
actually  grew  well  in  both  media  despite  an  initial  lack  of  pigmentation  and  eventual 
spontaneous transformation in Halaban medium. Cells in Halaban medium, however, may 
still have had enhanced transfection efficiency. Given that a transfectable capacity was an 
essential  test  using  primary  melanocytes  to  identify  transgenic  mouse  expressers  and 
mouse primary melanocytes were expected to be very difficult to transfect, transfection 
efficiency of cells cultured in 50/50 or Halaban medium was estimated. Here Fugene-6 had 
been verified to be the transfection reagent of choice via transfection into B16 cells. As  
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revealed in table 3, even the transfection efficiency was not high in 50/50 medium, the 
transfected cells in Halaban medium are only approximately 1/3 of cells cultured in 50/50 
medium  either  in  primary  or  sub-cultured  secondary  cells  under  exactly  the  same 
conditions.  
 
Taken together, murine primary melanocytes grew better in 50/50 and Halaban media than 
others. However, cells cultured in house optimised 50/50 medium gave advantages of no 
spontaneous transformation which is an essential factor for our in vitro modelling analysis, 
and of cell pigmentation (tyrosinase expression) which is also the necessary factor for our 
regulator  expressing.  Furthermore,  higher  transfection  efficiency  was  also  revealed  in 
50/50  than  in  Halaban  medium,  which  is  very  useful  for  identification  of  transgenic 
expressers  as  well  as  for  in  vitro  modelling.  Indeed  this  effort  proved  to  be  quite 
worthwhile, as it developed an in vitro transformation assay with a minimum degree of 
spontaneous  melanocyte  transformation,  which  allowed  a  successful  direct  test  of  the 
oncogenic potential of N-Ras and PTEN loss in this inducible system when concerns had 
arisen regarding an unexpected lack of a melanoma phenotype (below). 
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4.3. Modelling melanoma in vitro 
Due  to  the  failure  of  mouse  melanoma  production  by  inducible  N-Ras
lys61  expression 
accompanied  by  PTEN  function  deletion,  employing  our  optimized  murine  primary 
melanocyte  culture  protocol,  an  in  vitro  model  was  established  initially  to  confirm 
biological  activity  of  these  transgenes  and  later  to  investigate  the  role(s)  of  N-Ras
lys61 
expressing and PTEN loss and their potential synergism in melanocyte transformation.  
 
It was initially theorised that a low level of N-Ras
lys61 expression induced in adult mouse 
could  have  been  the  cause  of  melanoma  production  failure.  As  TRP2Cre  has  been 
identified to be a stronger regulator in the initial tests of transgene activity that resulted in 
higher target gene expression, despite its leakage (Fig 16, table 2), TRP2Cre, not EICre, 
was employed in the transfections for in vitro modelling. This showed that unlike in vivo, 
PTEN function loss could promote cell proliferation and was synergistic with mutant N-
Ras
lys61  expression  resulting  in  a  significant  change  of  melanocyte  morphology  which 
shows more aggressive by losing contact-inhibition characteristics, but critically did not 
induce immortalisation, a result consistent with the redundancy in cooperation revealed in 
vivo. The difference revealed here between in vitro and in vivo agreed with the finding that 
mutation of PTEN is quite common in melanoma cell lines but relative less in STC lines 
and  melanoma  specimens  (264)  and  thus,  different  roles  of  PTEN  function  loss  in 
melanoma cell line and solid melanoma are not surprising. 
 
It may be that PTEN-controlled cell renewal depends on modulation of G0-G1 transition 
and therefore, PTEN function loss would trigger G0-G1 arrested cell proliferation possibly 
without perturbing the fate of cell differentiation (475). PTEN function loss activates Akt 
which associates with p21Cip1/WAF1 to lead cytoplasmic localization of p21Cip1/WAF1 
and consequently results in HER-2/neu-mediated resistance to apoptosis and promotion of 
cell growth in tumours (496). Following co-transfection of TRP2Cre into D5PTEN
flx/flx  
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transgenic melanocyte and subsequent Ru486-mediated deletion of PTEN exon 5, PTEN 
function loss in transfected melanoblasts/melanocytes (EGFP tagging or G418 resistant) 
resulted in faster proliferation than wild type cells (Fig 32, 34-35) to produce colonies, but 
the  morphology  of  cells  remained  normal.  This  suggests  that  PTEN  conferred  a 
proliferative  ability  via  lack  of  modulation  of  downstream  molecules,  which  did  not 
interfere  with  the  cell  characteristic  of  retaining  monolayer  growth  and  cell  contact 
inhibition. This also implies that the combined effects of the loss of PTEN lipid and protein 
phosphatase activity may result in aberrant cell growth, but not overt transformation, hence 
the lack of tumourigenesis potential via PTEN deletion alone in the EICre model in vivo 
(apart from white hair/hair loss, below).  
 
Active forms of Ras play a causal role in more than one quarter of human cancers and, 
unlike PTEN functional deletion, is a well characterised initiator of tumourigenesis (497). 
Ras proteins are tethered to the inner cell membrane, coupling growth factor receptors to 
regulate downstream signalling pathways through further a series molecules activation or 
function loss that control cell growth, proliferation, survival and transformation despite in 
some cases expression of Ras active form resulted in non-transformed diseases (Fig 2). 
Comparing  Fig  32  with  Fig  33  and  Fig  35  with  36,  morphological  differences  were 
apparent between N-Ras
lys61 expressing and PTEN function loss melanoblasts/melanocytes 
following activation of CrePR1 recombinase by transfection and Ru486 treatment. Other 
than promoting  cell proliferation as observed in PTEN functional loss  cells, N-Ras
lys61 
expressing  cells  also  exhibited  a  transformed  morphology,  although  the  cells  remained 
monolayer growth and retained cell contact inhibition characteristics.  
 
As  PTEN  acts  downstream  of  Ras  signalling  to  down-regulate  Ras  functions  via  the 
MAPK pathway (Fig 2, 3), together PTEN functional loss in addition to the N-Ras
lys61 
expression in melanocytes resulted in more severe morphological changes (D-F of Fig 33  
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and  C-F  of  Fig  36)  which  presented  spindle  shape  and  lost  cell  contact  inhibition 
characteristic  to  cause  these  melanocytes  to  pile  up  and  therefore,  unlike  in  N-Ras
lys61 
expressing alone cells, it became impossible to distinguish any single cell. Thus, unlike the 
results obtained in vivo where PTEN function loss did not change the N-Ras
lys61 expressing 
mouse phenotypic profiles, except for a subtle increase in caspase-3 activity. Addition of 
PTEN function loss in vitro by transfection did co-operate with N-Ras
lys61 expression to 
produce  an  increased  transforming  morphology  but  no  immortalisation  as  these  cells 
senesced at approximately passage 5-6. PTEN is able to promote N-Ras initiation possibly 
due  to  being  in  vitro  but  the  transformed  cells  die  out  possibly  due  to  the  function 
redundancy between these two genes was also consistent with the results obtained from the 
in  vivo  model  (below)  in  which  a  compensatory  mechanism  of  PTEN  functional  loss 
resulted in caspase-3 mediated apoptosis as N-Ras expression induced, hence no PTEN 
promotion on N-Ras melanomagenesis in vivo. Thus, it would be an interesting study to 
investigate  whether  these  in  vitro  PTEN  loss  and  N-Ras  expressing  cells  gain  the 
characteristics to become immortalised if other genetic pathways deregulations and/or UV 
exposure are introduced.   
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4.4. Modelling in vivo 
In mouse skin, few melanocytes are present in interfollicular epidermis by day four after 
birth and declined gradually until no interfollicular epidermal melanocytes are detectable 
by day eighteen, except the occasional cells in the ear, whereas the follicular melanocytes 
increased for about two weeks after the birth during the first synchronised anagen but then 
undergo a programmed apoptosis as the hair growth ceases on progression from anagen to 
catagen (56;57). Their melanocyte stem cells remain quiescent in telogen until the next 
anagen phase, unless triggered following environmental stimulation to force telogen hair 
follicles re-enter hair cycle by proliferation, differentiation and migration of stem cells 
located in the follicular bulge (53). Thus in this inducible gene switch system, very few 
target  cells  (stem  cell/melanoblast/melanocyte)  existed  in  an  adult  mouse  skin  and 
induction of anagen at the time of Ru486 treatment was essential for regulator activation 
and subsequently resulting N-Ras
lys61 target gene expression and/or PTEN inactivation and 
unless treated, in any random anagen follicle, N-Ras
lys61 would be inactive while PTEN 
gene functions active as normal.  
 
Therefore, the mouse hair cycle was initiated by plucking back hair to obtain maximum 
melanoblasts/melanocytes expressing regulator EICre for activation by Ru486 treatment 
subsequently to activate oncogenic N-Ras
lys61 gene expression in a maximum number of 
melanocytes following excision of silence cassette of ‘Stop’ in target gene cmv.stop.N-
Ras
lys61. In initial experiments the maximum melanoblasts/melanocytes were achieved at 
day 7-9 post plucking (Fig 30) and declined gradually until finally became undetectable 
approximately at day 21 post-plucking (table 4). Thus, to obtain as many proliferative 
tyrosinase expressing melanocytes as possible for exposure to Ru486 treatment, back hairs 
were  plucked  to  initiate  anagen  and  the  time  course  for  maximum  numbers  of  Trp2 
expressing cells determined, and hair plucking was repeated every 4 weeks. Also in mouse, 
follicular melanocytes are well protected in the follicle from UV radiation and chemical  
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induction and therefore UV and/or chemical carcinogens induced mainly non-melanoma 
skin tumours (57;76). As no overt phenotypes had appeared, a second consideration was 
whether the penetration of Ru486 was sufficient to reach the papillary melanocytes. Thus, 
despite the indications from separate studies that this was so (246;467), to ensure Ru486 
was  delivered  to  its  target  cells  efficiently,  Ru486  was  dissolved  in  sesame  oil  for  IP 
injection once a week and in ethanol for topical painting twice a week at 0.4mg/kg (469) 
(average weight 25g of mouse was considered) and 10mg/100ml respectively.  
 
This IP injection protocol resulted in the eventual appearance of enlarged eyes with mild 
hyperplasia  in  the  RPE  layer  in  EICre/N-Ras
lys61  and  EICre/N-Ras
lys61/D5PTEN
flx/flx 
compound transgenics and thus indicated that the gene switch was working in vivo. These 
phenotypic  eyes  possessed  retinal  pigment  epithelia  hyperplasia  and  enlarged  choroid 
rather than melanoma. This histotype was quite similar to that produced in a similar, non-
inducible  model  of  Tyr-based  N-Ras
lys61  transgenic  mice  (215)  where  the  Ackermann 
model  eye  phenotype  appeared  in  adult  mice  by  6-8  weeks  old  presumably  due  to 
constitutive  oncogenic  N-Ras
lys61  expression  throughout  embryonic  development  as 
tyrosinase  transcriptional  elements  based  construct  would  be  expressed  in  neural  crest 
derived melanoblasts from day E10.5 (468).  
 
Phenotypic  eyes  from  both  models  have  enlarged  choroids  and  abnormal  folded 
neuroretinal, although the folding of the RPE was worse in the Ackermann model than the 
EICre model (Fig 51) consistent with constitutive expression throughout development in 
Ackermann model, unlike induction of phenotypes in EICre/N-Ras
lys61 where adults were 
allowed to develop normally. Apart from these phenomena as displayed in Ackermann 
model, phenotypic eyes from the EICre/N-Ras
lys61 model also displayed a larger size and 
more predominant melanin in the retinal pigmented epithelium (Fig 38).  
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Figure 51: Comparison of phenotypic eyes. Abnormal folded neuroretinal (dash arrow) and 
enlarged choroid (black arrow) were observed in phenotypic eyes from both Ackermann 
(left)  and  our  (right)  models.  Eye  of  Ackermann  model  was  copied  from  Ackermann, 
Cancer Research 65(10):4005, 2005 for comparison purpose.  
 
One  major  difference  between  the  two  models  was  the  harderian  gland  adenoma  in 
EICre/N-Ras
lys61  and  EICre/N-Ras
lys61/D5PTEN
flx/flx  mice.  These  harderian  gland 
adenomas displayed a much larger size (up to 4 times) as well as an adenoma histology 
from those harderian glands obtained from normal C57 mice which also have been treated 
with Ru486 or from bigenic mice which has been treated with vehicle, thus eliminating any 
integration  effects  or  background  responses  to  Ru486  (Fig  39-41).  Despite  lack  of 
melanoma production in this model, unlike that eventually produced in the constitutive 
Ackermann  model,  this  model  showed  a  separate  harderian  gland  phenotype.  This 
unexpected  phenotype  of  harderian  gland  adenoma  resulted  from  prolonged  systemic 
treatment  with  Ru486  as  this  only  appeared  in  treated  mice  because  following  the 
oncogenic  expression  and/or  TSG  inactivation.  However, a  subsequent  literature  search 
discovered a paper on the expression characteristics of the enhanced tyrosinase promoter, 
using a lacZ report transgene (468). This study reported novel lacZ staining in cells of 
the harderian gland consistent with eventual adenoma formation in mice expressing N-Ras 
(and/or PTEN) over long periods of time. 
 
Most likely this difference also centred on the different promoters employed, and in cell  
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lineage studies Tonks et al, showed that there was unexpected report activity in harderian 
gland  employing  this  tyrosinase  enhancer/promoter  combination  and  from  which  they 
concluded as a population of neural crest derived cells possibly melanocytes in this gland. 
As this report could not find a population of TRP2 staining cells in the harderian glands, 
and given the adenoma phenotype but not melanocytic-type tumour, we conclude that the 
difference between enhancers/promoters in these two models (0.22kb/2.2kb in our model 
vs. 3.6kb/6.1kb in Ackermann) might contribute to such extra phenomena, as well as to the 
production  of  melanoma  in  Ackermann  model  (discussed  below).  On  considering  the 
differences between enhancers/promoters used in Chin (3.6kb/6.5kb of enhancer/promoter) 
(217;223)  and  Huijbers  (0.8kb/2.5kb  of  enhancer/promoter)  models  (439),  these  two 
models  show  clear  different  locations  of  melanoma  development  and  a  difference  in 
tumour  pigmentation,  although  the  same  H-Ras  (V12G)  oncogene  was  used  in  both 
models. As discussed by Huijbers et al, Cre-mediated recombination was mainly observed 
in follicular melanocytes and consequently therefore, appearance of melanomas on hairy 
skin was to be expected in their model (shorter version). In contrast, melanomas produced 
in Chin’s model (long version) showed a preference on skin areas with sparse or no hairs, 
such as the pinna of the ear, the tail, or the anus where dermal melanocytes are primarily 
present  in  an  adult  mice  and  the  Cre  recombinase  expression  were  detected  and  thus, 
melanomas produced were mainly amelanotic.  
 
However, such difference between the Chin and Huijbers models could also be the results 
of the different gene switch systems used. CDKN2A was a conditional knock out and H-
Ras(V12G) gene was followed by P1A gene which used the same mRNA transcript of Ras 
to  encode  a  tumour  specific  antigen  in  Huijbers  model,  whereas  CDKN2A  gene  was 
permanently knocked out and H-Ras(V12G) was expressed by an independent construct in 
the Chin model. Thus, we conclude that such a size difference of promoters used in these 
independent models contributed to the phenotypic difference obtained from each model but  
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was not the sole contributor. 
 
Despite the appearance of an eye phenotype, the continued lack of cutaneous phenotypes 
and unexpected in addition of PTEN biological function loss in the light of the findings 
from these alternative models, prompted a careful re-analysis of treated EICre/N-Ras
lys61, 
EICre/D5PTEN
flx/flx  and  EICre/N-Ras
lys61/D5PTEN
flx/flx  skins.  As  an  oncogenic  gene, 
persistence of active N-Ras expression in normal melanocytes may not be well tolerated, 
and active Ras expression can result in developmental defects (Costello syndrome, Noonan 
syndrome) but not tumours (154;155). Oncogenic Ras expression also activates cellular 
defence mechanisms (e.g. apoptosis and senescence) which need to be overcome, typically 
by a cross-talk of co-operating oncogenic alteration(s) for full malignant transformation. 
Thus, in cells harbouring active Ras gene, the question whether Ras triggers cellular anti-
proliferation  defence  mechanisms  or  interferes  with  a  cell  capability  of  preventing  the 
completion  of  such  responses,  could  be  a  major  determinant  of  the  cell  fate  and  the 
eventual  phenotype  (474).  Active  Ras  has  either  positive  or  negative  effects  on  the 
regulation of apoptosis to determine cell fate depending on the balance of the apoptotic and 
anti-apoptotic signalling pathways which vary in different cell types (473). Ras stimulates 
apoptotic  signal  Raf-1  (C-Raf)  in  lymphocytes  or  fibroblasts  and  brown  adipocytes  in 
absence  of  survival  factors,  whereas  other  signalling  pathways  downstream  of  Ras 
stimulate PIP3/Akt, survival signals for epithelial and myeloid cells.  
 
In treated EICre/N-Ras
lys61 skin, careful analysis of oncogenic N-Ras expression in mouse 
epidermis found a consistency of white hair/hair loss (Fig 42) suggesting that melanocyte 
apoptosis in hair follicles (Fig 43) was responsible for the lack of overt melanoma. In this 
model, levels of N-Ras
lys61 (Fig 31) and expression being induced in the normal adult stage 
may be not efficient enough to cause dysregulation of cell proliferation, differentiation and 
transformation, but efficient enough to induce pro-apoptotic molecules and overcome those 
anti-apoptotic  molecules  induced  by  activated  N-Ras
lys61  which  results  in  the  observed  
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melanocyte apoptosis. Indeed the rapidity of the induced apoptosis suggests that specific 
mechanisms exist that act as sentinels to prevent the onset of melanoma and are hyper-
sensitive to changes in molecules that induce these early stages.  
 
It may be that only very high Ras expression in melanocytes (e.g. in Ackermann model) or 
through embryonic development (40;215-217) can induce an anti-apoptotic mechanism in 
melanocytes to overcome this defence system and thus dysregulate cell development to 
result  in  production  of  melanomas.  Whereas  in  other  models  (e.g.  this  report),  Ras 
expression  may  activate  cell  defence  mechanism  to  result  in  the  observed  apoptosis  if 
murine skin was allowed to develop normally. To assess whether this was so, an apoptotic 
analysis was performed finding that in all N-Ras
lys61 expressing mouse skin, caspase-3 was 
expressed in greater number of melanocytes and in more hair follicles compared to normal, 
although  melanocytes  do  normally  express  caspase-3  as  expected  and  shown  by  one 
follicle under going apoptosis at the catagen phase (Fig 45). This differs from previous 
observations in cell lines transformed by H- or K-Ras (474;498), which  probably reflects 
being an in vivo model vs. in vitro and different Ras alleles analysed, but clearly N-Ras 
expressing melanocyte undergo apoptosis in a caspase-3 dependant manner in vivo.   
 
Depending upon the study, even no or sometimes quite low N-Ras mutation incidence was 
detected in common acquired nevi, but higher rates in congenital nevi (9;11;12;220) and as 
up to 95% of INK4a mutated familial melanoma cases have N-Ras codon 61 mutation in 
human (212-214). These data indicate that activated N-Ras
lys61 expression alone was not 
sufficient to produce full melanoma, but maybe involved at pre-malignant stages (222). 
Indeed, induced N-Ras expression in central nerve cells only produced neurofibroma-like 
tumours but not any tumour suggested a requirement for signal(s) other than the activated 
N-Ras  pathway  to  induce  tumours  (499).  However,  N-Ras  clearly  plays  a  role  in 
melanomagenesis as shown by the short latency (two months) of melanoma induction in  
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H-Ras/p16
INK4a model (223). In this current study, the idea that a  conditional knock out 
mouse of PTEN gene, the second most abnormal TSG gene after CDKN2A in melanomas 
(250;252) and loss of heterozygosity (LOH) quite often observed in primary and metastatic 
melanomas  (264),  could  substitute  for  such  CDKN2A  mutation.  However,  PTEN 
involvement  did  not  change  the  course  of  melanoma  aetiology,  as  trigenic  EICre/N-
Ras
lys61/D5PTEN
flx/flx mice repeatedly failed to produce melanoma following more than one 
year of Ru486 application.  
 
Incorporation  of  PTEN  functional  loss  in  this  N-Ras
lys61  model  did  not  produce  the 
promotion of tumourigenesis as observed in H-Ras model of carcinogenesis (246) and 
CDKN2A did in other melanoma models, suggesting a redundancy between PTEN and N-
Ras  genes  in  melanocytes  in  vivo.  This  idea  was  supported  by  the  finding  that  PTEN 
function loss in melanocyte produced white hair was consistent with one of the PTEN 
primary  functions  of  which  is  to  regulate  cell  development  by  negatively  control  cell 
proliferation  through  apoptosis  (243;245;259;500).  Therefore,  there  may  also  be  an 
important component of compensatory surveillance system sensitive to PTEN loss which 
exists  in  melanocyte  in  vivo  and  that  prevents  cell  dysregulation  in  absence  of  PTEN 
function and results in  melanocyte programmed death to negate melanoma production. 
This lack of promotion of PTEN on N-Ras tumourigenesis may be due to PTEN functions 
to negatively regulate the N-Ras MAPK signalling pathway and thus its loss is redundant 
to  resultant  melanocytes  expressing  activated  Ras  and  elevated  MAPK  (Fig  3,  45) 
(152;271). In addition as outlined above, in vitro PTEN loss only accelerated/enhanced Ras 
transformation but not immortalisation, rather than cooperation with another potent Ras-
independent  pathway  which  could  co-operate  with  constitutively  activated  Ras-GTP 
pathway to induce full malignancy. 
 
To  assess  whether  PTEN  function  loss  also  induced  melanocyte  apoptosis  in  vivo  and  
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whether  any  additive  functions  in  addition  to  those  detected  in  N-Ras
lys61  expression, 
caspase-3 and -9 expression detections were performed in both EICre/D5PTEN
flx/flx and 
EICre/N-Ras
lys61/D5PTEN
flx/flx  mice  employing  immunofluorescence  staining  and  the 
results (Fig 45) revealed that as in N-Ras expressing mice, PTEN function loss resulted in 
melanocyte apoptosis in vivo again through caspase-3 dependant pathway but not caspase-
9.  Furthermore, as the same apoptosis mechanism involving caspase-3 and the number of 
caspase-3 expressing follicles are not additive in EICre/N-Ras
lys61/D5PTEN
flx/flx mice, it 
again  suggested  that  these  two  gene  functions  are  redundant  in  melanocytes  in  vivo.  
Therefore,  PTEN  promotion  capability  to  N-Ras
lys61  initiated  melanomagenesis  was 
prevented  and resulted in no production of melanoma in EICre/N-Ras
lys61/D5PTEN
flx/flx 
mice.  Such a gene redundancy in vivo is possibly due to PTEN and Ras functions on the 
same signal pathway to regulate cell death/proliferation/differentiation, but not providing 
alternative additional genetic signalling pathway to cross-talk with Ras signalling pathway 
which may be essential for Ras induced tumour formation. Moreover, this may indicate 
how vital these genes are to the development of melanoma as such sentinel systems have 
evolved to defend against these mutations and other pathways are required to circumvent 
these  mechanisms.  The  importance  of  these  genes  despite  the  failure  of  melanoma 
production was also consistent with the results obtained from the in vitro model (above) in 
which, PTEN is able to promote N-Ras initiation possibly due to being in vitro but the 
transformed  cells  promoted  by  PTEN  loss  are  not  immortalized  due  to  the  function 
redundancy between these two genes. 
 
Searching the literature, all successful Ras driven mouse melanoma models either were 
created in a CDKN2A (p16/p19) background (215-217;223;439) or melanoma cells bear 
hetero/homozygous deletion of CDKN2A locus if the models were produced by H-Ras 
expression  in  a  normal  background  followed  by  UV  radiation  or  chemical  treatment 
(221;349).  Therefore,  loss  of  function  of  CDKN2A  gene  seems  an  essential  event  for  
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melanoma  development  in  Ras  mouse  models  to  date.  Other  gene(s)  (e.g.  CDKN2A) 
cooperation is necessary for tumour development (152) although Ras activation is essential 
for  melanoma  maintenance  (223).  Inducible  N-  and  H-Ras  expression  alone  is  not 
sufficient  to  induce  melanoma  in  all  developed  mouse  models  and  only  constitutive 
expressing N-Ras
lys61 produced melanoma with longer latency (>12 vs. 6 month) and much 
lower penetrance (25% vs. >94%) compared to those melanomas induced in CDKN2A 
deficient background from the same experiment (215). This may have been due to higher 
expression from its larger promoter to cause CDKN2A ablation although CDKN2A gene 
mutations  in  these  late  onset  constitutive  N-Ras
lys61  expressing  melanomas  were  not 
analysed  and  therefore,  whether  the  CDKN2A  gene  expressed  normal  or  function 
inactivated eventually in those melanomas is unknown. Indeed, as only 4 melanomas were 
induced by N-Ras
lys61 expression control cohort, maintaining the characteristics of familial 
cutaneous melanoma with germline INK4a mutation, as the authors acknowledged that 
these melanomas may have had spontaneous CDKN2A mutation and thus, it is not N-
Ras
lys61  alone  but  cooperation  again  with  CDKN2A  ablation  which  is  the  causal 
mechanism underlying these 4 melanomas. 
 
Hence  in  those  H-Ras  expressing  generated  melanoma  following  UV  or  chemical 
application  (216;221),  the  other  gene(s)  that  undergo  ablation/mutation  may  be  the 
necessary hallmark to complete melanoma formation. Thus it is not surprising that there 
was no melanoma generated by N-Ras
lys61 expression alone in our inducible gene switch 
model because the induced N-Ras
lys61 expression in adult mice is not sufficient to cause 
hyperplasia from cell dysregulation as other models did during embryogenesis, without the 
consequent molecules aberration to co-operate and subsequently to overcome cell defence 
systems such as the induced apoptosis in adult follicular melanocytes.  
 
Although continual expression of fully activated Ras is unexpected to be well tolerated, to  
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form tumour eventually many other molecular steps are needed other than activation of 
Ras pathway components for progression (152) and thus, CDKN2A ablation provides such 
a  Ras-independent  pathway  to  co-operate  with  Ras  signalling  pathway  to  result  in 
melanoma formation in mouse models, but PTEN deletion in adult may not. Comparing 
our model with all relative close (H-Ras gene-switch and N-Ras constitutive expressing) 
successful mouse melanoma models (215;223;439), the main, possibly critical, points are 
that in all other three models Ras expressed in a CDKN2A deficient background which 
allows gene cooperation through different genetic pathways other than PTEN functional 
deletion  which  may  only  affect  Ras  signalling  pathway  by  enhancing/promoting  Ras 
function, but insufficient to provide the alternative additional molecular steps to form overt 
melanoma. Therefore, even in EICre/N-Ras
lys61/D5PTEN
flx/flx mice, targeted cells received 
essentially one hit in our model in adult rather than multiple hits (p16/p19 and Ras) in 
CDKN2A  deficient  models,  including  unknown  events  elicited  during  embryonic 
expression of these mutations in several of the models.  
 
In EICre/N-Ras
lys61/D5PTEN
flx/flx model despite PTEN loss, the N-Ras expression induced 
an  anti-apoptotic  mechanism  and  apparently  this  response  is  too  low  to  overcome  the 
induced cell defence apoptotic pathway. As discussed in 4.1, the enhancer/promoter as 
well as the 5’ and 3’ untranslated region may also influence the Ras expression level to 
consequently result in different phenotype (486). But it should not be the critical factor 
since  the  relative  short  enhancer/promoter  (very  similar  to  this  model)  employed  in 
Huijbers model generated mouse melanoma successfully using H-Ras(V12G) (439) despite 
the differences of phenotypic macrology and histology from another H-Ras (V12G) model 
by using a longer version of enhancer/promoter (223). 
 
Collectively, to date the mice have been successfully established and technical difficulties 
overcome such as awkward mouse hair cycle physiology (e.g. there are only 6-8 days for  
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tumourigenesis to begin) that provides the foundations of an inducible system. Inducible 
models where temporal effects are added into adult mice may be a better mimic of human 
carcinogenesis in somatic cells and thus gave different results to e.g. the closest model of 
Ackermann. This approach certainly lets us add more events in to test ideas including 
extrinsic  keratinocytes  and/or  more  gene  mutations.  This  may  be  a  critical  technical 
component for studying of melanoma development from nevi to RGP and RGP to VGP. 
 
This  in  vivo  inducible  model  shows  that  the  mouse  could  utilise  the  normal  defence 
systems to overcome anti-apoptotic mechanism triggered by N-Ras expression and PTEN 
function loss through the activation of pro-apoptotic system. Thus, the mouse will develop 
normal if any of these genes ablation is not accompanied by the subsequent molecular 
event(s)  to  cross-talk  to  Ras  initiated  pathway,  whereas  Ras  initiated  anti-apoptotic 
pathway more likely to overcome its pro-apoptotic system to result in cell dysregulation if 
Ras expression and/or other TSGs loss events happened through  embryonic process in 
other models. Comparing this model with other relative close models, we concluded that 
Ras mutation may not be an independent event in somatic melanoma but one of steps 
involved  with  many  other  molecules  (specifically  not  on  the  Ras  signalling  pathway) 
despite the high mutation rate of N-Ras had been revealed in human melanoma. To form 
tumour  successfully,  consequent  gene  ablation  which  can  supply  a  different  signalling 
pathway to co-operate with any oncogenic gene expression and/or loss of TSG is necessary 
to overcome mouse self-defence systems. Therefore, the formation of melanoma is highly 
expected if CDKN2A deficient mouse background was introduced into this model and 
such introduction is the primary goal of future work.  
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4.5. Investigation of the role of the microenvironment on EICre/N-Ras
lys61 
/D D D D5PTEN
flx/flx phenotypes 
White hair or hair loss produced by N-Ras
lys61 expression in melanocytes indicated that a 
premature melanocyte apoptosis occurred in anagen hair follicles which may have been 
responsible in part for the lack of melanoma, despite additional PTEN loss which also 
appeared to induce a pro-apoptosis via caspase-3 to stimulate cell defence system (Fig 45).  
 
In addition to these complex intrinsic genetic factors within melanocyte, regulation by the 
microenvironmental cells/tissues, especially keratinocytes, also play a very important role 
in the physiology underlying melanoblast/melanocyte survival, migration, proliferation and 
differentiation and in the development of melanoma, via a complex interaction of cues 
secreted by and releases from keratinocytes, the seed/soil hypothesis (reviewed in (470)).  
 
Increase of melanin-a in malignant melanoma cell lines augmented by the presence of a 
keratinocyte papilloma cell line SP-1, derived from the hair follicle stem cells in two stage 
chemical  carcinogenesis,  suggested  that  keratinocytes  secret  melanogens  toward 
melanocytes  and as outlined above SP1 action as a successful feeder layer occurred when 
cultures in low calcium media (457;458) and in a proliferative basal cell phase. In adult 
mice, pigmented spots in hairless mice were induced long after UVB exposure indicating 
that epidermal melanocyte proliferation and differentiation were regulated by keratinocytes 
rather than by melanocytes, which was verified by irradiated keratinocytes stimulating the 
proliferation  and  differentiation  of  non-irradiated  melanocytes  more  greatly  than 
keratinocytes from non-irradiated mice and whereas, irradiated adult keratinocytes have 
very  similar  affection  on  non-  and  irradiated  adult  melanocytes  proliferation  and 
differentiation (501;502).  
 
In melanoma models, melanomas are often accompanied by keratinocyte hyperplasia. In  
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the Ackermann system, constitutive N-Ras expression in melanocytes produced mice with 
epidermal hyperplasia, hyperkeratosis in adults (215). In model of Noonan, a good close 
mimic of human melanomagenesis as it elicits epidermal melanoma with the potential to 
investigate junctional pathology unlike the other models e.g. Chin (223), UV exposure on 
neonates gives melanomas in adults, this model also has neonatal keratinocyte hyperplasia 
from HGF expression in keratinocytes (40). Skin hyperplasia was also revealed by H-Ras 
constitutive expressing in H-Ras mediated mouse melanoma models (216). Both in vitro 
and in vivo models implied a role of abnormal keratinocyte during melanoma development.  
 
Therefore  to  test  whether  disruption  of  the  follicular  microenvironment  of  melanocyte 
would  change  the  in  vivo  responses  and  initiate  melanoma  production,  N-Ras
lys61 
expression and PTEN deletion in keratinocyte was incorporated into this model. This was 
achieved  employing  a  K14Cre  regulator  transgenic  line  bred  into  trigenic  EICre/N-
Ras
lys61/D5PTEN
flx/flx mice. Here, in a similar fashion to cooperation between PTEN loss 
and  H-Ras  (246),  disruption  of  follicular  morphology  was  envisaged  via  induction  of 
keratinocyte  hyperplasia  as  K14  promoter  is  expressed  in  the  hair  follicles,  including 
keratinoyte stem  cells.  This proved to be the  case but instead of producing melanoma 
phenotype following K14Cre/EICre/N-Ras
lys61/PTEN
flx/flx treatment with Ru486, N-Ras
lys61 
expression  cooperated  with  PTEN  functional  loss  in  keratinocytes  give  squamous  cell 
papillomas which possessed a population of melanocytes creating pigmented papillomas.  
 
These  results  firstly  indicated  that  in  keratinocytes  N-Ras
lys61  expression  acted  as  an 
initiator with which PTEN loss acted as a promoter given that N-Ras or PTEN loss alone in 
controls did not produce tumours. This was similar to the findings employing H-Ras mice 
(246).  Secondly,  by  active  regulator  and  consequent  dysregulation  downstream  of  Ras 
signalling pathway (including PTEN function loss) in keratinocytes may have contributed 
to the decision of melanocytes fate in addition to regulation of the melanocyte own genetic  
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factors as clearly here anagen melanocytes now survived and did not undergo apoptosis. 
 
As discussed above, level and the initial time of N-Ras
lys61 expression may contribute to 
papilloma genesis because expression in keratinocytes using the K14 promoter may be 
stronger than EICre in melanocytes, including stem cells (467;503) and therefore, more 
cells expressing strong K14Cre than melanocytes expressing relative weak EICre to result 
in keratinocyte hyperplasia and papillomas, or it may be that keratinocytes do not respond 
to N-Ras via induction of apoptosis, as this would compromise their important  barrier 
functions.  
 
  The pigmentation of induced papillomas could be derived from interfollicular relocation of 
melanocytes  which  migrated  out  of  the  hair  follicle  following  N-Ras
lys61  expression  in 
melanocytes  (215)  and  in  its  microenvironmental  keratinocytes.  Given  the  lack  of 
interfollicular melanocytes in adult murine skin the pigmentation of induced papillomas 
could be derived from survival of melanocytes from an anagen hair follicle following N-
Ras
lys61  expression  in  melanocytes  (215).  In  this  microenvironment  of  keratinocyte 
hyperplasia,  melanocytes  were  able  to  continue  to  proliferate  during  papilloma 
development  (see Fig 46b, 47) or simply continue to exist as hair follicle residues during 
papilloma development due to there is no interfollicular melanocytes exist (please see Fig 
46b, 47). To confirm that these were indeed melanocytes and not melanin produced in 
melanocytes and melanosomes transferred into neighbouring keratinocytes, TRP2 antibody 
immunostaining  demonstrated  the  survival  of  melanocytes  during  pigmented  papilloma 
development, similar to those hyperproliferative examples of Powell or Ackermann Ras 
alone controls (215;216). Moreover, employing a combination of suprabasal keratin 1 (K1) 
and basal keratin 14 (K14) expression against TRP2 staining, it became clear that these 
melanocytes  occupied  mainly  the  proliferative  keratinocyte  basal  layers  of  papillomas 
(503).  Thus  N-Ras
lys61  expressing  and/or  PTEN  function  loss  in  keratinocyte  allowed  
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melanocyte to survive from the apoptosis and therefore proliferated and accumulated to 
result in pigmentation in papillomas during the papillomagenesis. 
 
These kinds of pigmented papillomas, may relevant to seborrheic keratoses in human, are 
of  intense  worry  to  patients  whether  the  possibility  of  melanoma  is  high  prior  to 
histological analysis. Thus, the mechanism of melanocyte survival was investigated further 
to  answer  the  questions  of  why  melanocytes  in  hair  follicle  programmes  exhibited 
premature  apoptosis  when  N-Ras
lys61  was  expressed  in  melanocytes  but  anagen 
melanocytes survived when keratinocyte hyperplasia and then papillomagenesis occurred 
in  parallel.  The  disruption  of  the  microenvironment  in  addition  to  N-Ras
lys61/PTEN 
mutation  in  melanocytes  and  resultant  melanocytes  survival  rather  than  apoptosis, 
suggested that a survival loop was initiated that by-passed the apoptotic response allowing 
melanocytes  survival  and  proliferation.  That  this  did  not  produce  overt  melanomas 
suggested that this was provided by keratinocytes disruption to the normal regulation of 
melanocyte survival factors.  
 
As  cited  above,  microenvironmental  regulation  of  melanocytes  specifically  by 
keratinocytes  is  indispensable  to  their  physiology  in  addition  to  the  regulation  of 
melanocytes  by  their  own  intrinsic  factors.  One  important  growth  regulatory  loop  in 
melanocyte development is mediated by  Kit and its ligand SCF (Kit/SCF), which plays an 
essential role during embryogenesis for melanocyte survival, migration, proliferation and 
differentiation and may well define the melanocyte stem cell niche, hence the importance 
of correct Kit/SCF regulation in the development of melanomas (414). Indeed, malignant 
melanomas and cell lines established from melanoma samples and transformed murine 
melanocytes do not express detectable Kit, in contrast to readily detectable Kit protein 
observed in normal human and murine (review in (504)) melanocytes, which suggested Kit 
loss or a marked reduction either promoted or was a consequence of transformation in  
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melanocytes (293;294). Moreover, this may have profound effects on metastasis, the most 
clinically relevant stage in terms of patient survival as while RGP melanocytes retained Kit 
expression, and thus a relative degree of control by keratinocytes, VGP melanomas lost Kit 
expression and thus escaped this control (505). 
 
Data shown in Fig 48 and 49 revealed that Kit and its ligand SCF were expressed in a 
complementary  fashion  in  either  normal  or  hyperplastic  skin  and  papillomas.  Kit  was 
expressed mainly in the proliferative layers of epidermal and hair follicle in normal and 
hyperplastic skin where the strongest expression remained in hair follicles (Fig 48, A and 
B) and expression levels of Kit were significantly elevated in all papillomas investigated 
(Fig  48,  C-F).  That  this  Kit  expression  was  involved  in  melanocyte  survival  in  these 
pigmented  papillomas,  was  suggested  by  the  very  strong  Kit  expression  observed 
throughout  the  proliferative  epidermal  papilloma  layers  where  most  of  the  surviving 
melanocytes  were  located  (Fig  46b,  Fig  48)  and  later  confirmed  by  co-localisation 
experiments  (below,  Fig  50),  which  further  verified  Kit  involvement  in  pigmented 
melanocytes  survival.  Significant  increases  in  SCF  expression  levels  in  pigmented 
papillomas  (Fig  49)  also  indicated  that  disrupted  keratinocytes  in  the  immediate 
melanocyte  microenvironment  secreted  high  levels  of  SCF  and  thus  could  complete  a 
paracrine growth signalling loop for the Kit receptor expression in melanocytes and thus 
provide a Kit/SCF melanocyte survival loop during tumourigenesis.  
 
To confirm that increased Kit and SCF expression levels were involved in melanocytes 
survival and not just that this expression was the result of keratinocytes dysregulation in 
papillomagenesis,  double  staining  of  Kit  and  TRP2  (Figs  50)  was  performed.  The  co-
localisation  of  Kit  expression  with  TRP2  in  melanocytes  in  pigmented  papillomas 
confirmed  that  as  disrupted  keratinocytes  released  SCF  it  provided  the  ligand  to  Kit 
receptor in melanocytes which therefore managed to escape apoptosis driven by the cell  
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defence system and to result melanocyte survival. This predominantly basal location of 
melanocytes was in direct agreement with the use of hair follicles derived SP1 papilloma 
cells  as  a  good  feeder  for  primary  melanocytes  culture  (457)  and  also  the  growth  of 
proliferative  melanocytes  in  low  calcium  conditions  alongside  SCF–secreting  primary 
keratinocytes, as mentioned in 4.2. However as revealed in Fig 47 and Fig 48, melanocytes 
and  Kit  expressing  occasionally  detected  as  cluster  pattern  although  these  cells  also 
surrounded by some proliferative keratinocytes (Fig 48) and therefore, whether there is an 
autocrine functional survival loop taking in part in those survived melanocytes is unknown 
and would be interesting to investigate further. 
   
Melanoma cells and the microenvironment have an intimate relationship and regulate each 
other in both positive and negative aspects that prevent or assist the process of tumour 
growth and invasion. On one hand melanoma cell released cues, for instance Nodal, as a 
potent  embryonic  morphogen,  can  induce  ectopic  formation  of  the  embryonic  axis.  Its 
presence in human metastatic tumours but not in normal skin suggested that Nodal may be 
involved in melanoma pathogenesis.  Using zebrafish developmental system as a biosensor 
for tumour-derived signals study, Topczewska et al revealed that aggressive melanoma 
cells secrete Nodal and consequently inhibition of Nodal signalling reduces melanoma cell 
invasiveness, colony formation and tumourigenicity (8). On the other hand, embryonic 
microenvironmental regulation could re-programme metastatic melanoma cell to lose its 
tumourigenicity and to assume a neural crest cell-like phenotype(506). The results obtained 
in this study are consistent with previous studies which indicated that the interaction of 
melanocytes and the microenvironment is critical to the determination of melanocytes fate. 
Inducible N-Ras
lys61 expression and/or PTEN function loss in melanocyte alone failed to 
produce any melanocytic phenotype in mice until pigmented papilloma induction by N-
Ras
lys61 and PTEN loss in keratinocyte allowed melanocyte to avoid apoptosis and is a 
classic example of the results of cooperation of melanocyte and its microenvironment.   
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4.6. Requirement for melanoma transgenic models and the relevance of 
the models to human disease 
Employing transgenic technology, the first transgenic melanoma model was developed in 
1991 using the SV40 transforming gene driven by a tyrosinase promoter (441;442). The 
mice were categorized according to susceptibility of tumour development, with gene copy 
number  delineating  the  groups.  UV  exposure  promoted  the  more  susceptible  lines  to 
develop  cutaneous  tumours,  but  aggressive  ocular  tumours  limited  investigation  of 
cutaneous tumour development giving a short life span. Thus to study cutaneous tumours 
they were transplanted to less susceptible mice where they progressed to metastasis. While 
being the first model to develop melanoma using transgenic technology, proving a targeted 
model in principle, the SV40 early transform gene is not a melanoma related gene and as 
lethal  ocular  melanomas  developed  prior  to  cutaneous  melanoma  this  was  not  a  good 
melanoma mouse model to mimic human melanoma development. 
 
To develop a mouse model closer to human melanoma aetiology, an activated Ras gene 
(albeit  the  H-allele)  was  expressed  again  under  control  of  a  mini-tyrosinase  promoter. 
These H-Ras transgenic mice however developed only dermal melanocytic hyperplasia, a 
mutated agouti coat and pigmented skin (216) and were again prone to ocular melanoma 
(507).  Nonetheless,  following  DMBA/TPA  or  UV  treatment,  the  H-Ras  expressing 
transgenic mice develop nevi as well as cutaneous melanoma, of which more than 40% are 
metastatic  and  these  results  demonstrated  a  good  model  for  multistage  melanoma 
development (221;222). Melanomas developed in mouse dermis directly and only albino 
phenotype  mice  developed  cutaneous  melanomas,  this  model  was  therefore  not  the 
fulfilment of melanoma development as a multistage disease in human. 
 
In 1994 CDKN2A, as a candidate tumour suppressor gene, was pinpointed to chromosome 
9p21 because of deletions in melanoma cell lines and later identified as a candidate for the  
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chromosome  9p  melanoma  susceptibility  locus  (93;311;313).  Initially  production  of 
INK4a/ARF knockout mice did not exhibit melanoma susceptibility (316), but p16
INK4a 
specific  gene  targeting  can  facilitate  melanomagenesis,  particularly  after  exposure  to 
DMBA.  The  cutaneous  melanoma  developed  in  H-Ras  expressing  transgenic  mice 
following DMBA treatment was also accompanied by either complete or partial loss of the 
p16 (221). By expressing active oncogenic H-Ras gene in melanocytes in INK4a deficient 
background  mouse,  the  first  melanoma  transgenic  mouse  model  without  the  need  of 
chemical/UV  promotion  was  generated  and  this  model  provides  the  first  in  vivo 
experimental  evidence  for  a  causal  relationship  between  INK4a  deficiency  and  the 
pathogenesis of melanoma (217). This H-Ras/p16 model was further developed by using 
the Tet-gene switch system and provided the genetic evidence that H-Ras is important in 
both  the  genesis  and  maintenance  of  solid  tumours  (223).  The  cutaneous  melanomas 
generated from both models are again originated in dermis directly as the other models 
(221;278)  did  with  no  apparent  epidermal  involvement,  which  does  not  mimic  human 
melanoma development. Further  H-Ras, an allele of Ras  gene, has a  much less often 
mutation  rate  than  its  counterpart  N-allele  in  human  melanoma  although  the  Tet-gene 
switch  model  provided  a  very  good  system  to  be  able  to  control  the  melanoma 
development by application/removal of gene-switch inducer.   
 
It  is  widely  recognized  that  UV  is  at  least  partly  responsible  for  the  development  of 
melanoma  (22;508;509).  Using  H-Ras  expressing  transgenic  mouse,  UV  promotion  on 
melanoma development was revealed (222) and in groundbreaking classical work, a later 
model employing HGF/SF transgenic expression Noonan et al demonstrated  that a single 
neonatal dose of UV was sufficient to induce staged melanocytic lesions (40) and p16/p19 
deficiency promoted this UV induced melanomagenesis (349) although chronic UV failed 
to  accelerate  melanoma  development  (510).  Furthermore,  this  model  overcame  the 
problem of the previous models that tumours are dermal origin and lack the epidermal  
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component  that  characterizes  conventional  human  melanoma  (40).  By  possessing  a 
junctional  as  well  as  a  dermal  component  and  lesions  exhibiting  upward  migration  of 
single and nested atypical melanocytes into the epidermis, reminiscent of the authors called 
‘pagetoid’ spread that characterizes human RGP melanoma, this model directly mimic the 
human melanoma multistage aetiology.  This model still does not fulfil an ability to mimic 
the development of RGP to VGP in human, which is the most important clinical event for 
patient  survival  (511).  Furthermore,  HGF  expression  alone  spontaneously  produces 
melanoma alongside many other malignancies, and the embryonic HGF expression is not 
often seen in melanoma although HGF, ligand of receptor tyrosine kinase c-MET, is a 
multifunctional  regulator  of  cellular  growth,  motility  and  invasiveness  including  in 
cutaneous melanoma development (512-514). The involvement of the most abnormal TSG 
gene  (CDKN2A)  of  melanoma  in  this  model  resulted  in  lethality  (349)  indicating  that 
constitutive HGF overexpression may cause potential developmental problem beside the 
effects on melanocytes.   
 
All the previous transgenic mouse melanoma models were developed by expressing H-
allele but not the highly mutated N-allele of Ras oncogene in human melanoma specimen, 
only recently was a mouse model with melanotic and metastatic melanoma produced that 
recapitulated genetic lesions frequently found in human melanoma. This was achieved by 
crossing activated N-Ras(Q61K), a hot spot N-Ras mutation in human melanomas, to a 
CDKN2A  deficient  mouse  (215;225).  But  again,  the  N-Ras  expressed  embryonic  not 
inducible and therefore, the control of N-Ras expression is impossible which limits the full 
investigation  of  N-Ras  roles  during  melanoma  development,  whereas  a  recent  study 
revealed that Ras functional outcome including downstream genes regulation is expression 
level-dependent (515). 
 
An  ‘ideal’  animal  model  would  accurately  recapitulate  human  disease  particularly  the  
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molecular genetics and the histopathological architecture of human cutaneous melanoma. 
As a multistage disease of melanoma, the conditional gene switch approach which leaves 
animal free until inducer treatment to activate regulator and subsequently to switch the 
target on, may be an ‘ideal’ transgenic model for melanoma investigation because it allows 
melanoma related genetic and environmental factors involved at the time as designed to 
investigate their stage related effect. Up to date, there are only two gene-switch melanoma 
mouse  models  available  (223;439)  which  are  not  yet  fulfilment  all  the  criteria  for 
modelling  human  melanoma  development.  In  both  models,  melanomas  originated  in 
dermis and invade the surrounding tissues locally whereas the epidermal remained intact 
possibly due to relying on the less common H-Ras activation rather than N-Ras or B-Raf. 
Also in the more recent model (439), target gene can not be switched off because the 
regulator Cre was inactivated following the target gene on.   
 
Chin’s model seems to be a perfect model if the more specific melanoma related gene such 
as  N-Ras,  B-Raf  and  the  other  not  N-Ras  pathway  related  genes  MC1R,  MITF  etc 
investigated. Very surprisingly, however, there is no further investigation published up to 
date using this system. Furthermore, there is not any B-Raf, the most mutated gene in 
human melanoma, mouse model generated yet by any means neither overexpression alone 
nor co-operation with TSG genetic deficiency mouse apart from a zebrafish model created 
by Patton in 2005. In this fish model, active B-Raf (V600E) led to dramatic patches of 
ectopic  melanocytes  (authors  termed  fish  nevi  ─f-nevi)  and  induced  formation  of 
melanocyte lesions that rapidly developed into invasive melanomas in p53-deficient fish 
(413) which different from the most of mouse models generated in a CDKN2A deficient 
background as discussed above. The reason of why there is not a B-Raf mouse model yet 
given the high incidence V600E mutation reported in human melanoma specimens in 2002 
remains unclear, but it is interesting to speculate that activated B-Raf expression in mouse 
melanocytes induced apoptosis as N-Ras in this model to negate melanoma formation. If  
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this is true how can we modify the mouse transgenic expression profile to overcome such a 
surveillance  mechanism  and  to  generate  an  ‘ideal’  mouse  model  to  mimic  human 
melanoma development aetiology? This could be a big challenge to scientists who are 
studying the melanoma molecular aetiology employing mouse transgenic models. 
 
One  feature  created  by  experiments  designed  to  assess  the  effects  of  destabilising 
interactions between melanocytes and keratinocytes in this model was the development of 
pigmented  tumours  during  N-Ras/PTEN-mediated  papillomagenesis.  These  murine 
tumours may shed light on the aetiology of pigmented benign lesions in human skin termed 
seborrheic keratoses (SK), a benign skin tumour neither nevi nor melanoma. SKs are a 
keratinocyte-derived, benign acanthotic skin tumour that never progresses to an invasive 
phenotype, which exhibit several histological sub-types (5). Seborrheic keratoses progress 
from an initial hyper-pigmented maculae to the characteristic plaque (516) and eventually 
exhibit a wart-like papilloma appearance, although no HPV involvement has been recorded 
(517).  Histologically,  prominent  melanocytes  and  their  dendritic  processes  are  usually 
quite obvious and scattered individually throughout the section, and dendritic melanocytes 
presented in the basal and suprabasal layers (516;518;519) in melanoacanthoma, one of 
variant of seborrheic keratoses. These lesions can have dendritic melanocytes in the basal 
layers (Fig 46b and 47 E), as appeared in human oral melanoacanthoma (6). Thus it may be 
that the expression of N-Ras and D5PTEN in melanocytes and keratinocytes creating the 
SCF/Kit survival loop during papillomagenesis (Fig 46a) provides a microenvironment that 
similar to aetiology of such seborrheic keratoses in humans.  
 
Whether this aetiology depends on the genes mutated or simply establishment of a survival 
loop for proliferative melanocytes (e.g. SCF /Kit or HGF/Met (520)) is unclear and there 
are  few  studies  exploring  the  relationship  of  gene  mutation,  expression  and  SK 
development. Among the genes studied in SKs, some show a similar expression profile to 
that of normal skin, such as p120 catenin (521), proliferating cell nuclear antigen (PCNA)  
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(522), proto-oncogenes c-fos and c-jun,(523), p63 (524), E-cadherin and p-STAT3 (525);  
while the others show a different expression pattern compared to the normal skin. p16 
expressed  in  all  keratinocytes  from  SK  lesions  but  only  in  granular  cells  of  normal 
keratinocytes in culture (526). p53 and Bcl-2 expression is higher in SK than in normal 
skin but significant lower than in SCC in keratinocytes (527) although p53 binding protein-
1 remained unchanged in SK (528) while Bcl-2 may be increased as an anti-apoptotic 
mechanism (529). Strong expression of the cyclin-dependent kinase inhibitor p27(KIP1) in 
SK revealed that p27(KIP1), which is regulated by PTEN via cyclin E,  may be a major 
mechanism controlling keratinocyte proliferation (530). Similarly a role for FGF3 mutation 
has been confirmed by a series studies both in transgenic model (531) and in human SK 
samples (532-535) but without intra-individual hot spot (533) revealed. The mechanism for 
the high rate of somatic FGFR3 mutations in SK remains elusive although UV may play a 
potential role, especially in the R248C mutations (535). FGF3b bears transforming ability 
by transfection of NIH-3T3 cells with a mutated form S249C (536) but FGF3 mutations 
obviously do not account for all papillary urothelial cancers and acanthotic skin tumours 
implied  that  further  genes  must  be  involved  in  tumourigenesis  (537;538).  Downstream 
pathways  of  FGFR3  such  as  the  PI-3K/PTEN/Akt  or  the  Ras/Raf/MAPK  pathway  are 
therefore  suggested  to  be  promising  candidates  (537).  Linking  this  idea  to  the  data 
presented here together with the previous studies that revealed a role of Ras expression in 
SK development (539;540), which imply that deregulated Ras expression in keratinocytes 
may  contribute  to  SK  development,  either  independently  or  in  co-operation  with  FGF 
pathway, although further studies will be necessary to confirm this hypothesis.  
 
A more recent interesting study that links to PTEN functions, revealed that PIK3CA (p110 
a subunit of PIK3) mutation in seborrheic keratoses bears no relevant risk of progression 
to  malignancy  (541).  This  finding  and  the  N-Ras/PTEN  results  reported  here  in  the 
melanoma model and lack of progression in the pigmented papilloma development, show 
that other genetic alterations must occur to progress to a more malignant phenotype. Our  
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results  are  also  consistent  with  previous  studies  that  specific  mutations  may  activate 
protective cellular mechanisms which act as a barrier for tumour progression (542). For 
instance  employing  the  doxycycline-inducible  transgenic  mice  that  permit  K-Ras 
activation to be titrated, authors found that physiological levels of Ras stimulate cellular 
proliferation and mammary epithelial hyperplasia and but surprisingly, high levels of Ras 
activation induced a CDKN2A-dependent cellular senescence (515). A three-stage model 
for Ras-induced tumourigenesis was thus suggested that consists of an initial Ras mutation, 
overexpression  of  the  activated  Ras  allele  and  evasion  of  p53-CDKN2A-dependent 
senescence  checkpoints  (515).  Hence  failed  melanoma  production  in  our  model  is 
supportive  for  this  3-stage  theory  because  the  last  step  of  Ras-independent  senescence 
checkpoint  is  not  interrupted  in  our  model.  These  studies  support  the  conclusion  that 
introduction of p16/p19 deficient mice in this system may be essential for production the 
early stages of a useful model to investigate multistage melanoma complete with junctional 
pathology in the epidermis, to then investigate progression from RGP to VGP, as there is 
no model available yet able to model this most significant change in relatively benign to 
highly malignant/metastatic melanoma.  
 
Another lesser phenotype developed in this murine model was the loss of hair at treated 
sites, although it may be possible that inducible expression of N-Ras in the follicle, gave 
rise to an immune response. One such disease in humans is Alopecia Areata (AA), an 
autoimmune disease where white blood cells attack the hair follicles. This mainly depends 
on  an  individual’s  genetic  makeup  in  combination  with  other  factors  that  trigger  AA 
(543;544). Apart from a familial occurrence of AA (545) where the pattern of familiality 
suggests  that  the  genetic  basis  is  multifactorial  (546),  the  aetiopathogenesis  of  AA  is 
poorly understood (543;544). Although AA is thought to be a tissue-specific autoimmune 
disease directed against the hair follicle, an association with other autoimmune diseases 
has been reported (547-549). To date, only the involvement of the major histocompatibility  
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complex (MHC) has been confirmed by means of independent replication (550-552) and it 
has been postulated that various genes related to immune response are associated with AA.  
 
Although the only confirmation is the involvement of the MHC in AA aetiology, there are 
a few other immuno-related genes have also been suggested the relationships with AA 
development.  The  non-synonymous  C1858T  substitution  in  the  PTPN22  gene,  a  gene 
encodes  lymphoid  protein  tyrosine  phosphatase  and  is  associated  with  susceptibility  to 
autoimmune disorders, may have an influence on the severity of AA and further evidence 
provided for autoimmunity as an aetiological factor in this disorder (553). Freyschimidt-
Paul’s  study  revealed  an  essential  requirement  for  interferon-gamma-mediated  Th1 
activation in the induction of AA (554). Loss-of-function mutations in the filaggrin gene 
may be considered as promising candidates in AA because when AA occurs in conjunction 
with filaggrin gene-associated atopic disorder, the clinical presentation of AA may be more 
severe (555). Substance P (SP) plays a critical role in the cutaneous neuroimmune network 
and influences immune cell functions through the neurokinin-1 receptor (NK-1R) may also 
serve as important regulators in the molecular signalling network modulating inflammatory 
response in autoimmune hair loss (556). Ran, a Ras related nuclear protein, may play a role 
in shrimp immunity against virus infection (557) and N-Ras or K-Ras inhibition increases 
the number and enhances the function of Foxp3 regulatory T cells (558). A recent more 
interesting  study  revealed  that  activities  of  Rho/Ras  family  GTPases  were  reduced  by 
lovastatin while myelin repair is induced in experimental autoimmune encephalomyelitis 
(EAE) (559). These recent studies as well as our finding of Ras-induced hair loss imply 
that oncogenic Ras not only causes carcinogenesis and developmental diseases (154;155) 
but may also be related to development of some immune diseases like AA,  although this 
hypothesis is at its initial stage and many further studies need to be done to verify it. 
 
The hair loss found in this murine study may bear some similarities to AA in humans, but  
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it is not a model designed to study this disease, nor does it resemble androgenetic alopecia 
(AGA) ―a disease is characterized by a defined pattern of hair loss from the scalp (560), 
neither  congenital  atrichia  (AUC)  ―a  form  of  isolated  alopecia  with  an  autosomal 
recessive mode of inheritance and the patients are born with normal hair but this is shed 
almost completely during the first weeks or months of life and never re-grows (546). It 
may simply be a feature of the inducible N-Ras expression in melanocytes, induces an 
immune  response  that  on  occasion  can  attack  the  specific  target  structure  where  the 
apoptotic melanocytes reside ―i.e. anagen hair follicles, and the hair cycle re-entry was 
subsequently arrested. Another similar feature of AA in humans to this murine model is 
that the hair may re-grow white and very fine (543;544). In N-Ras mice, fine hairs can 
grow back although these areas are still mainly ‘bare’, whilst the hair generally grows back 
white in other areas (Fig 42) which may be the results of melanocytes apoptosis induced by 
Ras expression as discussed at section 4.4. As in the hairless areas of human AA (543), in 
N-Ras mice there was no actual loss of hair follicles (i.e. the "root") in these fine white 
hairs (Fig 43). Therefore, this unexpected hair loss produced in this study may offer a 
surprise model for the study of AA in human.  
 
 
   
  243 
4.7. Summary and future work 
4.7.1. Summary  
All  current  available  Ras  transgenic  models  either  employ  constitutive  expression  of 
oncogenic or/and null TSGs, often on a CDKN2A background, through embryonic stages 
which only happens in melanoma prone families in humans and often utilise the H-Ras 
allele which is seldom mutated in human melanomas. The exact gene-switch models to 
accurately  mimic  this  human  disease  therefore  still  need  to  be  developed.  In  addition, 
although PTEN biological function loss lacks promotion of N-Ras initiated tumourigenesis 
and inducible N-Ras expression in adult mouse triggered normal body defence system to 
overcome its anti-apoptotic mechanism to result melanocyte apoptosis, the identification of 
such  protective  mechanisms  may  provide  further  insights  to  identify  new  targets  that 
encourage  these  sentinel  pathways  in  novel  therapeutic  approaches  to  prevent  human 
melanomagenesis. This initial early model provides the foundations and technical insights 
for the successful development of further inducible gene-switch approaches by introducing 
additional melanoma relevant molecules into the system.  
 
The eye phenotypes developed in this model were a consequence of technical needs to 
ensure that the gene switch was working in vivo and unlike other models are not expected 
to occur in straight forward topical administration. Such additional phenotypes are not 
good  for  a  cutaneous  melanoma  model  because  they  reduce  viability  and  would 
compromise multistage compound mice attempting to asses several mutations in a stage 
specific manner. Indeed, this was a real problem for the early models developed in Mintz 
(441;442) and Merlino (510) labs resulting in early death or disease in alternate tissue(s). 
Even in the recent Ackermann model, phenotypic eyes were also produced by constitutive 
N-Ras  expression  although  no  uveal  melanoma  developed  (215).  The  phenotypic  eyes 
displayed in our inducible model is very similar to those displayed in Ackermann model 
and resulted in the termination of these experiments given our operating licence, however,  
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we  concluded  that  the  eye  problem  in  our  model  was  a  result  of  systemic  Ru486  IP 
injection rather than topical administration and thus would be eliminated by withdrawal of 
IP  injection.  Furthermore,  only  2  out  of  5  expressers  were  viable  for  analysis  in  the 
Ackermann model indicating that constitutive N-Ras expressing resulted in developmental 
problems,  which  is  avoidable  in  our  inducible  system  because  N-Ras  would  only  be 
expressed in adults, once the anti-Ras apoptosis mechanism could be overcome.   
 
The caspase-3 detection in those N-Ras expression and/or PTEN loss skins show that there 
is a defence system in normal mouse body to  protect melanocyte from oncogenic Ras 
protein expression, which is consistent with the concept of that oncogenic protein is not 
really well tolerated by normal body, whereas constitutive N-Ras expressing resulted in 
melanoma formation in adult and/or developmental defects (215). This finding could be 
important for causal role study of oncogenic protein expression in cancer development 
because the level and time of oncogene expression in specific contexts may be important 
for the determination of eventual outcome. For instance, discovery of caspase-3 dependant 
apoptosis  in  vivo  melanocyte  differs  from  MEK  caspase-independent  pathway  in  vitro 
induced by Ras, possibly indicates factors of MEKs vs. melanocytes; the different alleles 
employed or possibly that Ras simply plays different roles between in vivo and in vitro, as 
revealed for PTEN gene functions in this study.    
 
PTEN  did  promote  N-Ras  tumourigenesis  in  vitro  as  discussed  above,  being  another 
difference of in vitro from in vivo experimentation and the results are consistent with the 
finding of that PTEN ablation more often being detected in cell lines than in solid tumours 
and STC. The reason that PTEN loss lacked synergism with N-Ras initiation is possibly 
due to functional redundancy being on the same signalling pathway it provides the same 
neoplastic  hit  at  this  stage  unlike  CDNK2A  deletion  which  provides  different  genetic 
ablation of p16/p19 and cross-talk to numerous synergistic Ras pathways e.g. p53, Rb, cell  
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cycle regulators such as cyclin D1. This is supported by colony melanocytes promoted by 
PTEN function loss in vitro were not immortalised which is consistent with melanoma 
induction failure in a double genes (N-Ras/PTEN) ablation line in vivo. It appears most 
likely that at this stage, the combination of PTEN loss and N-Ras activation could not 
overcome  a  sentinel  mechanism  of  caspease-3  mediated  apoptosis.  Thus,  if  this  was 
compromised in other conditions, the observations of N-Ras cooperation with PTEN may 
prove to be positive, as in papillomagenesis. However the pigmented papillomas obtained 
from the current microenvironment disruption, appear to depend on establishment of a 
paracrine  Kit/SCF  survival  loop  and  N-Ras  expression  alongside  PTEN  loss  gives 
hyperplastic melanocytes.  Even so this may be relevant to the human condition, because 
the  data  suggest  that  this  kind  of  pigmented  papilloma  may  develop  when 
papillomagenesis and anagen melanocytes exist in parallel. Thus in humans, pigmented 
papillomas may arise when tumourigenesis occurs in parallel to hair follicle growth and 
follicular  melanocyte  survival  is  maintained  by  Kit  and  SCF  expression  allowing  this 
survival loop.   
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4.7.2. Future work  
All other Ras melanoma models employed a CDKN2A deficient background as well the 
necessity of TSG deficiency for tumourigenesis from other studies discussed above and 
therefore, introduction of the p16/19 floxed mice into this model is the primary task of 
future work to mimic human disease. PTEN redundancy to N-Ras in this model does not 
rule out its cooperation at the later stage of melanoma development and thus, the role of 
PTEN  and  its  synergism  are  also  of  interest  in  the  future  CDKN2A  deficient  models, 
specifically to investigate the different roles at different stages of melanomagenesis.  
 
The  increased  size  of  promoter  containing  additional  elements  to  enhance  regulator 
expression and melanocyte specificity  is another point to define in future work, since the 
same  allele  of  H-Ras  expressed  from  different  sized  promoters  displayed  different 
expression patterns in mouse skin and subsequently melanomas at different locations and 
with different histology. From this model, another interesting study to undertake is whether 
increased N-Ras expression under longer versions of the Tyr promoter would also activate 
this mouse defence mechanism to either overcome it or remain susceptible to it as revealed 
in this model. If so, this result may produce the further evidence for the study by Sarkisian 
and colleagues in which they found that near physiological levels of Ras (K-allele) led to 
hyperproliferation  of  epithelial  cells  whilst  high  levels  of  Ras  expression  led  to  cell 
senescence but not in CDKN2A deficient mice (515), by using the longer version promoter 
in regulator Cre it may result in higher N-Ras expression as discussed at section 4.1 to 
increase Ras expression level in vivo. If not will this still proceed through a caspase-3 
dependant manner or different manner if apoptosis is induced, i.e. is caspase-3 mediated 
apoptosis a default programme to prevent the initiation of melanoma? 
  
p53 gene is the most mutated TSG in human cancers, however, mutational analyses by 
many groups have reported a complete absence or very low incidence of point mutation or  
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allelic  loss  of  p53  in  surgical  specimens  of  primary  and  metastatic  melanomas,  while 
others  have  estimated  the  incidence  of  p53  mutation  to  be  15–25%  of  primary  and 
metastatic samples (561-563). Current data collected in Sanger centre in UK also revealed 
a reasonable high mutation rate in malignant melanoma (564). Therefore, the role of p53 in 
melanoma remained still controversial. Indeed, p53 heterozygous and null mice harbouring 
H-Ras did develop cutaneous melanomas which are very similar with those developed in 
p19 mull mice (565), whereas p16  remained intact. The results indicated that p19-p53 
functions  as  a  melanoma  suppression  axis  in  vivo.  In  zebrafish  expressing  the  most 
common B-Raf mutant (V600E) under the control of the melanocyte promoter (see below), 
led  to  dramatic  patches  of  ectopic  melanocytes  in  wild  type  p53  but  B-Raf  induced 
melanocyte  lesions  rapidly  developed  into  invasive  melanoma  in  a  p53  deficient 
background (413). These models implied the functional roles of p53 gene in melanoma 
development  and  therefore,  the  introduction  of  p53  mouse  into  this  model  could  be 
interesting too and the difference (if any) compared to p16 and p19 mice. 
 
Kit/SCF loops may play different roles at different stages or in different contexts. Kit/SCF 
provided a survival function in those pigmented papilloma melanocytes and is essential to 
melanoblast migration and survival during embryogenesis. Kit function is lost or greatly 
reduced  in  later  stage  melanoma(505),  which  significantly  appears  to  be  the  facts 
underlying  the  melanocyte  stem  cell  niche  (53)  and  thus  could  lead  to  the  rise  of  a 
melanoma stem cell, or at least cells that no longer are regulated by keratinocyte SCF 
signalling. Thus, conditional deletion of Kit locus would be really interesting to introduce 
in this model for the study of gene function patterns at difference stages of melanoma 
development.  
 
Melanocytes survival from apoptosis by disruption of its microenvironment but no further 
progression from dysregulated by N-Ras
lys61 expressing  and PTEN aberrant to produce  
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melanoma is interesting. As cells release cues to microenvironment and numerous growth 
factor signalling loops are overexpressed to promote tumour progression, it is likely that 
many other intrinsic (seed) and extrinsic (soil) factors (e.g. Nodal, Notch signalling) are 
involved in this survival model and currently under intensive study. By secreting Nodal 
factor, a potent embryonic morphogen in melanoma cells but not in normal human skin, 
melanoma cells modulated its immediate microenvironment to induce ectopic formation of 
the embryonic axis when transplant melanoma cells into blastula-stage embryo (8), and its 
expression  can  be  induced  by  Notch  signalling  (446;566;567).  The  Notch  signalling 
pathway is simple but other signalling pathways cross-talk with Notch signalling appears 
to be extraordinarily complex (567). Involvement of Notch in cancers was first highlighted 
in  human  T-cell  leukaemia  in  which  the  aberrant  Notch  signalling  promotes 
tumourigenesis  (568).  Notch1  directly  stimulates  expression  of  the  cell-cycle  regulator 
Waf1  in  primary  mouse  keratinocytes  (569),  which  negatively  links  Notch1  and  Wnt 
signalling (570) and was downregulated by p53 homology p51/p63 (571). Notch signalling 
pathway was also identified to promote primary melanoma progression through regulation 
of  PIP3-Akt  pathway  activities  and  expression  of  N-Cadherin  (572).  Notch  signalling, 
acting through Hes1, plays a  crucial role in the survival of immature  melanoblast and 
melanocyte  stem  cell  by  preventing  initiation  of  apoptosis  (573).  However,  there  is 
mounting  evidence  that  Notch  signalling  is  not  exclusively  oncogenic.  It  can  instead 
function as a tumour suppressor (574;575). Whether Nodal, Notch signalling and other cell 
survival factors would induce overt melanoma in this inducible model by cross-talk to the 
Ras pathway would be also very interesting to investigate.  
 
While  a  redundancy  was  apparently  created  in  vivo,  the  results  in  vitro  verified  that 
D5PTEN cooperated with N-Ras initiated tumourigenesis, which was consistent with the 
previous reports in cell lines. However, despite the fact that these cells were viable for 
months they eventually senesced, implying that these insults were similar but insufficient  
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to  achieve  immortalisation,  consistent  with  the  redundancy  observed  in  vivo  between 
PTEN  loss  and  N-Ras  genes.  Thus  by  introducing  UVR-B  irradiation,  a  well  know 
environment  risk  factor  cause  DNA  damage  in  melanocyte  (66),  D5PTEN/N-Ras 
transformed  cells  may  gain  an  immortalised  potential  for  further  studies.  For  instance, 
UVR also induces melanocyte apoptosis and alpha-MSH has the anti-apoptotic activity 
(66), while a-MSH’s immunosuppressive effects in humans through MC1R on monocyte 
and B lymphocyte (31) involves beta-defensin 103 (CBD103), a protein family previously 
implicated in innate immunity, that binds with high affinity to the MC1R, and has a simple 
and strong effect on pigment type-switching in transgenic mice (397). Thus these MC1R 
pathway related factors, would also be of significant interest to be introduced in this model 
and generate a very good melanogenesis model, separate to that of the Ras/PTEN pathway, 
to  explore  the  potential  cross-talk  of  different  pathways  involved  in  melanoma 
development. 
 
The  development  of  appropriate  models  may  require  several  other  genetic  aberrations 
which  function  on  a  different  signalling  pathway  to  cross-talk  with  Ras,  possibly  to 
overcome protective responses and develop cutaneous melanoma. The other genes which 
function on the Ras signalling pathway e.g. B-Raf, PTEN and those genes (e.g. Kit/SCF, 
Nodal, Notch, b-FGF, HGF etc) involved in melanocyte/melanoma development, including 
survival, migration and differentiation would also be of interest to investigate their roles 
and to develop successful highly flexible inducible models, specifically to delineate the 
possible different roles underlying the developmental stages of melanoma and identify new 
therapeutic targets.  
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